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ABSTRACT 
 
Design and Development of Intricate Nanomedical Devices 
through Compositional, Dimensional and Structural Control. (May 2012) 
Yun Lin, B.S., University of Nebraska at Omaha; 
M.S., Washington University in St. Louis 
Chair of Advisory Committee:  Dr. Karen L. Wooley 
 
Nanomedicine, the medical application of nanotechnology, uses nanoscale 
objects that exist at the interface between small molecule and the macroscopic world for 
medical diagnosis and treatment.  One of the healthcare applications of nanomedicine is 
drug delivery: the development of nanoscale objects to improve therapeutics' 
bioavailability and pharmacokinetics.  Shell crosslinked knedel-like nanoparticles 
(SCKs), that are self assembled from amphiphilic block copolymers into polymeric 
micelles and then further stabilized with crosslinkers isolated throughout the peripheral 
shell layer, have been investigated for drug delivery applications that take advantage of 
their core-shell morphology and tunable surface chemistry.  SCKs are attractive 
nanocarriers because the cores of the SCKs are used for sequestering and protecting 
guests.  The readily adjustable shell crosslinking density allows for gating of the guest 
transport into and out of the core domain, while retaining the structural integrity of the 
SCKs.  Moreover, the highly functionalizable shell surface provides opportunity for 
incorporation of targeting ligands for enhanced therapeutic delivery.   
 iv 
The optimization of nanoparticle size, surface chemistry, composition, structure, 
and morphology has been pursued towards maximization of the SCKs' therapeutic 
efficacy.  With distinctively different dimensions, compositions and structures of the 
core and shell domains of SCKs, and an ability to modify each independently, probing 
the effects of each is one of the major foci of this dissertation.  Utilization of a living 
radical polymerization technique, reversible addition-fragmentation chain transfer 
(RAFT) polymerization, has allowed for facile manipulation of the block lengths of the 
polymer precursors and thus resulted in various dimensions of the nanoparticles.  SCKs 
constructed from poly(acrylic acid)-b-polystyrene (PAA-b-PS) with various chain 
lengths, have been investigated on the loading and release of doxorubicin (DOX).  The 
effect of PEGylation on paclitaxel (PTX) loaded SCKs on the cell internalization and 
killing was investigated.  Apart from chemotherapies, the SCKs were explored as 
antimicrobial agents by incorporating silver species.  Conjugation of the SCK surface 
with a protein adhesin through amidation chemistry to promote epithelial cell targeting 
and internalization was developed.  Nanoscale assemblies with complex morphologies 
constructed from a linear triblock copolymer was investigated.  Furthermore, a highly 
multifunctional nanodevice for imaging and drug delivery functionalized with a chelator 
for radio-labeling, polyethylene glycol (PEG) for improved biodistribution, targeting 
ligands, a chromophore and a therapeutic agent was evaluated in vivo as active-targeted 
delivery of therapeutics.   
 v 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
To my father, Zhen Lin and my mother Lizhong Yin 
 vi 
ACKNOWLEDGEMENTS 
 
When I entered graduate school, I have never even heard of most of the topics 
that were covered in this dissertation, thus to be able to accomplish all the cutting-edge 
work included here is a surreal experience.  Though only one person’s name appears on 
the cover of this dissertation, its production would not have been possible without many 
people’s contribution and guidance.  I owe my greatest appreciation to all those people 
who have helped with the completion this dissertation and because of whom my 
graduate experience has been the one that I will cherish forever. 
My deepest and most sincere gratitude is to my advisor, Dr. Karen L Wooley, for 
her guidance, support, patience and most importantly trust during my graduate study at 
both Washington University in St. Louis and Texas A&M University.  I was most 
fortunate to have an advisor who has given me the freedom to explore on my own and 
develop self-sufficiency to grow as an independent thinker yet at the same time she had 
provided insightful advice and constructive criticism at different stages of my research to 
help me focus.  Dr. Wooley has high expectations for me and she guides me to meet 
those expectations with constant support, encouragement and self-demonstration.  I am 
grateful to her for holding me to a high research standard and enforcing strict 
validations, which has not only taught me to be a thorough research scientist, but a better 
person with positive and healthy attitude.  I also want to thank my committee members, 
Dr. Kevin Burgess, Dr. Paul S. Cremer and Dr. Melissa A. Grunlan for their valuable 
advice, input and discussions towards the completion of this dissertation.   
 vii 
The majority work of this dissertation was a collaborative effort with many 
brilliant scientists from both industry and academia.  I have learned tremendously and 
enjoyed the collaboration with Dr. Richard B. Dorshow and his team from Covidien 
Pharmaceuticals.  Intellectual contributions from Dr. John N. Freskos, Dr. Jeng J. Shieh, 
Mr. Amolkumar Karwa, Dr. James G. Kostelc, Dr. Gary E. Cantrell, Dr. David 
Berberich, Dr. Dennis A. Moore, Dr. William McGhee, Dr. Thomas Rogers, Dr. Amruta 
R. Poreddy, and Dr. Raghavan Rajagopalan are greatly appreciated.  Professor David A. 
Hunstad’s brilliant ideas, insightful advice and professional opinions have yielded one of 
the most important chapters in this dissertation, the relationship with his group was a 
very enjoyable experience.  I also want to thank Dr. Jeffery R. Leonard and Dr. Carolyn 
L. Cannon for allowing me to learn in vitro/in vivo techniques in their labs and 
performing experiments.   
I would like to acknowledge many past and present Wooley group members’ 
mentorship and friendship.  Particularly, I would like to thank Dr. Andreas M. Nyström 
and Dr. Guorong Sun for teaching me many useful techniques and having many valuable 
discussions that helped me understand my research areas better.  Support and care from 
many friends have not only helped me overcome setbacks and stay focused on my 
graduate study but in my life as well.  I greatly value the friendship from Dr. Yali Li, Dr. 
Ke Zhang, Dr. Jeremy Bartles, Dr. Jiong Zou, Mr. Ang Li, Mr. Shiyi Zhang and Mr. 
Fuwu Zhang.  I appreciate many faculty, staff members and colleagues from both 
Washington University in St. Louis and Texas A&M University department of chemistry 
for their help in many aspects of my graduate school career.   
 viii 
The most important person during my graduate school career other than my 
advisor is Dr. Nam S. Lee.  Nam has believed in my ability to succeed even before I 
believed in myself.  Nam’s meticulous work ethics, innovative spirit, and positive 
attitude have influenced me to be a better scientist and taking on challenges with full 
confidence.  The accomplishments of my graduate school career and the completion of 
this dissertation are undeniably attributed to the encouragement, patience, support and 
dedication from Nam.  I was able to concentrate on the writing of my dissertation 
because Nam assumed full responsibility of our Goldendoodle, Mulligan, and for that I 
owe him my deepest gratitude.   
Most importantly, none of this would have been possible without the love of my 
Mom and Dad, to whom this dissertation is dedicated to.  They have been a constant 
source of love, support, encouragement and strength all these years.  I was unable to 
fulfill my daughterly duties during the study of my graduate school career; the 
accomplishments and achievements are a small token to express my sincere gratefulness 
towards their unwavering love, devotion and nourishments.   
 ix 
NOMENCLATURE 
 
AFM Atomic force microscopy 
AIBN 2,2'-Azobis(isobutyronitrile) 
CFU Colony-forming unit 
CMC Critical micelle concentration 
CTA Chain transfer agent 
DDMAT S-1-dodecyl-S'-(α, α'-dimethyl-α''-acetic acid)trithiocarbonate 
DLS Dynamic light scattering 
DMAP 4-(Dimethylamino)pyridine 
DMF N, N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DOX Doxorubicin 
DPn Degrees of polymerization 
DSC Differential scanning calorimetry 
EDCI 1-[3´-(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide 
EDDA 2,2´-(ethylenedioxy)bis(ethylamine) 
EPR Enhanced permeation and retention 
FITC Fluorescein isothiocyanate 
GPC Gel permeation chromatography 
HOBt 1-Hydroxybenzotriazole hydrate 
HPLC High performance liquid chromatography 
 x 
ICP-MS Inductively coupled plasma mass spectrometry 
IR Infrared spectroscopy 
MIC Minimum inhibitory concentration 
MWCO Molecular weight cut-off 
NAS N-Acryloyloxysuccinimide 
NHS N-Hydroxysuccinimide 
NMR Nuclear magnetic resonance spectroscopy 
PAA Poly(acrylic acid) 
PBS Phosphate buffered saline 
PDI Polydispersity index 
PEG Poly(ethylene glycol) 
PEO Poly(ethylene oxide) 
PS Polystyrene 
PTA Phosphotungstic acid 
PtBA Poly(tert-butyl acrylate) 
PTX Paclitaxel 
RAFT Reversible addition-fragmentation chain transfer 
SATP N-succinimidyl-S-acetylthiopropionate 
SANS Small angel neutron scattering 
SCK Shell crosslinked knedel-like nanoparticle 
SEC Size exclusion chromatography 
SDS Sodium dodecyl sulfate 
 xi 
Tg Glass transition temperature 
Tm Crystalline melting temperature 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
UPEC Uropathogenic strains of  Escherichia coli 
UTI Urinary tract infections 
UV-vis Ultraviolet-visible 
 xii 
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  iii 
DEDICATION ..........................................................................................................  v 
ACKNOWLEDGEMENTS ......................................................................................  vi 
NOMENCLATURE ..................................................................................................  ix 
TABLE OF CONTENTS ..........................................................................................  xii 
LIST OF FIGURES ...................................................................................................  xv 
LIST OF TABLES ....................................................................................................  xxiv 
CHAPTER 
 I INTRODUCTION ................................................................................  1 
 
 II TUNING CORE VS. SHELL DIMENSIONS TO ADJUST THE 
PERFORMANCE OF NANOSCOPIC CONTAINERS FOR THE 
LOADING AND RELEASE OF DOXORUBICIN ............................  14 
  
   2.1.  Introduction ............................................................................  14 
   2.2.  Materials and methods ...........................................................  18 
   2.3.  Results and discussion ............................................................  30 
   2.4.  Conclusions ............................................................................  52 
   2.5.  Acknowledgments ..................................................................  53 
  
 III PACLITAXEL-LOADED SCK NANOPARTICLES:  AN 
INVESTIGATION OF LOADING CAPACITY AND CELL  
  KILLING ABILITIES IN VITRO ........................................................  54 
  
   3.1.  Introduction ............................................................................  54 
   3.2.  Materials and methods ...........................................................  57 
   3.3.  Results and discussion ............................................................  66 
   3.4.  Conclusions ............................................................................  81 
   3.5.  Acknowledgments ..................................................................  82 
 
 xiii 
CHAPTER                                                                                                                   Page 
 
 IV SYNTHESIS, CHARACTERIZATION, AND IN VIVO EFFICACY 
EVALUATION OF SHELL CROSSLINKED NANOPARTICLE 
FORMULATIONS CARRYING SILVER ANTIMICROBIALS AS  
  ANTI-PSEUDOMONAL THERAPEUTICS ......................................  83 
  
   4.1.  Introduction ............................................................................  83 
   4.2.  Materials and methods ...........................................................  88 
   4.3.  Results and discussion ............................................................  93 
   4.4.  Conclusions ............................................................................  101 
   4.5.  Acknowledgments ..................................................................  101 
 
 V SYNTHETIC POLYMER NANOPARTICLES CONJUGATED  
  WITH FIMHA FROM E. COLI PILI TO EMULATE THE  
  BACTERIAL MODE OF EPITHELIAL INTERNALIZATION .......  102 
  
   5.1.  Introduction ............................................................................  102 
   5.2.  Materials and methods ...........................................................  105 
   5.3.  Results and discussion ............................................................  110 
   5.4.  Conclusions ............................................................................  116 
   5.5.  Acknowledgments ..................................................................  118 
 
 VI MORPHOLOGICAL EVOLUTION OF A TRIBLOCK  
  COPOLYMER AND CHEMICAL MANIPULATIONS  
  THEREOF ............................................................................................  119 
  
   6.1.  Introduction ............................................................................  119 
   6.2.  Materials and methods ...........................................................  122 
   6.3.  Results and discussion ............................................................  128 
   6.4.  Conclusions ............................................................................  152 
   6.5.  Acknowledgments ..................................................................  152 
 
 VII F3-PEPTIDE-CONJUGATED, DOXORUBICIN LOADED  
  NANOPARTICLES AS COMPLEX THERANOSTICS IN  
  THE TREATMENT OF PEDIATRIC BRAIN CANCERS ................  153 
 
   7.1.  Introduction ............................................................................  153 
   7.2.  Materials and methods ...........................................................  158 
   7.3.  Results and discussion ............................................................  167 
   7.4.  Conclusions ............................................................................  179 
   7.5.  Acknowledgments ..................................................................  179 
 
 VIII CONCLUSIONS ..................................................................................  181 
 xiv 
REFERENCES ..........................................................................................................  187 
VITA .........................................................................................................................  206 
  
 xv 
LIST OF FIGURES 
 
FIGURE                                                                                                                        Page 
 1.1 Schematic representation of the composition of multifunctional  
  shell crosslinked knedel-like nanoparticles (SCKs) for drug  
  delivery applications ..................................................................................  4 
 
 1.2 Schematic representation of the interaction between doxorubicin  
  (DOX) incorporated into SCKs constructed from poly(acrylic acid)-b- 
  polystyrene (PAA-b-PS) ............................................................................  7 
 
 1.3 Schematic representation of the incorporation of PTX into SCKs  
  and cell internalization of PTX-SCKs ........................................................  9 
 
 1.4 Schematic and chemical representation of a shell crosslinked  
  nanoparticle assembled from poly(acrylic acid)-b-polystyrene  
  loaded with silver carbene complexes in the core and silver  
  cation in the shell ........................................................................................  10 
 
 1.5 Schematic representation of a shell crosslinked nanoparticle  
  functionalized with FimHA adhesin protein and confocal  
  microscopy of the FimHA-SCKs being internalized into  
  bladder epithelial cells ................................................................................  11 
 
 2.1 Preparation of PtBA macro-CTA, chain extension with styrene, and  
  removal of tert-butyl protecting groups to produce PAAm-b-PSn  
  polymers of various chain lengths ..............................................................  32 
 
 2.2 Schematic representation of the supramolecular assembly of  
  PAAm-b-PSn block copolymers into micelles and their subsequent  
  crosslinking with EDDA to form SCKs .....................................................  35 
 
 2.3 Characterization of SCKs 12 - 15 by TEM (drop deposited on  
  carbon-coated copper grids and stained negatively with  
  phosphotungstic acid) of A) 12, B) 13, C) 14, and D) 15 ..........................  36 
 
 2.4 Characterization of SCKs 12 - 15 by DLS.  DLS histograms of  
  intensity-averaged, volume-averaged, number-averaged hydrodynamic 
  diameters :  A) SCK 12, B) SCK 13, C) SCK 14, and D) SCK 15 in  
  nanopure water ...........................................................................................  37 
 
 xvi 
FIGURE                                                                                                                        Page 
 2.5 A). Small angle neutron scattering (SANS) data of SCK 12 - 15. 
  Black solid lines present fitting curves of “smeared polydispersed  
  core-shell sphere” model.  B).  Model fitting results for SANS profile  
  of SCK 12 with "core-shell sphere" model, "smeared core-shell  
  sphere" model, "polydispersed core-shell sphere" model and  
  "smeared polydispersed core-shell sphere" model .....................................  39 
 
 2.6 Schematic representation of the loading of DOX into the core, 
  core-shell interface and shell region of the SCKs while suspended  
  in aqueous solution, and release of DOX from the SCK in pH 5.0 or  
  pH 7.4 buffer at 37 °C ................................................................................  44 
 
 2.7 DOX release profiles of free DOX, micelles, and SCK12, SCK13, 
  SCK14 and SCK15 at pH 7.4 or pH 5.0 .....................................................  45 
 
 2.8 Higuchi plots of DOX release profiles of SCK12, SCK13, SCK14  
  and SCK15 at pH 7.4 or pH 5.0 .................................................................  47 
 
 3.1 Co-assembly of PAA70-b-PS555 block copolymers in DMF with  
  paclitaxel in DMSO to construct 60 nm PTX-loaded micelles  
  (PTX-micelle-60nm), followed by dialysis to remove the organic  
  solvents.  Crosslinking with the pyrazine chromophore crosslinker,  
  using EDCI as the coupling agent followed by dialysis to remove  
  free crosslinker and EDCI byproducts to obtain PTX-loaded SCKs  
  (PTX-SCK-60nm) ......................................................................................  67 
 
 3.2 Left column: TEM images (drop deposited on carbon-coated copper  
  grids and stained negatively with 1% aqueous uranyl acetate) of  
  A. SCK-60nm; C. PTX-SCK-60nm-20%; E. PTX-SCK-60nm-15%;  
  G. PTX-SCK-60nm-10%; I. PTX-SCK-60nm-5%.   
  Right column:  DLS histograms (determinations were average values  
  from ten measurements, with the standard deviations being calculated  
  as the breadth of the distributions) of B. SCK-60nm;  
  D. PTX-SCK-60nm-20%; F. PTX-SCK-60nm-15%;  
  H. PTX-SCK-60nm-10%; J. PTX-SCK-60nm-5% ....................................  69 
 
 3.3 Viability of KB cells incubated with A. SCK-60nm; B. Free PTX;  
  C. PTX-SCK-60nm-20%; D. PTX-SCK-60nm-15%;  
  E. PTX-SCK-60nm-10%; F. PTX-SCK-60nm-5%.   
  The percentage cell viability was measured by WST-1 assay. 
  Blue squares, 2 h; red diamonds, 72 h ........................................................  72 
 
 xvii 
FIGURE                                                                                                                        Page 
 3.4 Illustration of the location of free PTX vs. PTX-SCK in a centrifugal  
  filtering experiment using 50 kDa MWCO filter .......................................  73 
 
 3.5 Co-assembly of PAA-b-PS or PEGylated PAA-b-PS in DMF with  
  PTX in DMSO to construct 20 nm PTX loaded micelles, followed  
  by in situ crosslinking with the pyrazine chromophore crosslinker,  
  using EDCI as the coupling agent.  The final 20 nm PTX-loaded  
  SCKs in aqueous solutions were obtained after performing dialysis  
  to remove organic solvent, free crosslinker and EDCI by products ...........  75 
 
 3.6 Left column: TEM images (drop-deposited on carbon-coated copper  
  grids and stained negatively with 1% aqueous uranyl acetate) of  
  A. SCK-20nm; C. PTX-SCK-20nm-5%; E. PEG-SCK-20nm;  
  G. PTX-PEG-SCK-20nm-5%.  Right column:  DLS histograms  
  (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadths of the 
  distributions) of B. SCK-20nm; D. PTX-SCK-20nm-5%;  
  F. PEG-SCK-20nm; H. PTX-PEG-SCK-20nm-5% ...................................  77 
 
 3.7 Viability of KB cells incubated with A. SCK-20nm; B. PEG-SCK-20nm; 
  C. PTX-SCK-20nm-5%; D. PTX-PEG-SCK-20nm-5%.   
  The percentage cell viability was measured by WST-1 assay.   
  Blue squares, 2 h; red diamonds, 72 h ........................................................  79 
 
 3.8 Intracellular uptake of A. SCK-20nm; B. PEG-SCK-20nm;  
  C. PTX-SCK-20nm-5%; D. PTX-PEG-SCK-20nm-5% in KB cells.   
  Cells were incubated with a single concentration of each different  
  type of SCK for 2 h.  Cells were then fixed with 4% PFA, mounted  
  with media containing DAPI, and subsequently imaged with Nikon A1 
  confocal microscope.  Fragmented nuclei in cells were observed after 
  incubation with PTX-SCK-20nm-5% for 2 h: E. DAPI staining;  
  F. Transmission detector (TD) image; G. Acridine orange staining;  
  H. Overlay of DAPI staining, TD, and acridine orange staining ...............  80 
 
 4.1 Schematic representation of physical encapsulation of AgNO3  
  or AgCOOCH3 partitioned into the shell of the SCK, and  
  silver carbene complex 10 (SCC10) being incorporated into  
  the core of the SCK ....................................................................................  94 
  
 xviii 
FIGURE                                                                                                                        Page 
 4.2 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% aqueous uranyl acetate) of:   
  A. Empty SCK nanoparticles; B. AgNO3-SCK; C. AgCOOCH3-SCK,  
  and D. SCC10-SCK ....................................................................................  95 
 
 4.3 DLS histograms of intensity-averaged (first row), volume averaged  
  (second row), and number averaged (third row) hydrodynamic  
  diameters (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadth of the  
  distributions) of:  A. blank SCKs; B. AgNO3-SCK; C AgCOOCH3-SCK,  
  and D. SCC10-SCK ....................................................................................  96 
 
 4.4 STEM dark field images (drop deposited on carbon-coated copper  
  grids with no stain) of A. AgNO3-SCK; B. SCC10-SCK; and  
  STEM bright field images (drop deposited on carbon-coated copper  
  grids with no stain) of C. AgNO3-SCK; D. SCC10-SCK ..........................  97 
 
 4.5 Wight loss diagram of mice inoculated with P. aeruginosa treated  
  with sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and  
  SCC10-SCK treatment groups ...................................................................  99 
 
 4.6 Clinical score diagram of mice inoculated with P. aeruginosa treated  
  with sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and  
  SCC10-SCK treatment groups ...................................................................  99 
 
 4.7 Percent survival rate diagram of mice inoculated with P. aeruginosa  
  treated with sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and  
  SCC10-SCK treatment groups ...................................................................  100 
 
 5.1 Schematic and chemical representation of FimHA-functionalized  
  and FITC cadaverine-labeled SCK nanoparticles ......................................  104 
 
 5.2 A. Schematic representation of 5-FITC cadaverine labeling and  
  FimHA conjugation to the shell of SCK nanoparticles via amidation  
  chemistry; B.  TEM and DLS characterization of 5-FITC cadaverine- 
  tagged, FimHA-conjugated SCK nanoparticles.   
  Diameter (TEM) = 20 ± 3 nm, Dh(intensity) = 80 ± 30 nm,  
  Dh(volume) = 50 ± 20 nm, Dh(number) = 40 ± 10 nm .........................................  112 
  
 xix 
FIGURE                                                                                                                        Page 
 5.3 Functionalization of FimHA onto SCK surfaces.  Naked SCKs  
  (A) and FimHA-functionalized SCKs (B) viewed by immunogold  
  transmission EM after incubation with rabbit anti-FimHA antibody  
  and gold-conjugated anti-rabbit IgG.  Labeling of FimHA-SCKs was 
  significantly greater than that of naked SCKs; representative images  
  are shown.  Scale bars, 100 nm ..................................................................  113 
 
 5.4 Binding of FimHA-SCK nanoparticles to cultured bladder epithelial  
  cells.  Monolayers of 5637 cells were treated with the indicated doses  
  of 5-FITC cadaverine-tagged (green) SCKs, naked or conjugated with  
  FimHA, and with or without 2% mannose.  Cells were liberated from the 
  surface and stained circumferentially with AlexaFluor 594-conjugated  
  wheat germ agglutinin (WGA; red).   
  Scale bar (upper left panel), 20 µm ............................................................  115 
 
 5.5 Epithelial cell internalization of FimHA-SCKs.  In this example of an  
  internalized particle, the SCK of interest is viewed at the cross-hairs  
  in the XY plane; orthogonal views (top and right of the panel)  
  show the particle encircled by the red cell-surface stain (arrowheads).   
  Scale bar, 20 µm .........................................................................................  116 
 
 6.1 Schematic representation of self assembly of  
  PEO45-b-PNAS66-b-PS30 to form both cylindrical nanostructure and 
  multicompartment nanostructure:  A. micellization in DMF to form  
  cylindrical micelles; B. crosslinking with pyrazine crosslinker to  
  form shell crosslinked cylindrical nanostructures (SCCN);  
  C. SCCN after dialysis for 3 days; D. SCCN after 3 months storage  
  at room temperature; E. cylindrical micelles after dialysis for 3 days;  
  F. cylindrical micelles after 3 month storage at room temperature;  
  G. micellization in DMSO to form multicompartment micelles (MCM);  
  H. crosslinking with pyrazine crosslinker to form shell crosslinked 
  multicompartment nanostructure (MCN); I. MCN after dialysis for  
  3 days; J. MCN after 3 months storage at room temperature. K. MCM 
  disassembled into individual micelles upon dialysis; L. individual  
  micelles disassembled from MCM are stable after 3 months storage  
  at room temperature. ..................................................................................  121 
  
 xx 
FIGURE                                                                                                                        Page 
 6.2 DLS histograms of intensity-averaged (first row), volume averaged  
  (second row), and number averaged (third row) hydrodynamic  
  diameters (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadth of the 
  distributions) of PEO45-b-PNAS66-b-PS30 in DMF self assembled into 
  cylindrical micelles upon addition of water at various water addition rate:   
  A. 10 mL/h; B. 15 mL/h; C. 20 mL/h, and D. 30 mL/h. ............................  129 
 
 6.3 TEM images (drop deposited on carbon-coated copper grids and  
  stained negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30 in  
  DMF self assembled into cylindrical micelles upon addition of  
  water at :  A. 10 mL/h; B. 15 mL/h; C. 20 mL/h; and D. 30 mL/h. ...........  130 
 
 6.4 TEM images (drop deposited on carbon-coated copper  
  grids and stained negatively with 1% PTA) of the transition of  
  PEO45-b-PNAS66-b-PS30 in DMF self assembled into spherical  
  micelles to cylindrical micelles upon increased addition of water  
  from:  A. 10 wt%; B. 21 wt%; C. 32 wt%; to D. 41 wt% at a rate  
  of 15 mL/h ..................................................................................................  132 
 
 6.5 DLS histograms of intensity-averaged (first row), volume averaged  
  (second row), and number averaged (third row) hydrodynamic  
  diameters (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadth of the 
  distributions) of PEO45-b-PNAS66-b-PS30 shell crosslinked cylindrical 
  nanoparticles (SCCN) dialyzed against A. nanopure water; 
  B. pH 6.3 PBS; C. pH 7.4 PBS and D. pH 8.1 PBS ...................................  133 
 
 6.6 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30  
  cylindrical micelles dialyzed against A. nanopure water;  
  B. pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS for 3 days. ................  134 
 
 6.7 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of shell crosslinked  
  cylindrical nanostructures (SCCN) dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and  
  D. pH 8.0 PBS for 3 days. ..........................................................................  137 
 
  
 xxi 
FIGURE                                                                                                                        Page 
 6.8 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of cylindrical micelles  
  dialyzed against A. nanopure water 6.3; B. pH 6.3 PBS;  
  C. pH 7.2 PBS, and D. pH 8.0 PBS after 3 months of storage  
  at room temperature. ..................................................................................  138 
 
 6.9 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of shell crosslinked  
  cylindrical nanostructures (SCCN) dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and  
  D. pH 8.0 PBS after 3 months storage at room temperature ......................  139 
 
 6.10 DLS histograms of intensity-averaged (first row), volume averaged  
  (second row), and number averaged (third row) hydrodynamic  
  diameters (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadth of the 
  distributions) of PEO45-b-PNAS66-b-PS30 in DMSO self assembled. ........  141 
 
 6.11 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30  
  in DMSO self assembled into MCM upon addition of water at :   
  A. 10 mL/h; B. 15 mL/h; C. 20 mL/h; and D. 30 mL/h. ............................  142 
 
 6.12 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of the transition of  
  PEO45-b-PNAS66-b-PS30 in DMSO self assembled into spherical  
  micelles to MCMs upon increased addition of water from:   
  A. 9 wt%; B. 19 wt%; C. 31 wt%; to D. 40 wt% at a rate  
  of 15 mL/h ..................................................................................................  144 
 
 6.13 DLS histograms of intensity-averaged (first row), volume averaged  
  (second row), and number averaged (third row) hydrodynamic  
  diameters (determinations were average values from ten measurements,  
  with the standard deviations being calculated as the breadth of the 
  distributions) of PEO45-b-PNAS66-b-PS30 MCM dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.4 PBS and  
  D. pH 8.1 PBS. ...........................................................................................  146 
  
 xxii 
FIGURE                                                                                                                        Page 
 6.14 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of MCMs retained structure  
  integrity when dialyzed against A. nanopure water but disassembled  
  into individual nanoparticles upon dialysis against B. pH 6.3 PBS;  
  C. pH 7.2 PBS, and D. pH 8.0 PBS for 3 days ...........................................  148 
 
 6.15 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of MCM dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and  
  D. pH 8.0 PBS after 3 months of storage at room temperature ..................  149 
 
 6.16 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of MCNs dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and  
  D. pH 8.0 PBS for 3 days with retention to morphology ...........................  150 
 
 6.17 TEM images (drop deposited on carbon-coated copper grids  
  and stained negatively with 1% PTA) of MCNs dialyzed against  
  A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and  
  D. pH 8.0 PBS after 3 months storage at room temperature. .....................  151 
 
 7.1 Schematic representation of synthesis of DOTA containing  
  PEGylated PAA52-b-PS30 with activated ester-functionalized PEG,  
  PAA45-g-(CONH-lysine-DOTA-COOH)3-g-(CONH-PEG3kDa- 
  NHCO-C3H6-SCOCH3)2-g-(CONH-PEG2kDa-OMe)2-b-PS30 ....................  169 
 
 7.2 Schematic representation of incorporation of cascade blue dye with  
  sulfo-NHS onto the polymer backbone segments within the shell of  
  the SCKs, conjugation of maleimide-functionalized F3 peptide onto  
  the thiol functionalized PEG graft termini to produce F3-CB-SCK 7,  
  followed by encapsulation of DOX into the nanoparticles through  
  physical encapsulation to produce F3-CB-DOX-SCK 8 ............................  171 
  
 xxiii 
FIGURE                                                                                                                        Page 
 7.3 Upper row:  A. TEM image (drop deposited on carbon-coated  
  copper grids and stained negatively with 1% aqueous uranyl acetate)  
  of SCK, diameter = 8 ± 3 nm;  DLS histograms (determinations were  
  average values from ten measurements, with the standard deviations  
  being calculated as the breadth of the distributions) of B. SCK intensity 
  average, 130 ± 60 nm; C. SCK volume average, 40 ± 20 nm;  
  D. SCK number average 26 ± 6 nm;  Lower row:  E. TEM image of  
  F3-CB-DOX-SCK, diameter = 7 ± 3 nm; DLS histograms of  
  F. F3-CB-DOX-SCK intensity average, 100 ± 70 nm;  
  G. F3-CB-DOX-SCK volume average, 30 ± 10 nm;  
  H. F3-CB-DOX-SCK number average, 21 ± 4 nm ....................................  173 
 
 7.4 Cellular uptake of FITC labeled F3 peptide in primary normal  
  human astrocytes (NHA) and U87MG glioma cells.  Primary normal  
  human astrocytes and U87MG glioma cells were both incubated  
  with FITC-labeled F3 peptide (1μM) at 37 °C for 2 h before fixed  
  with 4% PFA and then mounted for observation.  As a control,  
  U87MG glioma cells were pre-incubated with anti-human specific  
  nucleolin antibody (10µg/ml) to block the binding.   
  The nuclei were counterstained with DAPI ...............................................  174 
 
 7.5 Live cell imaging of cellular uptake of untargeted DOX-loaded  
  (DOX-SCK) vs. targeted DOX-loaded (F3-DOX-SCK)  
  nanoparticles (at 1 µg/mL x 1 h) into U87MG glioma cells,  
  20 x magnifications.  DOX molecules were shown by intrinsic  
  red fluorescence within the treated cells ....................................................  176 
 
 7.6 Enhanced tumor cell killing effects by F3-DOX-SCK nanoparticle  
  in vitro compared with non-targeted SCKs.  U87MG glioma cells  
  were treated with naked SCK, DOX-SCK or F3-DOX-SCK for 3  
  days before assayed for their viability by MTT assay................................  177 
 
 7.7 Enhanced tumor specific delivery of targeted nanoparticle in  
  U87MG intracranial xenograft in vivo of targeted nanoparticles,  
  F3-CB-DOX-SCK, compared with systemic distribution with  
  non-targeted nanoparticles, CB-DOX-SCK, especially within  
  the heart, kidney and liver ..........................................................................  178 
 xxiv 
LIST OF TABLES 
 
TABLE                                                                                                                          Page 
 
 2.1 Experimental and calculated dimensions of the SCKs, and  
  quantified DOX loading values ..................................................................  40 
 
 2.2 DOX release rate, k (h-½), obtained from fitting drug release  
  experimental data to the Higuchi model ....................................................  48 
 
 2.3 Difference factor (f1) values of SCK12-SCK15 against free  
  DOX or against micelles as the references .................................................  50 
 
 2.4 Difference factor (f1) values of SCK12-SCK15 against each  
  other as references ......................................................................................  50 
 
 2.5 Similarity factor (f2) values of SCK12-SCK15 against free  
  DOX or against micelles as the references .................................................  51 
 
 2.6 Similarity factor (f2) values of SCK12-SCK15 against each  
  other as references ......................................................................................  51 
 
 3.1 Summary of characterization data for 60 nm SCKs  
  by TEM and DLS .......................................................................................  68 
 
 3.2 Summary of various formulations of PTX-loaded SCKs  
  (IC50 values were measured at both 2 h and 72 h incubation  
  periods when incubated with KB cells in vitro) .........................................  71 
 
 3.3 Summary of characterization data for the 20 nm SCKs  
  by TEM and DLS  ......................................................................................  76 
 
 3.4 Summary of various formulations of PTX-loaded SCKs  
  (IC50 values were measured at both 2 h and 72 h incubation  
  periods when incubated with KB cells in vitro) .........................................  78 
 
 4.1 Summary of characterization data for empty and silver-loaded  
  SCK nanoparticles by TEM and DLS ........................................................  95 
 
 6.1 Summary of characterization data for cylindrical micelles  
  assembled from PEO45-b-PNAS66-b-PS30 in DMF by  
  TEM and DLS ............................................................................................  131 
 xxv 
TABLE                                                                                                                          Page 
 
 6.2 Summary of characterization data for PEO45-b-PNAS66-b-PS30  
  cylindrical micelles dialyzed against nanopure water and PBS  
  by TEM and DLS .......................................................................................  135 
 
 6.3 Summary of characterization data for MCMs assembled  
  from PEO45-b-PNAS66-b-PS30 in DMSO by TEM and DLS .....................  143 
 
 6.4 Summary of characterization data for PEO45-b-PNAS66-b-PS30  
  MCMs dialyzed against nanopure water and PBS by  
  TEM and DLS ............................................................................................  147 
 
 1 
CHAPTER I 
 
INTRODUCTION 
 
 The medical application of nanotechnology, known as nanomedicine, concerns 
the use of precisely engineered materials at nanoscale for medical diagnosis and 
treatment.  One of the dominating healthcare applications of nanomedicine that accounts 
for three-quarters of the research activity and market is drug delivery.1  The development 
of nanoscopic objects that are able to improve the bioavailability and pharmacokinetics 
of therapeutics to achieve controlled drug delivery through modification of their 
fundamental properties such as solubility, blood circulation time, toxicity, diffusivity and 
immunogenicity is  the prime focus of drug delivery.2   
 In the last two decades, we have witnessed an explosive expansion of 
nanoparticle-based therapeutics both in the market and clinical development for 
treatment of broad spectrum of diseases including cancer (Doxil® /Caelyx®, Myocet®), 
leukemia (Oncaspar®), viral infection (Abelcet®, AmBisome®) and hepatitis (Pegasys®, 
Epaxal®) etc.2  The main route of administration for most nanoparticle-based 
therapeutics is through intravenous (i.v.) injection, other administration methods  
including subcutaneous (s.c.), intrathecal (i.t.), intravitreous (i.r.), intramuscular (i.m.) 
injection, and less invasive route such as oral, epidural, topical, and mucosal delivery 
 
____________ 
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are also under rigorous investigations.3  All of these routes require sophisticated design 
of the nanoparticles to be able to cross different biological barriers such as skin, blood, 
mucus, extracellular matrix before eventually delivering the payloads through the 
cellular and subcellular barriers.3   
 Nature has often provided the concepts and templates from which simple 
structures can be fabricated to provide excellent performances as hosts for packaging 
and releasing therapeutic guests.4  For instance, viruses and lipoproteins are stealthy, 
naturally-occurring vehicles for targeted delivery of nucleic acids and cholesterol esters, 
respectively.  Both viruses and lipoproteins feature architectural characteristics that 
would be favorable for a drug delivery system, such as:  1) nanoscopic dimensions to 
protect guest molecules having limited stability from their surroundings; 2) availability 
and accessibility of targeting moieties on the surface to achieve localized delivery; 3) 
robust and stealth structural integrity.5-7  Although the synthetic and biological processes 
for tailoring of such natural vehicles have witnessed significant advance,8-15  synthetic 
materials provide unique opportunities, including versatility of structure and 
composition, facile engineering, variation of parameters, control of stability vs. 
degradability, and avoidance of potential immunological effects.16   
 Polymer micelles, assembled from amphiphilic block copolymers, which mimic 
biological entities have been investigated for a number of potential applications that take 
advantage of their core-shell morphology and tunable surface chemistry.5,17-22  The core-
shell architecture enables the polymer micelle to incorporate hydrophobic drugs into the 
core domain that serves as a non-aqueous reservoir via either physical entrapment or 
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covalent linkages, thereby increasing the solubility and stability of the hydrophobic 
drugs under physiological conditions.  The shell domain, in turn, can protect the drug 
from its surroundings, modulating the pharmacokinetics and disposition of the carrier, 
and allowing manipulation over the surface chemistry.23  However, micelles can only 
maintain their morphological integrities at concentrations above the critical micelle 
concentration (CMC) and are dynamic systems, potentially limiting their use as 
injectable drug carriers.  Structural reorganization of the micellar structure will then 
result in dissociation of the therapeutic cargo and loss of sustained/controlled delivery.  
In addition, the polymeric assembly is subjected to change upon altering parameters in 
the surrounding environment, e.g., ionic strength, pH, etc.24-27   
 To overcome the limitations that the CMC of micelles poses on intravenous-type 
drug carriers,28-31 our research group and others have explored crosslinked micellar 
constructs, such as shell crosslinked knedel-like nanoparticles (SCKs), that combine the 
amphiphilic core-shell morphology of polymer micelles with stabilizing crosslinkers 
isolated throughout the peripheral shell layer.  Due to the regioselective crosslinks in the 
peripheral shell region, these nanoscale assemblies can be diluted without disassembly, 
and have increased dimensional stability compared to their non-crosslinked micellar 
counterparts.4,32-34  The core of the SCKs can retain its host capabilities, because the lack 
of crosslinks in the core region maintains chain mobility and access to the core volume, 
for sequestering of guests.35-37  Moreover, just as in the case of macroscopic crosslinked 
networks originating from linear polymers, the readily adjustable shell crosslinking 
density allows for gating of the transport of those guests into and out of the core domain, 
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while retaining the structural integrity of the SCK nanostructures (Figure 1.1).  SCK 
nanoparticles resemble the naturally-occurring vehicles and are a versatile drug delivery 
system with features including: nanosize scale, core/shell architecture, covalent 
stabilization, stimuli responsiveness, packaging of therapeutic cargos, solubilization of 
hydrophobic payloads and selective cellular uptake when functionalized with targeting 
ligands.38   
 
 
 
 
Figure 1.1.  Schematic representation of the composition of multifunctional shell 
crosslinked knedel-like nanoparticles (SCKs) for drug delivery applications.   
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 With the distinctively different dimensions, compositions and structures of the 
core and shell domains of SCKs, and an ability to modify each independently, probing 
the effects of each is of great interest.  Advances in controlled radical polymerization 
have enabled the fabrication of these nanomaterials with precise control over size, shape, 
morphology, architecture, surface charge and functionalization.  Facile tuning of these 
nanoscale dimensions arose from the ability to control the length of 
hydrophilic/hydrophobic units of the block copolymers that served as the building blocks 
for the nanoparticles.  Probing the drug release effects of the particle dimensions on the 
nanoscale, may be accomplished through the synthesis of block copolymer precursors 
with different block lengths, thereby creating micelles with independently tuned 
core/shell sizes.   
 In Chapter II, in an effort to better understand the effects of the core and shell 
dimensions, and the parameters governing the loading and release of a chemotherapy 
small molecule drug, doxorubicin (DOX), in SCK nanoparticles, we have prepared 
SCKs with retention of the core and shell compositions, while varying the overall 
amphiphilic particle dimensions, including differentiation of the hydrophobic particle 
core size and hydrophilic, ionic shell thickness, independently (Figure 1.2).39  Effects of 
composition were held constant, by employing SCKs constructed from a single type of 
amphiphilic diblock copolymer, poly(acrylic acid)-b-polystyrene (PAA-b-PS), having 
different relative block lengths and absolute chain lengths were synthesized via 
sequential reversible addition-fragmentation chain transfer (RAFT) polymerization 
reactions of t-butyl acrylate (tBA) and styrene, followed by removal of the t-butyl ester 
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protecting groups. A series of four SCK nanoparticle samples, ranging in number-
average hydrodynamic diameter from 14-30 nm, was prepared from four block 
copolymers having different relative block lengths and absolute degrees of 
polymerization.  The ratios of acrylic acid to styrene block lengths ranged from 0.65 to 
3.0, giving SCKs with ratios of shell to core volumes ranging from 0.44 to 2.1.  The 
SCKs were capable of being loaded with 340-2200 DOX molecules per each particle, 
with larger numbers of DOX molecules packaged within the larger core SCKs.  Their 
shell-to-core volume ratio showed impact on the rates and extents of release of DOX, 
with the volume occupied by the poly(acrylic acid) shell relative to the volume occupied 
by the polystyrene core correlating inversely with the diffusion-based release of DOX.  
Higher final extents of release and faster rates of release were observed for all DOX-
loaded particle samples at pH 5.0 vs. pH 7.4, respectively, ca. 60% vs. 40% at 60 h, 
suggesting promise for enhanced delivery within tumors and cells.  As the relative 
proportion of PAA shell to PS core volumes decreased, the rate and extent of release 
increased.  Because these proportions are conveniently tuned by the nature of the block 
copolymer precursor, SCK nanoparticles offer enormous opportunity for the production 
of nanoscopic drug carriers with finely-tuned performance potential.  These studies, 
therefore, point to future directions to craft sophisticated devices for controlled drug 
release.   
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Figure 1.2.  Schematic representation of the interaction between doxorubicin (DOX) 
incorporated into SCKs constructed from poly(acrylic acid)-b-polystyrene (PAA-b-PS).   
 
 
 
 The efficacy of nanoparticle-based drug delivery system is known to be limited 
by physiological barriers that are classified as external barriers (skin, mucus), en route 
barriers (blood, renal clearance, hepatic and splenic clearance, blood brain barriers and 
extracellular matrix), and cellular barriers (cellular uptake, endocytosis, cytoplasm and 
exocytosis).3  Thus, it is crucial to control the size when designing nanoparticles for drug 
deliver applications because it can greatly influence the circulation time, clearance, 
selective tissue distribution and intracellular fate.  Polymeric nanoparticles that are 
within the 20 to 100 nm range are large enough to avoid renal and lymphatic clearance 
and small enough to avoid opsonization, therefore, have the highest potential for in vivo 
applications.  In Chapter III, towards the goal of an enhanced safety profile and 
increased efficacy, paclitaxel was encapsulated in amphiphilic, SCK nanoparticles 
(PTX-SCKs) as a novel drug delivery system (Figure 1.3).  Paclitaxel-loaded SCK 
nanoparticles were synthesized from PAA-b-PS, in which PTX was encapsulated into 
 8 
the SCK nanoparticles through a co-assembly process at various concentration 
formulations.  The in vitro cell killing ability was investigated on two different sizes of 
PTX-loaded SCKs, having core diameters of 20 ± 3 nm or 60 ± 5 nm and overall 
hydrodynamic diameters of 50 ± 15 nm or 120 ± 30 nm, respectively.  Variable 
paclitaxel loading (5 to 20 wt% with respect to polymer weight) was prepared for their in 
vitro cytotoxicity evaluation.  A dual purpose small molecule, pyrazine-based dye, 
served both as the crosslinker and fluorescent tag for visualization of cell internalization 
in KB cells by confocal fluorescence microscopy.  Empty nanoparticles did not show 
any inherent cytotoxicity even at their highest concentration, whereas paclitaxel-loaded 
nanoparticles resulted in IC50 values that were better than free paclitaxel at 2 h 
incubation periods, and approximately equal to free paclitaxel at 72 h continuous 
incubation.  Furthermore, the effects of PEGylation were evaluated for the smaller SCK 
samples.   
 PEGylation and the length and number of poly(ethylene oxide) (PEO) chains per 
nanoparticle have been shown to produce significant differences in blood circulation 
times and elimination in clearance organs for polymer nanoparticles.40  Functionalization 
of the nanoparticle surfaces with PEO (2 kDa PEO, 5 PEO per block copolymer chain) 
did not affect the loading of paclitaxel or cell kill ability.  Separation assays with high 
molecular weight cut-off filters confirmed that the paclitaxel was loaded within the 
nanoparticles and not free in solution.  Thus, successful preparation of PTX-loaded, 
functional nanoparticles with varying sizes and surface characteristics were achieved, 
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and all of which demonstrated cell killing abilities that were comparable to or better than 
free PTX.   
 
 
 
 
Figure 1.3.  Schematic representation of the incorporation of PTX into SCKs and cell 
internalization of PTX-SCKs.   
 
 
 
 Apart from chemotherapy delivery, SCKs are also explored as antimicrobial 
therapeutics for the treatment of Pseudomonas aeruginosa caused lung infections 
associated with cystic fibrosis (CF).  In Chapter IV, SCK constructed from self assembly 
of PAA-b-PS was able to encapsulate hydrophobic silver carbene complexes (SCC) into 
the hydrophobic polystyrene domain and complex silver cation to the acrylic acid 
residues on the shell of the nanoparticles (Figure 1.4).  The incorporated silver 
concentration was determined by inductively coupled plasma mass spectrometry (ICP-
MS) and the location of the silver specie are revealed by high resolution scanning 
transmission electron microscopy (STEM) coupled with energy dispersive X-ray 
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spectroscopy (EDX).  The therapeutic efficacy of the silver-loaded SCKs is investigated 
in vivo through nebulization treatment in P. aeruginosa infected mice.   
 
 
 
 
Figure 1.4.  Schematic and chemical representation of a shell crosslinked nanoparticle 
assembled from poly(acrylic acid)-b-polystyrene loaded with silver carbene complexes 
in the core and silver cation in the shell.   
 
 
 
 SCKs as antimicrobial therapeutics can also be used as treatment of urinary tract 
infections (UTI) caused by uropathogenic strains of Escherichia coli (UPEC).  UPEC is 
able to attach to superficial bladder epithelial cells, mediated by an adhesin protein, 
FimHA.  In Chapter V, we have developed nanoparticle carriers that bind and enter 
bladder epithelial cells to deliver antimicrobial agents directly to the niche occupied by 
these harbored bacteria by emulating the bacterial mode of invasion.  In this study, we 
have designed SCKs that can be conjugated with FimHA for bladder epithelial cell 
binding and internalization, for the purpose of targeted delivery of various antimicrobial 
agents for the treatment and prevention of UTIs.  The acrylic acid residues on the 
 11 
surfaces and throughout the shell layers of the SCKs were utilized for amidation with 
native lysines of FimHA to conjugate the adhesin and promote epithelial cell targeting 
and internalization, and with the amine terminus of the fluorescein-based dye, 5-((5-
aminopentyl)thioureidyl)fluorescein (FITC cadaverine) to permit fluorescence 
microscopic imaging.  By fluorescence microscopy the association of SCKs with the cell 
surfaces was shown to be dose dependent, FimHA specific, and inhibited by addition of 
mannose to the medium (Figure 1.5).   
 
 
 
 
Figure 1.5.  Schematic representation of a shell crosslinked nanoparticle functionalized 
with FimHA adhesin protein and confocal microscopy of the FimHA-SCKs being 
internalized into bladder epithelial cells.   
 
 
 
We have investigated parameters including size, surface chemistry, conjugation 
chemistry as well as different therapeutic cargos of spherical nanoparticles constructed 
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from a simple diblock copolymer PAA-b-PS as drug delivery system.  Chapter VI 
discusses the versatile morphologies to which a triblock copolymer can access.  Building 
upon our understanding of drug gating properties, hydrophilic/hydrophobic drug 
encapsulation and release and bioconjugation, these complex nanoscale structures can 
further be utilized towards construction of next generation therapeutic material.  The 
construction of both cylindrical and multicompartment nanostructure with a single type 
of linear triblock copolymer of PEO45-b-PNAS66-b-PS30 was achieved, and their 
assembly and disassembly processes were studied.   
 In Chapter VII, we have combined everything we have investigated in the 
previous chapters, including size, surface chemistry, conjugation of targeting ligands 
into an all-in-one system to produce the multifunctional SCK nanoparticles.  
Multifunctional SCKs were constructed from amphiphilic block copolymer to achieve 
coincident imaging and treatment of diseases through functionalization with 
polyethylene glycol (PEG) to inhibit surface protein adsorption, chromophores for 
imaging and tracking, and angiogenesis marker targeting ligands, F3 peptide, for active 
targeting and then finally loaded with DOX, to accomplish in vivo delivery of DOX for 
the treatment of brain cancer.  The SCKs originated from the amphiphilic block 
copolymer, PAA-b-PS that were pre-functionalized with a total number of 5 PEGs:  ca. 
two and a half 2-kDa methoxy-terminated PEG chains (PEG2k) and two and a half 3-kDa 
mono-Boc-protected diamino PEGs (PEG3k) per polymer chain, in order to extend the 
blood circulation time and introduce sites for surface conjugation of F3 targeting ligands.  
Removal of the Boc group allowed for PEG3k chain ends to undergo amidation reactions 
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with N-succinimidyl-S-acetylthiopropionate to introduce an acetyl-protected thiol at the 
end of the PEG3k graft.  Following self assembly of the block copolymer into micelles 
and subsequent crosslinking, the SCKs were further functionalized within the PAA shell 
layer with cascade blue immunofluorescence dye to allow for ex vivo visualization of the 
nanoparticles by antibody binding of histological tissue slices.  The acetyl-protected 
thiol bearing SCKs were deprotected to reveal the thiol functionality and reacted with a 
maleimide-functionalized targeting ligand, F3 peptide.  The cascade blue-labeled, F3 
peptide-conjugated SCKs were then loaded with DOX through physical encapsulation 
and evaluated for their cytotoxicity against U87MG glioma cells in vitro.  SCKs 
demonstrated IC50 values that were comparable to free DOX.  Contrary to untargeted 
SCKs, which showed accumulation to perinuclear regions of U87MG glioma cells in 
vitro and systemic distribution throughout the heart, kidney and liver in vivo; F3 peptide-
conjugated SCKs were able to achieve nuclear localization of the doxorubicin in vitro 
and enhanced uptake into U87MG intracranial xenografts in vivo.   
 In summary, the scope of this dissertation is focused on the design and 
development of polymeric nanoparticles for their application in biomedical and 
nanomedicine field.  Fundamental parameters of the nanoparticles, including size, 
surface chemistry, chemical modification techniques and morphology evolution are 
investigated.  It is anticipated that those fundamental studies will have great impact on 
the development of next generation nanomaterials in therapeutic delivery applications.   
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CHAPTER II 
 
TUNING CORE VS. SHELL DIMENSIONS TO ADJUST THE PERFORMANCE OF 
NANOSCOPIC CONTAINERS FOR THE LOADING AND RELEASE OF 
DOXORUBICIN* 
 
2.1.  Introduction 
Synthetic materials that are capable of sequestering, containing and releasing 
biologically-active agents have been of great interest for many years, as drugs and drug 
delivery systems.  Inspiration for the designs of such materials comes from a variety of  
microparticles for, ideally, irreversible sequestration of bile acids or phosphates has led 
to the development of polymer drugs for lowering of serum cholesterol (e.g. WelChol®) 
or phosphate levels (e.g. Renagel®), respectively.  Most often, however, synthetic 
materials are expected to retain their guests for a limited period of time and then allow 
for their release at controlled rates and under predetermined conditions.  Such situations 
sources.  For instance, the translation of polymeric ion-exchange resins into demand 
higher degrees of engineering complexity with respect to the synthetic material structure, 
composition, and morphology.   
 
____________ 
*Reprinted with permission from Lily Yun Lin, Nam S. Lee, Jiahua Zhu, Andreas M. 
Nyström, Darrin J. Pochan, Richard B. Dorshow and Karen L. Wooley, J. Controlled 
Release, 2011, 152, 37-48, Copyright 2012 Elsevier. 
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 Nature has often provided the concepts and templates from which simple 
structures can be fabricated to provide sophisticated performances as hosts for packaging 
and releasing therapeutic guests.4  For instance, viruses and lipoproteins are stealthy, 
naturally-occurring vehicles for targeted delivery of nucleic acids and cholesterol esters, 
respectively.  Both viruses and lipoproteins feature architectural characteristics that 
would be favorable for a drug delivery system, such as:  1) nanoscopic dimensions to 
protect guest molecules having limited stability from their surroundings; 2) availability 
and accessibility of targeting moieties on the surface to achieve localized delivery; 3) 
robust and stealth structural integrity.6,7,18  Although the synthetic and biological 
processes for tailoring of such natural vehicles have witnessed significant advance,8-15  
synthetic materials provide unique opportunities, including versatility of structure and 
composition, facile engineering, variation of parameters, control of stability vs. 
degradability, and avoidance of potential immunological effects.16   
 Polymer micelles, assembled from amphiphilic block copolymers, which mimic 
biological entities have been investigated for a number of potential applications that take 
advantage of their core-shell morphology and tunable surface chemistry.5,17-22  The core-
shell architecture enables the polymer micelle to incorporate hydrophobic drugs into the 
core domain that serves as a non-aqueous reservoir via either physical entrapment or 
covalent linkages, thereby increasing the solubility and stability of the hydrophobic 
drugs under physiological conditions.  The shell domain, in turn, can protect the drug 
from its surroundings, modulating the pharmacokinetics and disposition of the carrier, 
and allowing manipulation over the surface chemistry.23  However, micelles can only 
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maintain their morphological integrities at concentrations above the critical micelle 
concentration (CMC) and are dynamic systems, potentially limiting their use as 
injectable drug carriers.  Structural reorganization of the micellar structure will then 
result in dissociation of the therapeutic cargo and loss of sustained/controlled delivery.  
In addition, the polymeric assembly is subjected to change upon altering parameters in 
the surrounding environment, e.g., ionic strength, pH, etc.24-27  Such factors have been 
used as a trigger for controlled release in specific tissue, such as in acidic tumor 
environments.41  Block copolymer micellar assemblies have also taken advantage of 
hydrolytically-degradable polymer segments to mediate their controlled release 
performances, such as those derived from lactide and/or glycolide, for which a rich 
literature describes extensive study of their physical, chemical and biological properties 
in their utilization as platforms for drug packaging and release.42-49  Most recently, Park 
and co-workers reported successful preparation of monodisperse microparticles arising 
from biodegradable poly(lactic-co-glycolic acid) through a top-down hydrogel template 
strategy--a unique nanofabrication method that allowed for control over the dimensions 
of these microparticles.  Through release studies of various drug molecules, including 
progesterone, felodipine, risperidone and paclitaxel, the authors investigated the impact 
of size and shape on the drug release kinetics.50  Probing the drug release effects of the 
particle dimensions on the nanoscale, may be accomplished through the synthesis of 
block copolymer precursors with different block lengths, thereby creating micelles with 
independently tuned core/shell sizes.   
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 To overcome the limitations that the CMC of micelles poses on intravenous-type 
drug carriers,28-31 our research group and others have explored crosslinked micellar 
constructs, such as shell crosslinked knedel-like nanoparticles (SCKs), that combine the 
amphiphilic core-shell morphology of polymer micelles with stabilizing crosslinkers 
isolated throughout the peripheral shell layer.  Due to the regioselective crosslinks in the 
peripheral shell region, these nanoscale assemblies can be diluted without disassembly, 
and have increased dimensional stability compared to their non-crosslinked micellar 
counterparts.4,32-34  The core of the SCKs can retain its host capabilities, because the lack 
of crosslinks in the core region maintains chain mobility and access to the core volume, 
for sequestering of guests.35-37  Moreover, just as in the case of macroscopic crosslinked 
networks originating from linear polymers,51 the readily adjustable shell crosslinking 
density allows for gating of the transport of those guests into and out of the core domain, 
while retaining the structural integrity of the SCK nanostructures.52  With the 
distinctively different dimensions, compositions and structures of the core and shell 
domains of SCKs, and an ability to modify each independently, probing the effects of 
each is of great interest. 
 In our recent work, we have investigated the effects of the chemical composition 
and thermal characteristics of the hydrophobic core polymer material for the loading and 
release of doxorubicin (DOX),53 a widely used chemotherapy drug for first line 
treatment of metastatic breast cancer, as well as other therapeutic regimes.  The two 
classes of SCKs used in our previous study were constructed from poly(acrylic acid)-
based (PAA) amphiphilic diblock copolymers with either glassy amorphous polystyrene 
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(PS) block segment, possessing a high glass transition temperature (Tg), or 
semicrystalline poly(octadecyl acrylate-co-decyl acrylate) (P(ODA-co-DA)), possessing 
a low Tg and a crystalline melting temperature (Tm).  The Tm of the P(ODA-co-DA) core 
domains could be tuned to be either below or above physiological temperature.54  It was 
demonstrated that the SCKs containing core material with higher Tg and Tm values 
retained DOX to higher loading extents and resulted in slower release rates.  However, 
the release profiles were similar, which suggested that the release behavior of these two 
classes of SCKs was governed predominantly by the core-shell morphology of these 
nanoparticles and was less dependent upon the core composition.53  In this current study, 
we probed effects of the core and shell dimensions, independently, on the loading and 
release of small molecule guests.  Effects of composition were held constant, by 
employing SCKs constructed from a single type of amphiphilic diblock copolymer, 
poly(acrylic acid)-b-polystyrene (PAA-b-PS), and using DOX as a model 
chemotherapeutic compound. 
 
2.2.  Materials and methods  
2.2.1.  Materials 
 All chemicals were purchased from Aldrich Chemical Co. (St. Louis, MO) and 
used without further purification unless otherwise noted.  Slide-A-Lyzer dialysis 
cassettes (10 kDa molecular weight cut-off, MWCO) were purchased from Pierce 
Biotech. (Rockford, IL).  Amicon® ultra centrifugal filter devices (30 kDa MWCO) 
were purchased from Millipore Corp. (Bedford, MA).  The Supor 25 mm 0.1 µm 
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Spectra/Por Membrane tubes (MWCO 6-8 kDa), used for dialysis, were purchased from 
Spectrum Medical Industries Inc.  Nanopure water (18 MΩ·cm) was acquired by means 
of a Milli-Q water filtration system, Millipore Corp. (Bedford, MA).   
2.2.2.  Instruments 
 1H NMR and 13C NMR spectra were collected on a Varian Mercury 300 
spectrometer, using the residual solvent signal as internal standard.  Infrared spectra 
were acquired on an IR Prestige 21 instrument from Shimadzu Corporation (Columbia, 
MD).  UV-Vis spectra were collected at 37 °C in the region of 200 - 800 nm, using a 
Varian Cary 100 Bio UV-visible spectrophotometer.  The molar extinction coefficient 
(ε) of doxorubicin (ε = 13050 M-1cm-1 at 488 nm) was determined by a calibration curve 
in DMF/PBS, 4:1.  The DOX concentrations in the nanoparticles were determined by 
UV-vis spectroscopy measured directly in the aqueous DOX-nanoparticle solution 
aliquots as a function of time.  
 Gel permeation chromatography was performed on a Waters Chromatography, 
Inc., 1515 isocratic HPLC pump equipped with an inline degasser, a model PD2020 
dual-angle , light scattering detector (Precision Detectors, Inc.), a model 2414 
differential refractometer (Waters, Inc.), and four PLgel polystyrene-co-divinylbenzene 
gel columns (Polymer Laboratories, Inc.) connected in series:  5 µm Guard (50 × 7.5 
mm), 5 µm Mixed C (300 × 7.5 mm), 5 µm 104 (300 × 7.5 mm), and 5 µm 500 Å (300 × 
7.5 mm) using the Breeze (version 3.30, Waters, Inc.) software.  The instrument was 
operated at 35 °C with THF as eluent (flow rate set to 1.0 mL/min).  Polymer solutions 
were prepared at a known concentration (ca. 3 mg/mL) and an injection volume of 200 
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µL was used.  Data collection was performed with Precision Acquire 32 Acquisition 
program (Precision Detectors, Inc.) and analyses were carried out using Discovery32 
software (Precision Detectors, Inc.) with a system calibration curve generated from 
plotting molecular weight as a function of retention time for a series of broad 
polydispersity poly(styrene) standards.   
 Glass transition temperatures (Tg) were measured by differential scanning 
calorimetry on a Mettler-Toledo DSC822® (Mettler-Toledo, Inc., Columbus, OH), with a 
heating rate of 10 °C/min.  Measurements were analyzed using Mettler-Toledo Stare v. 
7.01 software.  The Tg was taken as the midpoint of the inflection tangent, upon the third 
heating scan.  Thermogravimetric analysis was performed under N2 atmosphere using a 
Mettler-Toledo model TGA/SDTA851e, with a heating rate of 5 °C/min.  Measurements 
were analyzed using Mettler-Toledo Stare v. 7.01 software.   
 Dynamic light scattering measurements were conducted with a Brookhaven 
Instruments, Co. (Holtsville, NY) DLS system equipped with a model BI-200SM 
goniometer, BI-9000AT digital correlator, and a model EMI-9865 photomultiplier, and a 
model Innova 300 Ar ion laser operated at 514.5 nm (Coherent Inc., Santa Clara, CA).  
Measurements were made at 25 ± 1 °C.  Prior to analysis, solutions were filtered through 
a 0.45 μm Millex®-GV PVDF membrane filter (Millipore Corp., Medford, MA) to 
remove dust particles.  Scattered light was collected at a fixed angle of 90 °.  The digital 
correlator was operated with 522 ratio spaced channels, and initial delay of 5 μs, a final 
delay of 50 ms, and a duration of 8 minutes.  A photomultiplier aperture of 400 μm was 
used, and the incident laser intensity was adjusted to obtain a photon counting of 
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between, 200 and 300 kcps.  The calculations of the particle size distributions and 
distribution averages were performed with the ISDA software package (Brookhaven 
Instruments Company), which employed single-exponential fitting, Cumulants analysis, 
and CONTIN particle size distribution analysis routines.  All determinations were 
average values from ten measurements.  
 Transmission electron microscopy (TEM) bright-field imaging was conducted on 
a Hitachi H-7500 microscope, operating at 80 kV.  The samples were prepared as 
follows:  4 μL of the dilute solution (with a polymer concentration of ca. 0.2 - 0.5 
mg/mL) was deposited onto a carbon-coated copper grid, which was pre-treated with 
absolute ethanol to increase the surface hydrophilicity.  After 5 min, the excess of the 
solution was quickly wicked away by a piece of filter paper.  The samples were then 
negatively stained with 4 μL of 1 wt% phosphotungstic acid (PTA) aqueous solution.  
After 1 min, the excess PTA solution was quickly wicked away by a piece of filter paper 
and the samples were left to dry under ambient conditions overnight. 
 Small angle neutron scattering (SANS) experiments were performed on the 30m 
instrument (NG-3) at the NIST Center for Neutron Research (NCNR), National Institute 
of Standards and Technology (NIST).  A series of fresh SCK samples was prepared in 
D2O for the SANS studies.  Each block copolymer as a powder (2 mg) was dissolved in 
DMF-d7 (2 mL) and an equal amount of D2O was added dropwise.  Then the solution 
was dialyzed against D2O for two days (which brought the volume up to ca. 8 mL).  The 
micelle solutions were crosslinked with 2,2´-(ethylenedioxy)bis(ethylamine) (EDDA) 
crosslinker (dissolved in D2O) and then the SCK nanoparticle solutions were dialyzed 
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against D2O.  The final concentrations of the SCKs in D2O were ca. 0.25 mg/mL.  
Samples were loaded in titanium sample cells with 30 mm diameter quartz windows at a 
2 mm path distance.  Monochromatic neutrons at λ= 6Å and a wavelength spread (Δλ/λ) 
of 0.14 were incident on the sample.  The scattered neutrons were captured by a 64 cm × 
64 cm 2D detector.  Sample-to-detector distances were applied at 1.33, 4.50, and 13.17 
m to cover a large scattering wavevector Q range (0.004 < Q <0.4 Å-1), defined by Q = 
(4π/λ) sin(θ/2), where λ is the neutron wavelength and θ is the scattering angle.  Sample 
data were corrected for background and empty cell scattering.  The scattering length 
densities (Å-1) used for PAA, PAA and EDDA, PS, and D2O are 1.39e-6, 5.82e-6, 1.41e-6 
and 6.31e-6, respectively.  Intensities were normalized to an absolute scale using main 
beam transmission measurements and were reduced according to published protocol.55  
The related densities were calculated to compare the differences between the corona of 
the four samples, and are unitless ratios. 
2.2.3.  Synthesis of block copolymers and preparation of nanoparticles 
General procedure of preparation of poly(tert-butyl acrylate), PtBA, 2 - 3:  A flame-
dried 100-mL Schlenk flask equipped with a magnetic stir bar was charged with 
DDMAT (S-dodecyl-S′-(α,α′-dimethyl-α″-acetic acid) trithiocarbonate, 1, 1 eq.), t-BA 
(70 - 200 eq.), azobisisobutyronitrile (AIBN) (0.05 eq.), and 2-butanone (10 - 20 mL).  
The flask was sealed with a rubber septum and allowed to stir for 10 min at room 
temperature to ensure homogeneous mixing.  The reaction mixture was degassed by 
several freeze-pump-thaw cycles (> 3), after which the flask was allowed to return to 
room temperature and was allowed to stir for an additional 10 min.  The flask was then 
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immersed into a pre-heated oil bath at 60 °C to start the polymerization.  The 
polymerization was monitored by analyzing aliquots collected at pre-determined times 
by 1H-NMR spectroscopy.  As the expected monomer conversion was reached, after ca. 
3 - 6 h depending on desired block chain lengths, the polymerization was quenched by 
quick immersion of the reaction flask into liquid N2 and opening to air.  THF (20 mL) 
was added to the reaction flask and the polymer was purified by precipitation into 2 L of 
a methanol/ice mixture three times.  The precipitants were collected and dried under 
vacuum overnight to afford 2 and 3 as a yellow powder.  IR (KBr):  3000-2900, 1723, 
1446, 1366, 1248, 1124, 843, 754 cm-1.  1H NMR (CDCl3):  δ 0 . 8 5  (t,  J = 5  Hz,  
CH3CH2-), 1.19 - 1.90 (br, -CHCH2- of the polymer backbone, alkyl chain of initiator, 
and HOOCC(CH3)2-), 1.28 - 1.63 (br, CH3C), 2.17 - 2.41 (br, -CHCH2- of the polymer 
backbone), 3.22 - 3.36 (br, -SCSCH2-), 4.58 - 4.78 (br, -CH2CHS) ppm.  13C NMR 
(CDCl3):  δ 28.1, 32.1 - 37.3, 40.1 - 42.6, 80.4 - 80.6, 172.3 - 174.1 ppm.   
PtBA52, 2:  A total of 10.2 g (60% yield, 80% conversion) of the polymer was isolated.  
MnNMR = 7100 Da, MnGPC(RI) = 7500 Da, PDI = 1.07, (Tg) = 50 °C, TGA in N2: 230-245 
°C, 40% mass loss; 245-450 °C, 55% mass loss.   
PtBA120, 3:  A total of 12.6 g (70% yield, 67% conversion) of the polymer was isolated.  
MnNMR = 15700 Da, MnGPC(RI) = 16700 Da, PDI = 1.04, (Tg) = 51 °C, TGA in N2: 230-
250 °C, 45% mass loss; 245-450 °C, 50% mass loss.   
General procedure for preparation of poly(acrylic acid)-b-polystyrene (PtBA-b-PS) 
by chain extension of PtBA with styrene, 4 - 7:  To a flame-dried 50 mL Schlenk flask 
equipped with a magnetic stir bar, PtBA (1 eq.), styrene (200 - 400 eq. based on desired 
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polymer chains), AIBN (0.05 eq.) and 1, 4-dioxane (5 - 10 mL) were added.  The flask 
was sealed with a rubber septum and allowed to stir for 10 min.  The reaction mixture 
was then degassed by several freeze-pump-thaw cycles (>3).  After allowing the flask to 
return to room temperature, it was allowed to stir in a pre-heated oil bath at 60 °C to start 
the polymerization.  The polymerization was monitored by analysis of aliquots taken at 
various times by 1H NMR spectroscopy.  The polymerization was quenched at ca. 10 - 
70 h (depending on desired block chain lengths) by immersing the flask in liquid 
nitrogen and opening to air.  The reaction mixture was dissolved in THF (5 mL) and 
precipitated into methanol/water (5:1) mixture twice to yield a fine yellow powdery 
product, 4 - 7.  The product was collected and dried under vacuum overnight.  IR:  3100-
2900, 1729, 1447, 1372, 1243, 1148, 849, 829, 760 cm-1.  1H NMR (CDCl3):  δ 0.83 (t, J 
= 5 Hz, CH3CH2-), 1.20 - 1.80 (br, –CHCH2– of the polymer backbone, alkyl chain of 
initiator, and HOOCC(CH3)2–), 1.30 - 1.61 (br, CH3C), 2.18 - 2.27 (br,–CHCH2– of the 
polymer backbone), 3.38 - 3.44 (br, –SCSCH2–), 5.22 - 5.68 (br, –CH2CHS), 6.65 - 7.21 
(br, Ar–H) ppm.  13C NMR (CDCl3):  δ 28.2, 35.1 - 36.3, 39.5 - 41.6, 80.3, 127.9 - 
128.9, 140.3, 170.2 - 173.4 ppm. 
PtBA52-b-PS80, 4:  MnNMR = 15,500 Da, MnGPC(RI) = 14,300 Da, PDI = 1.2, (Tg)PtBA = 48 
°C, (Tg)PS = 104 °C, TGA in N2: 225-260 °C, 35% mass loss; 260-450 °C, 50% mass 
loss.  10% mass remaining above 450 °C.  Compound 4 was prepared from PtBA52, 2 
(2.0 g, 0.3 mmol).  The polymerization was carried out for 10 h before precipitation to 
afford the final product (0.50 g, 70% yield, 25% conversion). 
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PtBA120-b-PS100, 5:  MnNMR = 26,100 Da, MnGPC(RI) = 22,500 Da, PDI = 1.1, (Tg)PtBA = 50 
°C, (Tg)PS = 106 °C, TGA in N2: 225-260 °C, 25% mass loss; 260-450 °C, 65% mass 
loss.  10% mass remaining above 450 °C.  Compound 5 was prepared from PtBA120, 3 
(1.01 g, 0.064 mmol).  The polymerization was carried out for 18 h before precipitation 
to afford the final product (0.67 g, 80% yield, 50% conversion). 
PtBA52-b-PS30, 6:  MnNMR = 10,200 Da, MnGPC(RI) = 8,400 Da, PDI = 1.1, (Tg)PtBA = 48 
°C, (Tg)PS = 105 °C, TGA in N2: 230-255 °C, 30% mass loss; 255-450 °C, 60% mass 
loss.  10% mass remaining above 450 °C.  Compound 6 was prepared from PtBA52, 2 
(2.01 g, 0.13 mmol).  The polymerization was carried out for 70 h before precipitation to 
afford the final product (2.5 g, 97% yield, 25% conversion). 
PtBA120-b-PS40, 7:  MnNMR = 19,900 Da, MnGPC(RI) = 17,200 Da, PDI = 1.2, (Tg)PtBA = 47 
°C, (Tg)PS = 105 °C, TGA in N2: 225-260 °C, 34% mass loss; 260-450 °C, 56% mass 
loss.  10% mass remaining above 450 °C.  Compound 7 was prepared from PtBA120, 3 
(2.5 g, 0.16 mmol).  The polymerization was carried out for 15 h before precipitation to 
afford the final product (0.60 g, 85% yield, 10% conversion). 
General procedure of preparation of PAAm-b-PSn, 8 - 11:  A flame-dried 25 mL 
round bottom flask equipped with a magnetic stir bar was charged with PtBA-b-PS 5 
(0.50 g - 1.50 g), and 15 mL of dichloromethane.  Trifluoroacetic acid (TFA, 10 mL) 
was added to the stirring solution and the reaction was allowed to stir over night at room 
temperature, after which the solvent was removed under vacuum.  The crude product 
was resuspended in 10 mL of THF and transferred to a pre-soaked dialysis tubing 
(MWCO ca. 6 - 8 kDa), and dialyzed against nanopure water for 4 days, to remove all of 
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the impurities.  The solution was then lyophilized to yield the resulting yellowish solid 
of PAAm-b-PSn, 8 - 11.  IR:  3700-2400, 1710, 1554, 1447, 1410, 1240, 1170, 1061, 
1025, 798, 790 cm-1.  1H NMR (CDCl3):  δ 0.85 (t, J = 5 Hz, CH3CH2-), 1.36 - 2.46 (br,–
CHCH2– of the polymer backbone), 3.42 - 3.83 (br, –SCSCH2–), 5.65 - 5.87 (br, –
CH2CHS), 6.65 - 7.21 (br, Ar–H) ppm, 11.3 - 13.8 (br, COOH).  13C NMR (CDCl3):  δ 
35.4 - 36.6, 42.5 - 45.6, 127.9 - 128.9, 140.1, 175.2 ppm.   
PAA52-b-PS80, 8:  MnNMR = 12,500 Da, (Tg)PAA = 127 °C, (Tg)PS = 106 °C, TGA in N2: 
200-300 °C, 15% mass loss; 300-450 °C, 70% mass loss.  10% mass remaining above 
450 °C.  8 was prepared from PtBA120-b-PS100, 4 (0.63 g, 0.040 mmol).  A total of 0.58 
g of 8 was produced (85% yield). 
PAA120-b-PS100, 9:  MnNMR = 19,500 Da, (Tg)PAA = 127 °C, (Tg)PS = 103 °C, TGA in N2: 
200-300 °C, 18% mass loss; 300-450 °C, 72% mass loss.  9 was prepared from PtBA120-
b-PS100, 5 (1.51 g, 0.048 mmol).  A total of 1.07 g of 9 was produced (95% yield).   
PAA52-b-PS30, 10:  MnNMR = 7,400 Da, (Tg)PAA = 130 °C, (Tg)PS = 101 °C, TGA in N2: 
200-290 °C, 17% mass loss; 290-450 °C, 74% mass loss.  10 was prepared from 
PtBA120-b-PS100, 6 (1.49 g, 0.15 mmol).  A total of 0.97 g of 10 was produced (89% 
yield). 
PAA120-b-PS40, 11:  MnNMR = 13,200 Da, (Tg)PAA = 127 °C, (Tg)PS = 99 °C, TGA in N2: 
210-300 °C, 23% mass loss; 300-450 °C, 67% mass loss.  11 was prepared from 
PtBA120-b-PS100, 7 (0.54 g, 0.025 mmol).  A total of 0.44 g of 11 was produced (90% 
yield). 
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General procedure for micellization and crosslinking (50% crosslinked) of PAA-b-
PS to form SCKs, 12 - 15:  PAA-b-PS (ca. 50 mg) polymers were dissolved in DMF 
(50 mL) in a 250 mL round bottom flask and allowed to stir for 30 min at room 
temperature.  To this solution, an equal volume of nanopure water was added dropwise 
via a syringe pump over a period of 3 h.  The reaction mixture was allowed to stir for 
additional 24 h at room temperature and dialyzed against nanopure water for 4 days in a 
presoaked dialysis tubing (MWCO ca. 6 - 8 kDa) to afford a micelle solution with a final 
polymer concentration of ca. 0.25 mg/mL.  To the micelle solution of PAAm-b-PSn was 
added a solution of EDDA in nanopure water (ca. 0.007 g/mL, 1.1 eq, nominal 50% 
crosslinking) dropwise via a syringe pump over a period of 2 h.  To this solution, 1-[3´-
(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide (EDCI) in nanopure water 
(0.011 g/mL, 1.4 eq) was added dropwise via a syringe pump over 20 min and the 
resulting mixture was allowed to stir overnight before dialysis against nanopure water 
for 4 days in presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) to afford SCK solutions 
12 – 15 with a final polymer concentration of ca. 0.25 mg/mL. 
SCK of PAA52-b-PS80, 12:  To a stock solution of PAA52-b-PS80 aqueous micellar 
solution (~0.25 mg/mL, 30 mL) prepared from 8 (0.020 g, 1.6 µmol), was added a 
solution of EDDA in nanopure water (175 µL, 8.3 µmol, 1.1 eq., calculated based on 
50% of number of poly(acrylic acid) units).  The mixture was allowed to stir for 2 h at 
room temperature before a solution of EDCI in nanopure water (21 µL, 0.8 µmol, 1.4 
eq.) was added.  The reaction mixture was stirred for 24 h at room temperature and then 
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transferred to a dialysis tube and dialyzed against nanopure water for 3 days.  The 
resulting SCK solution had a concentration of 0.24 mg/mL.   
SCK of PAA120-b-PS100, 13:  To a stock solution of PAA120-b-PS100 aqueous micellar 
solution (~0.25 mg/mL, 30 mL) prepared from 9 (0.02 g, 0.98 µmol), was added a 
solution of EDDA in nanopure water (256 µL, 0.01 mmol, 1.1 eq., calculated based on 
50% of number of poly(acrylic acid) units).  The mixture was allowed to stir for 2 h at 
room temperature before a solution of EDCI in nanopure water (14 µL, 0.5 µmol, 1.4 
eq.) was added.  The reaction mixture was stirred for 24 h at room temperature and then 
transferred to a dialysis tube and dialyzed against nanopure water for 3 days.  The 
resulting SCK solution had a concentration of 0.24 mg/mL.  
SCK of PAA52-b-PS30, 14:  To a stock solution of PAA52-b-PS30 aqueous micellar 
solution (~0.25 mg/mL, 30 mL) prepared from 10 (0.02 g, 2.6 µmol), was added a 
solution of EDDA in nanopure water (290 µL, 0.01 mmol, 1.1 eq., calculated based on 
50% of number of poly(acrylic acid) units).  The mixture was allowed to stir for 2 h at 
room temperature before a solution of EDCI in nanopure water (36 µL, 1.4 µmol, 1.4 
eq.) was added.  The reaction mixture was stirred for 24 h at room temperature and then 
transferred to a dialysis tube and dialyzed against nanopure water for 3 days.  The 
resulting SCK solution had a concentration of 0.25 mg/mL.   
SCK of PAA120-b-PS40, 15:  To a stock solution of PAA120-b-PS40 aqueous micellar 
solution (~0.25 mg/mL, 30 mL) prepared from 11 (0.02 mg, 1.5 µmol), was added a 
solution of EDDA in nanopure water (387 µL, 0.02 mmol, 1.1 eq., calculated based on 
50% of number of poly(acrylic acid) units).  The mixture was allowed to stir for 2 h at 
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room temperature before a solution of EDCI in nanopure water (21 µL, 0.8 µmol, 1.4 
eq.) was added.  The reaction mixture was stirred for 24 h at room temperature and then 
transferred to a dialysis tube and dialyzed against nanopure water for 3 days.  The 
resulting SCK solution had a concentration of 0.25 mg/mL.   
2.2.4.  DOX loading and release studies 
General procedure for DOX loading experiments into PAA-b-PS SCK 
nanoparticles:  To a vial containing a magnetic stir bar and SCK solution (10 mL, 
polymer concentration ~ 0.25 mg/mL), a solution of doxorubicin (2.273 mg/mL in DMF 
and 3 eq of triethylamine, 50 wt% with respect to the SCK) was added.  The solution 
was shielded from light and stirred over night before being transferred to a centrifugal 
filter device (Amicon Ultra 4, 100 kDa MWCO, Millipore corp., Billerica MA, USA) 
and washed extensively with 5 mM pH 7.4 PBS at 37 °C to remove free DOX.  The 
filtrate was analyzed by UV-Vis spectroscopy to confirm the removal of free DOX after 
several washing cycles.  The DOX-nanoparticle solution was then reconstituted to a final 
volume of 5 mL with 5 mM pH 7.4 PBS buffer. The amount of incorporated DOX was 
determined by UV-Vis spectroscopy (488 nm, ε = 13050 M-1cm-1 determined by a 
calibration curve in a 4:1 v/v mixture of DMF and DOX-SCK solution in PBS) . 
DOX-SCK 16:  Prepared from 12.  The final volume of the DOX-SCK 16 was 9.99 mL 
with a DOX concentration of 0.054 mg/mL (22 wt%).   
DOX-SCK 17:  Prepared from 13.  The final volume of the DOX-SCK 17 was 10.00 
mL with a DOX concentration of 0.060 mg/mL (20 wt%). 
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DOX-SCK 18:  Prepared from 14.  The final volume of the DOX-SCK 18 was 10.01 
mL with a DOX concentration of 0.043 mg/mL (16 wt%). 
DOX-SCK 19:  Prepared from 15.  The final volume of the DOX-SCK 19 was 10.01 
mL with a DOX concentration of 0.047 mg/mL (18 wt%). 
General procedure for DOX release experiments:  Each DOX-SCK solution was 
partitioned into two parts of 5 mL each and transferred to a presoaked dialysis cassette 
(Slide-A-Lyzer, 10 kDa MWCO, Pierce Biotechnology, Rockford IL).  The cassette was 
allowed to stir in a beaker containing 4 L of 5 mM PBS at pH 7.4 and 37 °C for a period 
of 48 h.  Another 5 mL of DOX-nanoparticle solution was also transferred to a 
presoaked dialysis cassette and allowed to stir in a beaker containing 4 L of 5 mM PBS 
at pH 5.0 and 37 °C for a period of 60 h.  Samples (~1.5 mL) were removed from the 
cassette at 1, 2, 3, 4, 6, 9, 12, 18, 24, 30, 40, 50, and 60 h, and quickly analyzed by UV-
Vis spectroscopy (488 nm) and injected back into the dialysis cassette.   
 
2.3.  Results and discussion 
 In our previous study, we investigated the effects of the core material within 
SCK nanoparticles (amorphous PS vs. semicrystalline P(DA-co-ODA)) on the loading 
and release of DOX.  It was found that both of these two classes of SCKs were capable 
of sequestering sufficient amounts of DOX in the interior of the nanoparticle, due to the 
favorable ionic and hydrophobic interactions.  For the PS core SCKs, a relatively higher 
loading capacity was observed, which could be attributed to π-π stacking interactions 
between the aromatic ring moieties of styrene and DOX molecules.  In an effort to better 
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understand the parameters governing the loading and release of guest molecules in SCK 
nanoparticles, we herein present a more comprehensive study on SCKs with retention of 
the core and shell compositions, PS and PAA, respectively, while varying the overall 
amphiphilic particle dimensions, including differentiation of the hydrophobic particle 
core size and hydrophilic, ionic shell thickness, independently.   
The dimensions of block copolymer micelles are known to be controlled by the 
relative and overall volumes occupied by the hydrophilic and hydrophobic polymer 
chain segments, which are determined by their chain lengths and chemical compositions.  
A series of SCK nanoparticles was produced from covalent crosslinking of 
corresponding block copolymer micelles, and therefore, the dimensions of SCKs could 
be tuned by varying their block copolymer constituents.  Block copolymers were 
designed to have predominantly hydrophilic or hydrophobic block segments, with 
sufficient structural differences, to provide measurable changes for the core diameter 
and/or shell thickness of the resulting nanostructures.  These structural discrepancies 
could further affect the loading and release profiles for molecular cargo.   
Four PAA-b-PS block copolymers having different relative block lengths and 
absolute chain lengths were synthesized via sequential reversible addition-fragmentation 
chain transfer (RAFT) polymerization reactions 56-65 of t-butyl acrylate (tBA) and 
styrene, followed by removal of the t-butyl ester protecting groups (Figure 2.1).  
Beginning from DDMAT, 1, chain transfer agent, two PtBA macro-chain transfer agents 
(macro-CTAs), with number-averaged degrees of polymerization (DPn) of 52 (2) and 
120 (3) were prepared by RAFT polymerization of tBA.  Chain extensions with styrene 
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were then conducted to produce the PtBA-b-PS block copolymers with different DPs of 
styrene.  In both polymerizations, AIBN was used as the initiator, and a relatively low 
reaction temperature (~ 60 - 70 °C) was employed to provide sufficient AIBN half-life 
for controlled polymerization.  Complete removal of the t-butyl groups of PtBA-b-PS 
was achieved by TFA treatment and the structures of the resulting amphiphilic PAA-b-
PS block copolymers were characterized by IR, 1H NMR and 13C NMR spectroscopies.   
 
 
 
 
Figure 2.1.  Preparation of PtBA macro-CTA, chain extension with styrene, and removal 
of the tert-butyl protecting groups to produce PAAm-b-PSn polymers of various chain 
lengths. 
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 The degrees of polymerization and well-defined structures for the polymers were 
confirmed by a combination of 1H NMR spectroscopy and GPC.  GPC analyses of the 
isolated polymers showed mono-modal molecular weight distributions with 
polydispersity indices (PDI) less than 1.3, indicating the controlled fashion during the 
polymerization process.  Assuming full retention of the trithiocarbonate chain end, 1H-
NMR spectra of 2 and 3 allowed for determination of the degrees of polymerization of 
the tBA, by comparing the unique methyl terminus resonating at 0.83 ppm with the 
broad backbone proton signals from 1.2 to 2.4 ppm, which were in agreement with the 
GPC data.  Maintenance of the trithiocarbonate chain end was further observed during 
growth of the PtBA-b-PS block copolymers.  In addition, the number average molecular 
weights determined by GPC for PtBA-b-PS were in agreement with those calculated by 
1H NMR spectroscopy (the PAA-b-PS adsorbs onto the column packing material and, 
therefore, cannot be analyzed directly by GPC).  The degrees of polymerization and the 
number average molecular weights of the PtBA-b-PS and PAA-b-PS block copolymers 
were calculated based on 1H NMR spectroscopy, by comparing the backbone proton 
signals to those of the aromatic rings at 6.6 - 7.2 ppm.   
 The significant differences in composition between the PS and PAA segments 
were revealed by the thermal properties of these block polymers.  Each PAA-b-PS block 
copolymer exhibited two glass transition temperatures, at ca. 100 and 127 °C, due to 
phase segregation of the two block segments in the bulk state.  This amphiphilic, phase 
segregating property was relied upon for self assembly of the block copolymers into 
discrete nanoscale objects in solution. 
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 The micelles and corresponding SCK nanoparticles were prepared from these 
four PAAm-b-PSn amphiphilic block copolymers, by following the conventional aqueous 
micellization methodology (Figure 2.2).  Water (a selective solvent for the PAA block 
segment) was introduced to the DMF (a good solvent for both PAA and PS) solutions of 
block copolymers to form discrete spherical micelles.  The PAA shell regions of these 
micelles were then crosslinked via amidation chemistry with 2,2´-
(ethylenedioxy)bis(ethylamine) (EDDA), as a diamine crosslinker, in the presence of 1-
[3´-(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide (EDCI) to afford SCK 
nanoparticles (Figure 2.2).  Under the protection of the crosslinked shell layer, the core 
domain is capable of serving as a nanoscopic host to encapsulate guest molecules.  It 
was expected that the composition of both the core and shell domains could exert 
influence on the overall characteristics of the SCK nanoparticles, such as the size, shape, 
flexibility, loading capacity, and release kinetics and/or extents. 
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Figure 2.2.  Schematic representation of the supramolecular assembly of PAAm-b-PSn 
block copolymers into micelles and their subsequent crosslinking with EDDA to form 
SCKs. 
 
 
 
 The dimensions of the SCKs (12-15), were characterized by TEM (Figure 2.3) 
and DLS (Figure 2.4).  The circularly-shaped images observed by TEM suggested that 
these nanoparticles were spherical with narrow size distributions.  The SCKs prepared 
from the block copolymer precursors with higher PS block length (i.e., DPPS = 80 and 
100) formed particles with larger core sizes and aggregation numbers (Table 2.1).  The 
size effect from larger PAA blocks was not distinguished by TEM, due to the difficulty 
in measuring accurately the entire particle diameter by the staining methods used in this 
study.  However, the effect of the PAA degree of polymerization on the SCK shell 
thickness was confirmed by DLS measurements (Figure 2.4).  As the DPn value of the 
PAA segments was increased from 52 (12) to 120 (13), ca. 25% increase of the 
hydrodynamic diameter of the resulting SCKs was observed, with no perceptible 
variation of the core domain size.  For 14 and 15, a similar trend was also observed.  
Based upon these data, the volumes occupied by the PS cores and PAA shells, the 
thicknesses of the PAA shells, and the core-shell interfacial areas were calculated (Table 
2.1).  The ratios of the volumes occupied by the PAA shells to those of the PS cores 
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increased from SCK 12-15, and they correlated directly with the proportions of acrylic 
acid-to-styrene block lengths for each of the block copolymer precursors.  The core-shell 
interfacial areas per particle for 12 and 13 were larger than for 14 and 15, but the core-
shell interfacial areas for the total number of particles for all samples were 
approximately equivalent, since there were fewer total particles present in samples 12 
and 13.   
 
 
 
 
 
Figure 2.3.  Characterization of SCKs 12 - 15 by TEM (drop deposited on carbon-coated 
copper grids and stained negatively with phosphotungstic acid) of A) 12, B) 13, C) 14, 
and D) 15. 
 
 
 
  
 37 
 
 
Figure 2.4.  Characterization of SCKs 12 - 15 by DLS.  DLS histograms of intensity-
averaged, volume-averaged, number-averaged hydrodynamic diameters :  A) SCK 12, 
B) SCK 13, C) SCK 14, and D) SCK 15 in nanopure water. 
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 SANS data of the SCKs in D2O solutions were fitted by a smeared polydispersity 
core-shell sphere (SPCSS) model (Figure 2.5).  The SPCSS model, which involves a 
variety of core sizes due to polydispersity and smearing effects, gives the best fitting 
results.  An example of different fitting model comparison for SCK 12 is shown in 
Figure 2.5B.  For 13 and 14, scattering intensity increased in the low-Q region, 
indicating possible aggregation of micelles.  However, all of the samples fit well by the 
SPCSS model to give the results of core sizes and shell thicknesses listed in Table 2.1.  
The overall particle dimensions from SANS were similar to the number-average 
hydrodynamic diameters as determined from DLS.  However, the core sizes from SANS 
fitting were slightly smaller than the particle core diameters observed by TEM, which 
may be caused by slight distortion of the spherical particles upon adsorption onto the 
TEM grid.  The added EDDA, which went into the corona through condensation with 
PAA, increased the scattering length density of the corona (from 1.39e-6 to 5.82e-6 Å-
2).  Assuming the hydrophobic polystyrene formed a homogeneously-dense core in 
aqueous solution, the densities of the corona for the four SCK nanoparticles were found 
to be inversely proportional to the corresponding lengths of the PAA block of the 
polymer precursors and it was observed that samples with longer PAA block segments 
had lower coronal densities.   
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Figure 2.5.  A). Small angle neutron scattering (SANS) data of SCK 12 - 15.  Black solid 
lines present fitting curves of “smeared polydispersed core-shell sphere” model.  B).  
Model fitting results for SANS profile of SCK 12 with "core-shell sphere" model, 
"smeared core-shell sphere" model, "polydispersed core-shell sphere" model and 
"smeared polydispersed core-shell sphere" model.   
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Table 2.1.  Experimental and calculated dimensions of the SCKs, and quantified DOX 
loading values. 
 
SCK 12 13 14 15 
Polymer precursors PAA52-b-PS80 PAA120-b-PS100 PAA52-b-PS30 PAA120-b-PS40 
DTEM [nm] 19 ± 2 20 ± 2 11 ± 2 13 ± 2 
VPS [nm3] 3600 4200 700 1200 
Aggregation 
number 270 260 140 180 
VPAA [nm3] 1600 3600 830 2500 
Tshell, calc [nm] 1.5 2.3 1.5 3.1 
VPAA/VPS 0.44 0.86 1.2 2.1 
(Dh)Int [nm] 88 ± 6 110 ± 16 81 ± 12 90 ± 12 
(Dh)Vol [nm] 30 ± 3 43 ± 6 20 ± 6 35 ± 2 
(Dh)Num [nm] 24 ± 2 30 ± 3 14 ± 3 18 ± 3 
SAcore/particle [nm2] 1100 1300 380 530 
Total # particles 
[x1014, 10 mL 
solution volume] 
4.4 3.0 14 6.1 
SAcore/total [x1017 
nm2, 10 mL 
solution volume] 
5 4 5 3 
Dcore,SANS [nm] 17.4 15.3 9.0 8.9 
Core size 
polydispersity 0.13 0.11 0.20 0.33 
DSANS [nm] 24.4 25.1 17.4 17.3 
Tshell, SANS [nm] 3.5 4.9 4.7 4.2 
Related density of 
shell 4.6 3.0 4.5 2.7 
DOX per particle 1400 2200 340 860 
DOX/VPAA 4.0 2.7 1.8 1.5 
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Table 2.1.  Continued 
DTEM = diameter by TEM 
Vps = volume of the PS core 
Aggregation number calculated based on diameter by TEM using previously reported 
equation  
VPAA = volume of the PAA shell, calculated from the TEM core volume to obtain the 
block copolymer aggregation number, convert to the PAA mass from the total 
number of AA repeat units, and finally the volume occupied by PAA was 
determined using a PAA density of 1.05 g/mL 
Tshell, calc = thickness of the PAA shell in the solid state, estimated from the volume of 
PAA + volume of PS minus the radius of the PS core 
Dh = intensity (Int), volume (Vol), number (Num) average diameters by DLS 
SAcore/particle = core-shell interfacial area per particle 
SAcore/total = core-shell interfacial area for total numbers of particles in 10 mL of aqueous 
solution 
Dcore,SANS = core diameter from SANS 
DSANS = particle size from SANS 
Tshell, SANS = shell thickness from SANS 
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 The encapsulation of DOX into SCK nanoparticles was carried out by incubating 
DOX solutions in DMF with SCKs in aqueous solutions (Figure 2.6).  The organic 
solvent was used to swell the polystyrene core of the SCKs and provide sufficient DOX 
concentration to drive the diffusion-controlled loading/encapsulation process.  This 
procedure for loading of DOX into pre-established SCKs was followed so that the 
dimensions of the SCKs could be accurately controlled and locked-in by the shell 
crosslinks, without potential complications that can occur for block copolymer assembly 
in the presence of additives.  In addition, if the DOX had been present during the 
crosslinking reaction employed, carbodiimide-mediated amidation, side reactions 
between the amine functionality of DOX and the AA residues throughout the micellar 
shell domain could have occurred, covalently linking the drug to the nanostructure.  
After 24 h of incubation, the unincorporated DOX molecules were removed from the 
DOX-SCK system by centrifugation and extensive washing using a centrifugal-filtration 
membrane and 5 mM PBS (with 5 mM NaCl) at 37 °C.  After the centrifugation 
filtration-based washing procedure, each SCK solution was reconstituted to its original 
concentration by the addition of PBS.  The resulting DOX concentrations in the SCKs 
were calculated from the absorption of DOX at 488 nm.  A ca 20 wt% loading capacity, 
relative to the mass of PAA-b-PS block copolymer precursors and independent of the 
SCK composition, was achieved for each SCK.  This result indicated that the core size of 
the SCKs did not affect the overall loading capacity for the entire series of nanoparticle 
solutions.  In fact, even for 14, with the smallest core volume (700 nm3), the 
encapsulated DOX could reach a concentration of ~ 75 µM, which was almost 400 times 
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the SCK nanoparticle concentration.  However, on a per particle basis, the larger PS 
cores gave higher numbers of the DOX molecules per particle.  It is well-known that the 
micellar hydrophobic core domain can sequester DOX through hydrophobic and π-π 
stacking interactions.  Meanwhile, other factors, such as electrostatic interactions and 
hydrogen bonding between DOX and the functionalities across the micellar shell domain, 
must also be taken into account for the overall loading capacity of the nanoscale 
vehicles.31,66  Because the ratio of the number of DOX molecules loaded per particle to 
the volume of PAA per particle decreased as the volume of PAA per particle relative to 
volume of PS increased (Table 2.1), we hypothesize that the DOX preferentially resided 
at the core-shell interface and/or in the core domain.  If the DOX molecules were 
localized in the shell layer, then these trends would have been increasing in parallel.  The 
PAA shell layer was critical, however, to the diffusion of the DOX, as revealed by 
release kinetics studies.   
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Figure 2.6.  Schematic representation of the loading of DOX into the core, core-shell 
interface and shell region of the SCKs while suspended in aqueous solution, and release 
of DOX from the SCK in pH 5.0 or pH 7.4 buffer at 37 °C.   
 
 
 
 The DOX release profiles from the SCK nanoparticles were studied by 
monitoring the decrease in DOX concentration over time, in dialysis cassettes.67  Based 
upon the chemical characteristics of DOX and PAA and similarities with literature 
studies,66 we hypothesized that the release of DOX from the SCK nanoparticles would 
be faster and proceed to a greater extent at more acidic pH conditions, compared with 
the release rate at physiological pH 7.4.  Promoted release was considered due to loss of 
electrostatic interactions between the amine functionality of DOX (pKa of 8.25)68 and 
the PAA shell regions of the nanoparticles upon protonation of acrylic acid groups at 
lower pH (pKa of ca. 5).66  At pH 7.4, DOX carries a positive charge that can form 
electrostatic interactions with the negatively-charged deprotonated PAA residues in the 
shell region of the nanoparticles, whereas at pH 5.0, a majority of the acrylic acid 
residues would be protonated and the loss of electrostatic interactions would trigger 
release of DOX.  This hypothesis was supported by all four SCK nanoparticles, which 
exhibited ca. 40% release at pH 7.4 and 60% at pH 5.0 over 60 h (Figure 2.7).  In 
addition, the final extents of release of DOX from the SCKs with smaller cores (14 and 
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15) were lower compared with the SCKs with larger cores (12 and 13).  These 
differences could be attributed to more frequent inter-particle exchange of the DOX 
molecules, enhanced by the higher numbers of 14 and 15 nanoparticles (2-3-fold 
increase, compared to 12 and 13, respectively, Table 2.1).  More importantly, however, 
is the ratios of the volume of PAA to the volume of PS, which increase from SCK 12-15, 
in agreement with the relative extents of release, due to the need for the DOX to diffuse 
through and escape from the PAA shell to be observed as released from the dialysis 
cassette.   
 
 
 
 
Figure 2.7.  DOX release profiles of free DOX, micelles, and SCK12, SCK13, SCK14 
and SCK15 at pH 7.4 or pH 5.0. 
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For a quantitative determination of the kinetics of DOX release, the experimental 
data were fit to an exponential relation for Fickian diffusion of a drug from spherical 
polymeric devices, the Higuchi equation:69-71   
𝑀𝑀𝑡𝑡
𝑀𝑀∞
= 𝑘𝑘𝑡𝑡12 
where 𝑀𝑀𝑡𝑡 𝑀𝑀∞⁄  is the proportion of drug released at a given time, k is the rate constant of 
drug release, and t is time.  The proportion of DOX release plotted against the square 
root of release time was approximately linear for the first 50% of drug release (Figure 
2.8), in agreement with the limitations of the Higuchi model.  The rate constants, k, 
calculated from the Higuchi plots, indicated faster release kinetics for the first 50% of 
drug release at pH 5.0 compared with pH 7.4, for all four SCKs 12 - 15 (Table 2.2).  
Faster release at pH 5 indicates that the rate determining step for release involves exit 
through the shell and not from the core, suggesting that a portion of the DOX resides in 
the shell and/or at the core-shell interface, in addition to potentially being within the core 
of the particles.   
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Figure 2.8.  Higuchi plots of DOX release profiles of SCK12, SCK13, SCK14 and 
SCK15 at pH 7.4 or pH 5.0. 
 
  
 48 
Table 2.2.  DOX release rate, k (h-½), obtained from fitting drug release experimental 
data to the Higuchi model.   
 
 
12 13 14 15 Micelles 
From Polymer Precursors 
PAA
52
-b-PS
80
 PAA
120
-b-PS
100
 PAA
52
-b-PS
30
 PAA
120
-b-PS
40
 PAA
120
-b-PS
40
 
pH 
7.4 k, h
-½ 0.0540 0.0431 0.0477 0.0441 0.245 
pH 
5.0 k, h
-½ 0.136 0.134 0.124 0.106 0.278 
 
 
 
As control experiments, we studied the release of free DOX from the dialysis 
cassette, which reached a complete release within 5 h, confirming that the measurements 
were not complicated by the dialysis cassette.  We also found that a complete release of 
DOX was reached within 30 h from the polymer micelles, with a final extent of release 
of ca. 70% at both pH values (Figure 2.7 and Table 2.2).  The faster release of DOX 
from the micelles (k = 0.245 or 0.278 h-½ at pH 7.4 or pH 5.0, respectively) compared to 
the SCKs (k ranges from 0.0431 to 0.136 h-½) suggests that crosslinking affects the 
release, which may be due to a combination of differences in compositions and polymer 
chain dynamics with the incorporation of crosslinkers.   
 To further quantitatively understand the differences and similarities in DOX 
release profiles, model-independent methods, which allow us to calculate f1, the 
difference factor, and f2, the similarity factor, were used:72,73   
𝑓𝑓1 = ∑ |𝑅𝑅𝑡𝑡 − 𝑇𝑇𝑡𝑡|𝑛𝑛𝑡𝑡=1∑ 𝑅𝑅𝑡𝑡𝑛𝑛𝑡𝑡 × 100 
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where t is the sampling time, n is the number of samples, Rt is the dissolution value of 
the reference (measured as the percentage of DOX release for the reference) and Tt is the 
dissolution value of the sample of interest (measured as the percentage of DOX release 
from the sample).  When the reference profile and the sample profile are identical, f1  is 
equal to zero and, generally, the profiles are considered similar with f1 values up to 15.  
The f2 factor is a logarithmic transformation of the sum of squared error of difference 
between the reference and the sample of interest.   
𝑓𝑓2 =  50 × log��1 +  1𝑛𝑛�(𝑅𝑅𝑡𝑡 − 𝑇𝑇𝑡𝑡)2𝑛𝑛
𝑡𝑡=1 �
−0.5
�⁡× 100 
When the reference profile and the sample profile are identical, f2  is equal to 100 and, 
generally, the profiles are considered similar when f2 values are greater than 50.  Both 
the difference factor f1  and the similarity factor f2 revealed that the SCK release profiles 
were significantly different from the free DOX and micelle release profiles (where all f1 
factors are greater than 15 and all f2 factors are less than 50).  There were similarities 
between SCK12 and SCK13 release profiles (f1 factors ~ 7 and f2 factors ~ 70), and 
SCK14 and SCK15 release profiles (f1 factors ~ 11 and f2 factors ~ 60).  In addition, 
there are mathematical differences between the release profiles of SCKs with larger 
cores (SCK12 and SCK13) vs. SCKs with smaller cores (SCK14 and SCK15).  
Moreover, the greatest difference observed for 12 (fastest release) vs. 15 (slowest release) 
is in agreement with the observation that the ratio of the volume occupied by the PAA 
shell vs. that of the PS core is least for 12 and greatest for 15 (Table 2.3 – Table 2.6).   
  
 50 
Table 2.3.  Difference factor (f1) values of SCK12-SCK15 against free DOX or against 
micelles as the references.   
 
Reference: Free DOX 
Sample SCK12 SCK13 SCK14 SCK15 
pH 5.0 46 50 61 65 
pH 7.4 60 62 75 84 
Reference: Micelles 
Sample SCK12 SCK12 SCK12 SCK12 
pH 5.0 16 16 16 16 
pH 7.4 35 35 35 35 
 
 
 
Table 2.4.  Difference factor (f1) values of SCK12-SCK15 against each other as 
references.   
 
Reference: SCK12 SCK13 
Sample SCK13 SCK14 SCK15 SCK12 SCK14 SCK15 
pH 5.0 7 28 36 8 23 31 
pH 7.4 8 39 60 8 35 57 
Reference: SCK14 SCK15 
Sample SCK12 SCK13 SCK15 SCK12 SCK13 SCK14 
pH 5.0 39 29 11 57 45 13 
pH 7.4 64 54 34 150 134 52 
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Table 2.5.  Similarity factor (f2) values of SCK12-SCK15 against free DOX or against 
micelles as the references.   
 
Reference: Free DOX 
Sample SCK12 SCK13 SCK14 SCK15 
pH 5.0 -8 -10 -14 -16 
pH 7.4 -14 -15 -19 -21 
Reference: Micelles 
Sample SCK12 SCK12 SCK12 SCK12 
pH 5.0 27 19 5 2 
pH 7.4 8 6 -4 -8 
 
 
 
Table 2.6.  Similarity factor (f2) values of SCK12-SCK15 against each other as 
references.   
 
Reference: SCK12 SCK13 
Sample SCK13 SCK14 SCK15 SCK12 SCK14 SCK15 
pH 5.0 70 41 36 70 46 41 
pH 7.4 75 42 32 75 45 35 
Reference: SCK14 SCK15 
Sample SCK12 SCK13 SCK15 SCK12 SCK13 SCK14 
pH 5.0 41 46 67 37 41 67 
pH 7.4 42 45 54 32 35 54 
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2.4.  Conclusions 
 In this study, SCK nanoparticles were designed to have various relative and 
absolute core and shell dimensions to mediate the packaging and release of DOX as a 
model chemotherapeutic system.  Variation over the nanoparticle dimensions was 
achieved through controlling of the block copolymer precursor chain lengths, to afford a 
series of well-defined and rigorously characterized nanoscopic vessels for drug molecule 
loading and release studies.  The amphiphilic core-shell morphology of the SCK 
nanostructures provided opportunities for tuning of the drug loading capacities and rates 
of release; increasing core diameters and core-shell interfacial surface areas were 
important for increased guest packaging capacity and decreasing proportions of shell-to-
core volume was the critical parameter for increased kinetics of release.  The 
electrostatic complexation of DOX and the PAA shell showed predominant effects on 
the rates of release, giving accelerated release at acidic pH vs. under physiological pH 
conditions, which may lead to enhanced selectivity of delivery in cancer therapy.  
Moreover, the amphiphilic core-shell morphology of the SCKs provided opportunities 
for tuning of the relative contributions of hydrophobic and/or π-π interactions with the 
core domain and electrostatic interactions with the shell layer to give significant impact 
on the extents of release of DOX.  The variety of contributing factors, of chemical 
composition, dimensions of the core and shell domains, and total particle concentrations, 
made direct determination of the effects of each parameter complicated, although the 
greatest correlation appeared to be the ratio of the volume of the shell vs. the volume of 
the core.  As the relative proportion of PAA shell to PS core volumes decreased, the rate 
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and extent of release increased.  Because these proportions are conveniently tuned by the 
nature of the block copolymer precursor, SCK nanoparticles offer enormous opportunity 
for the production of nanoscopic drug carriers with finely-tuned performance potential.  
These studies, therefore, point to future directions to craft sophisticated devices for 
controlled drug release. 
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CHAPTER III 
 
PACLITAXEL-LOADED SCK NANOPARTICLES:  AN INVESTIGATION OF 
LOADING CAPACITY AND CELL KILLING ABILITIES IN VITRO 
 
3.1.  Introduction 
 
 Paclitaxel (PTX) is a chemotherapeutic agent that has been used to treat a variety 
of cancers including, primary epithelial ovarian, colon, non-small cell lung and 
metastatic breast cancers.  Its mechanism of action is through stabilization of 
microtubules which promotes polymerization of tubulin, causing cell death by disrupting 
the dynamics necessary for cell division.74  Due to its high hydrophobicity and poor 
solubility in aqueous solutions, PTX is normally formulated with high percentages of 
additives such as Cremophor® EL (polyethoxylated castor oil), which can cause high 
incidences of adverse effects including hypersensitivity reactions,75 neurotoxicity, 
nyelosuppression and allergic reactions.  To avoid the toxicities associated with 
Cremophor® EL, a biologically interactive, nanometer-sized albumin-bound PTX 
particle (Abraxane®) has been developed (hydrodynamic diameter of ca. 110 nm), which 
uses the unique properties of albumin, a natural carrier of lipophilic molecules in 
humans.76  PEO groups have been serving as the synthetic analogue to impart 
stealthiness in vivo and have been used in conjunction with hydrophobic blocks such as 
poly(D,L-lactic acid),77 oligo(cholic acid),78,79 poly(ε-caprolactone),80,81 polycarbonates 
bearing pH-82,83 or thermally-responsive84 pendant groups or crosslinkable 
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polyaspartamide groups.  For example, NK105 micellar formulation, constructed from 
block copolymers of polyethylene oxide (PEO) and polyaspartate, can physically 
encapsulate up to 23 wt% of PTX, and is currently being investigated in phase II clinical 
trials.85,86  Micelle constructed from diblock copolymers of polyethylene glycol and 
poly(D,L-lactic acid) for delivery of PTX is approved in Korea (Genexol®-PM) for 
cancer treatment and is in phase IV clinical trials in the USA as a safer alternative to 
Cremophor® EL and ethanol in Taxol.77,87,88  Combinatorial delivery of PTX and siRNA 
has also been reported by utilizing cationic micelles self assembled from triblock 
copolymer poly(dimethylaminoethyl methacrylate)-b-poly(ε-caprolactone)-b-
poly(dimethylaminoethyl methacrylate), which undergoes co-assembly and 
complexation processes with the payloads (6.8 wt% drug, hydrodynamic diameters 
ranging from 60 to 130 nm and zeta potential ranging from +30 to +36 mV).89  Chemical 
modifications of the PTX molecule have also been achieved to covalently link the drug 
molecule onto the nanostructure vehicle.18,89   
 Amphiphilic block copolymer micelle structures, which mimic biological entities, 
have been investigated for drug delivery applications that take advantage of their core-
shell morphology and tunable surface chemistry.5,18,90  Our group and others have 
explored crosslinked micellar constructs, such as shell crosslinked knedel-like 
nanoparticles (SCKs) that combine the amphiphilic core-shell morphology of polymer 
micelles with stabilizing and release mediating crosslinkers isolated throughout the 
peripheral shell layer.39,91  Towards the goal of an enhanced safety profile and increased 
efficacy, in this current study, paclitaxel has been encapsulated in amphiphilic, SCK 
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nanoparticles (PTX-SCKs) as a novel drug delivery system.  Paclitaxel-loaded SCK 
nanoparticles were synthesized from an amphiphilic diblock copolymer, poly (acrylic 
acid)-b-polystyrene (PAA-b-PS), in which PTX was encapsulated into the SCK 
nanoparticles through a co-assembly process at various concentration formulations.  The 
in vitro cell killing ability was investigated on two different sizes of PTX-loaded SCKs, 
having core diameters of 20 ± 3 nm or 60 ± 5 nm and overall hydrodynamic diameters of 
50 ± 15 nm or 120 ± 30 nm, respectively.  Furthermore, the effects of PEGylation were 
evaluated for the smaller SCK samples.  A dual purpose small molecule, pyrazine-based 
dye, served both as the crosslinker and fluorescent tag for visualization of cell 
internalization in KB cells by confocal fluorescence microscopy.  Separation assays with 
high molecular weight cut-off filters confirmed that the paclitaxel was loaded within the 
nanoparticles and not free in solution. 
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3.2.  Materials and methods 
3.2.1.  Materials 
 All chemicals were purchased from Aldrich Chemical Co. (St. Louis, MO) and 
used without further purification unless otherwise noted.  Paclitaxel (PTX) was 
purchased from Cedarburg Hauser (Denver, CO).  The Supor 25 mm 0.1 µm Spectra/Por 
Membrane tubes (MWCO 6-8 kDa), used for dialysis, were purchased from Spectrum 
Medical Industries Inc.  Nanopure water (18 MΩ•cm) was acquired by means of a Milli-
Q water filtration system, Millipore Corp. (Bedford, MA).  Biology molecular grade 
water was purchased from Fisher Scientific (Pittsburg, PA).   
3.2.2  Instruments 
 Ultraviolet-visible spectroscopy (UV-vis) absorption measurements were made 
using a UV-2550 system (Shimadzu Corp., Japan) using PMMA cuvettes.  Spectra were 
analyzed with UV-Probe v. 2.33 software.  Dynamic light scattering (DLS) 
measurements were conducted using Delsa Nano C from Beckman Coulter, Inc. 
(Fullerton, CA) equipped with a laser diode operating at 658 nm.  Size measurements 
were made in nanopure water.  Scattered light was detected at 15° angle and analyzed 
using a log correlator over 70 accumulations for a 0.5 mL of sample in a glass size cell 
(0.9 mL capacity).  The photomultiplier aperture and the attenuator were automatically 
adjusted to obtain a photon counting rate of ca. 10 kcps.  The calculation of the particle 
size distribution and distribution averages was performed using CONTIN particle size 
distribution analysis routines using Delsa Nano 2.31 software.  The peak average of 
histograms from intensity, volume and number distributions out of 100 accumulations 
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were reported as the average diameter of the particles, with the standard deviations being 
calculated as the breadth of the distributions.  Transmission electron microscopy (TEM) 
bright-field imaging was conducted on a JOEL 1200 microscope, operating at 100 kV.  
The samples were prepared as follows:  4 μL of the dilute solution (with a polymer 
concentration of ca. 0.2 - 0.5 mg/mL) was deposited onto a carbon-coated copper grid, 
which was glow charged to increase the surface hydrophilicity.  After 5 min, the excess 
of the solution was quickly wicked away by a piece of filter paper.  The samples were 
then negatively stained with 4 μL of 1 wt% uranyl acetate aqueous solution.  After 1 
min, the excess uranyl acetate solution was quickly wicked away by a piece of filter 
paper and the samples were left to dry under ambient conditions overnight. 
 Paclitaxel levels were determined by (high performance liquid chromatography) 
HPLC analysis using two HPLC instruments.  The first one is an Agilent 1200 HPLC 
with a (diode array detectors) DAD set to 230 nm in isocratic mode.  A Kinetex XB-C18 
column (2.1 x 100 mm, 2.6 µM, 100 Å) employed a buffer system of 55% water and 
45% acetonitrile with both buffers modified with 0.05% trifluoroacetic acid (TFA) to 
minimize Paclitaxel degradation on the column.  The flow rate is at 0.25 mL/min with 
run time of 15 min.  The second one is a Shimadzu Prominence HPLC with RID-10A 
refractive index detector set to 227 nm in isocratic mode.  The column is a Waters 
xBridge CB column (4.6 x 150 mm, 5 µM, 100 Å) with a eluent system composed of 
55% 20 mM ammonium acetate buffer and 45% acetonitrile.  The flow rate is at 1 
mL/min with run time of 20 min.  Both HPLC methods employed an external calibration 
of Paclitaxel (>99% purity) between 1-200 ng/µL.  Paclitaxel level was also confirmed 
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by Agilent liquid chromatography mass spectrometry (LC/MS) with a triple quadrapole 
mass spectrometer.  The LC condition is same as the Agilent HPLC condition.  PTX 
concentration was determined by measuring and fragmenting the sodiated molecular ion 
at 876.3 m/z and monitoring a key fragment ion for quantification at 308 m/z at the 
appropriate retention time.   
3.2.3.  Experiment procedures 
General procedure for co-assembly of paclitaxel and PAA70-b-PS555 into micelles 
(PTX-micelles):  PAA70-b-PS555 (ca. 10 mg) polymers were dissolved in DMF (10 mL) 
in a 100 mL round bottom flask and allowed to stir for 20 min at room temperature.  
Paclitaxel in DMSO (1.14 mg/mL) was added to the solution and allowed to stir for 
additional 10 min at room temperature.  To this solution, an equal volume of nanopure 
water was added dropwise via a syringe pump over a period of 1 h.  The reaction 
mixture was allowed to stir for additional 24 h at room temperature and dialyzed against 
nanopure water for 3 days in a presoaked dialysis tubing (MWCO ca. 6 - 8 kDa) to 
afford a micelle solution with a final polymer concentration of ca. 0.25 mg/mL.   
60 nm micelles loaded with 20% PTX (PTX-micelle-60nm-20%):  The PTX-micelle-
60nm-20% solution had a final polymer concentration of 0.233 mg/mL, with PTX 
concentration of 0.0465 mg/mL.   
60 nm micelles loaded with 15% PTX (PTX-micelle-60nm-15%):  The PTX-micelle-
60nm-15% solution had a final polymer concentration of 0.247 mg/mL, with PTX 
concentration of 0.0370 mg/mL.   
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60 nm micelles loaded with 10% PTX (PTX-micelle-60nm-10%):  The PTX-micelle-
60nm-10% solution had a final polymer concentration of 0.253 mg/mL, with PTX 
concentration of 0.0253 mg/mL.   
60 nm micelles loaded with 5% PTX (PTX-micelle-60nm-5%):  The PTX-micelle-
60nm-5% solution had a final polymer concentration of 0.260 mg/mL, with PTX 
concentration of 0.0123 mg/mL.   
General procedure for crosslinking the paclitaxel loaded nanoparticle micelles with 
the crosslinker to afford SCKs (PTX-SCK): To the micelle solution of paclitaxel 
loaded PAA70-b-PS555 micelles was added a solution of fluorescent crosslinker in 
nanopure water (1.1 eq, nominal 20% crosslinking) dropwise via a syringe pump over a 
period of 2 h.  To this solution, 1-[3´-(dimethylamino)propyl]-3-ethyl-carbodiimide 
methiodide (EDCI) in nanopure water (1.4 eq) was added dropwise via a syringe pump 
over 10 min and the resulting mixture was allowed to stir overnight before dialysis 
against nanopure water for 4 days in a presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) 
to afford SCK solutions with a final polymer concentration of ca. 0.25 mg/mL.  The 
crosslinking density was measured by UV-vis spectroscopy to be about 7 - 10%.   
60 nm SCKs loaded with 20% PTX (PTX-SCK-60nm-20%):  The PTX-SCK-60nm-
20% solution had a final polymer concentration of 0.233 mg/mL, with PTX 
concentration of 0.0465 mg/mL, and crosslinker concentration of 0.0825 mM at 7% of 
crosslinking density.  Diameter = 63 ± 17 nm, Dh(intensity) = 230 ± 110 nm, Dh(volume) 
= 150 ± 60 nm, Dh(number) = 110 ± 30 nm. 
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60 nm SCKs loaded with 15% PTX (PTX-SCK-60nm-15%):  The PTX-SCK-60nm-
15% solution had a final polymer concentration of 0.247 mg/mL, with PTX 
concentration of 0.0370 mg/mL, and crosslinker concentration of 0.0748 mM at 8% of 
crosslinking density.  Diameter = 57 ± 16 nm, Dh(intensity) = 240 ± 100 nm, Dh(volume) 
= 140 ± 60 nm, Dh(number) = 110 ± 30 nm. 
60 nm SCKs loaded with 10% PTX (PTX-SCK-60nm-10%):  The PTX-SCK-60nm-
10% solution had a final polymer concentration of 0.253 mg/mL, PTX concentration of 
0.0253 mg/mL, and crosslinker concentration of 0.0874 mM at 9% of crosslinking 
density.  Diameter = 59 ± 12 nm, Dh(intensity) = 230 ± 90 nm, Dh(volume) = 140 ± 60 
nm, Dh(number) = 110 ± 30 nm. 
60 nm SCKs loaded with 5% PTX (PTX-SCK-60nm-20%):  The PTX-SCK-60nm-
5% solution had a final polymer concentration of 0.260 mg/mL, PTX concentration of 
0.0123 mg/mL, and crosslinker concentration of 0.0698 mM at 6% of crosslinking 
density.  Diameter = 65 ± 14 nm, Dh(intensity) = 220 ± 90 nm, Dh(volume) = 150 ± 60 
nm, Dh(number) = 120 ± 30 nm. 
General procedure for assembly of PAA120-b-PS100 into micelles and in situ 
crosslinking:  PAA120-b-PS100 (ca. 10 mg) polymers were dissolved in DMF (10 mL) in 
a 100 mL round bottom flask and allowed to stir for 20 min at room temperature.  
Paclitaxel in DMSO (1.14 mg/mL) was added to the solution and allowed to stir for 
additional 10 min at room temperature.  To this solution, an equal volume of nanopure 
water was added dropwise via a syringe pump over a period of 1 h.  The reaction 
mixture was allowed to stir for additional 24 h at room temperature.  A solution of 
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fluorescent crosslinker in nanopure water (1.1 eq, nominal 20% crosslinking) was added 
dropwise via a syringe pump over a period of 2 h.  To this solution, 1-[3´-
(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide (EDCI) in nanopure water 
(1.4 eq) was added dropwise via a syringe pump over 10 min and the resulting mixture 
was allowed to stir overnight before dialysis against nanopure water for 4 days in a 
presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) to afford SCK solutions with a final 
polymer concentration of ca. 0.25 mg/mL.  The crosslinking density was measured by 
UV-vis spectroscopy to be about 7 - 10%.   
20 nm SCKs loaded with 5% PTX (PTX-SCK-20nm-5%):  The PTX-SCK-20nm-5% 
solution had a final polymer concentration of 0.279 mg/mL, PTX concentration of 
0.0135 mg/mL, and crosslinker concentration of 0.0799 mM at 8% of crosslinking 
density.  Diameter = 24 ± 3 nm, Dh(intensity) = 120 ± 60 nm, Dh(volume) = 60 ± 30 nm, 
Dh(number) = 49 ± 13 nm. 
20 nm PEGylated SCKs loaded with 5% PTX (PTX-PEG-SCK-20nm-5%):  The 
PTX-PEG-SCK-20nm-5% solution had a final polymer concentration of 0.222 mg/mL, 
PTX concentration of 0.0111 mg/mL, and crosslinker concentration of 0.0563 mM at 5% 
of crosslinking density.  Diameter = 21 ± 6 nm, Dh(intensity) = 400 ± 379 nm, 
Dh(volume) = 70 ± 50 nm, Dh(number) = 49 ± 15 nm. 
3.2.3.4  General procedure for assembly of PAAm-b-PSn into micelles:  PAAm-b-PSn 
(ca. 10 mg) polymers were dissolved in DMF (10 mL) in a 100 mL round bottom flask 
and allowed to stir for 20 min at room temperature.  To this solution, an equal volume of 
nanopure water was added dropwise via a syringe pump over a period of 1 h.  The 
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reaction mixture was allowed to stir for additional 24 h at room temperature and 
dialyzed against nanopure water for 3 days in a presoaked dialysis tubing (MWCO ca. 6 
- 8 kDa) to afford a micelle solution with a final polymer concentration of ca. 0.25 
mg/mL.   
60 nm micelles (Micelle-60nm):  The Micelle-60nm solution had a final polymer 
concentration of 0.267 mg/mL.   
20 nm micelles (Micelle-20nm):  The Micelle-20nm solution had a final polymer 
concentration of 0.269 mg/mL.   
20 nm PEGylated micelles (PEG-micelle-20nm):  The PEG-micelle-20nm solution 
had a final polymer concentration of 0.260 mg/mL.   
General procedure for crosslinking the paclitaxel loaded nanoparticle micelles with 
the fluorescent crosslinker to afford SCKs (PTX-SCK):  To the micelle solution of 
paclitaxel loaded PAAm-b-PSn micelles was added a solution of MP-3142 in nanopure 
water (1.1 eq, nominal 20% crosslinking) dropwise via a syringe pump over a period of 
2 h.  To this solution, 1-[3´-(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide 
(EDCI) in nanopure water (1.4 eq) was added dropwise via a syringe pump over 10 min 
and the resulting mixture was allowed to stir overnight before dialysis against nanopure 
water for 4 days in a presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) to afford SCK 
solutions with a final polymer concentration of ca. 0.25 mg/mL.  The crosslinking 
density was measured by UV-vis spectroscopy to be about 7 - 10%.   
60 nm SCKs (SCK-60nm):  The SCK-60nm solution had a final polymer concentration 
of 0.267 mg/mL, and MP-3142 concentration of 0.0783 mM at 7% of crosslinking 
 64 
density.  Diameter = 55 ± 15 nm, Dh(intensity) = 244 ± 105 nm, Dh(volume) = 151 ± 58 
nm, Dh(number) = 116 ± 30 nm. 
20 nm SCKs (SCK-20nm):  The SCK-20nm solution had a final polymer concentration 
of XX 0.269 mg/mL, and MP-3142 concentration of 0.0723 mM at 7% of crosslinking 
density.  Diameter = 23 ± 3 nm, Dh(intensity) = 110 ± 50 nm, Dh(volume) = 70 ± 30 nm, 
Dh(number) = 56 ± 15 nm. 
20 nm PEGylated SCKs (PEG-SCK-20nm):  The PEG-SCK-20nm solution had a final 
polymer concentration of 0.260 mg/mL, and MP-3142 concentration of 0.0564 mM at 
5% of crosslinking density.  Diameter = 25 ± 5 nm, Dh(intensity) = 320 ± 280 nm, 
Dh(volume) = 70 ± 50 nm, Dh(number) = 48 ± 14 nm. 
Cell viability studies:  All the SCKs and free paclitaxel were tested in KB cells.  KB 
cells (ATCC, Mansas, VA) were maintained in monolayer cultures in folate free RPMI 
(Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) 
and penicillin/streptomycin antibiotics.  For screening purposes, 2,500 cells in 100 µL of 
complete RPMI were plated in a 96 well plate (Corning, Lowell, MA) in triplicates and 
were then incubated for 24 h in a humidified CO2 cell culture incubator maintained at 37 
°C.  Serial dilutions of SCKs and paclitaxel were prepared in PBS and added to cells in a 
volume of 10 µL.  The cells were either incubated for a short period of 2 h or for 
continuous incubation of 72 h.  After 2 h incubation the media was replaced with 110 µL 
of fresh complete RPMI.  Cell viability was assessed by using a colorimetric WST-1 cell 
proliferation kit (Roche, Indianapolis, Indiana).  Cell viability was calculated as a 
percentage of the control cells treated with no drugs.  The percent cell viability assay 
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values were then plotted in Graph Pad Prism (GraphPad Software Inc, La Jolla, CA) and 
IC50 values were obtained using non-linear regression four parameters curve fit.  Cell 
studies were performed in triplicates and each experiment was performed twice.   
Confocal microscopy:  KB cell internalization of SCKs was investigated using Nikon 
A1 confocal microscope.  KB cells were plated in an eight well chamber Labtek II glass 
slide system (Nalgene Nunc, Denmark) at a density of 35,000 cells per well.  The slides 
were incubated overnight in a humidified CO2 incubator at 37 ºC.  Cells were then 
incubated with SCKs for 2 h followed by extensive washing with PBS.  The cells were 
fixed with 4% formaldehyde for 20 min at room temperature, then mounted with 
ProGold Antifade mounting media containing DAPI (Life Technologies, Carlsbad, CA) 
and visualized with Nikon A1 confocal microscope (Nikon Instruments, Melville, NY).  
The pyrazine crosslinkers of the SCKs were excited with 488 nm laser and emission was 
collected with a Texas Red filter (595 nm - 630 nm).  The images were collected with a 
60X oil immersion objective.   
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3.3.  Results and discussion 
 The PTX-loaded SCK nanoparticles were prepared from previously reported 
PAA-b-PS amphiphilic block copolymers,39 through a co-assembly process that allowed 
the particle formation in the presence of the drug molecule to incorporate the highly 
water insoluble PTX into the hydrophobic core of initial block copolymer micelles, and 
then further stabilization of the nanostructures by covalent crosslinking using a pyrazine-
based dye serving both as the crosslinker and a chromophore.  The crosslinking 
chromophore92 has been investigated previously as a pH-reporting93-95 and as a guest-
gating moiety.91  Water (a selective solvent for the PAA block segment) was introduced 
to a DMF (a good solvent for both PAA and PS) solution of the block copolymer 
homogeneously mixed with PTX dissolved in DMSO, dropwise via a syringe pump to 
form discrete spherical micelles loaded with PTX.  The PAA shell regions of these 
micelles were then crosslinked via amidation chemistry with the pyrazine diamine 
crosslinker, in the presence of 1-[3′-(dimethylamino)propyl]-3-ethylcarbodiimide 
methiodide (EDCI) to afford PTX-loaded SCK nanoparticles.   
  
 67 
 
Figure 3.1.  Co-assembly of PAA70-b-PS555 block copolymers in DMF with paclitaxel in 
DMSO to construct 60 nm PTX-loaded micelles (PTX-micelle-60nm), followed by 
dialysis to remove the organic solvents.  Crosslinking with the pyrazine chromophore 
crosslinker, using EDCI as the coupling agent followed by dialysis to remove free 
crosslinker and EDCI byproducts to obtain PTX-loaded SCKs (PTX-SCK-60nm).  . 
 
 
 
 To achieve high PTX incorporation, nanoparticles with a relatively large 
polystyrene core diameter, 60 nm, were used to accommodate the hydrophobic PTX 
(Figure 3.1).  The 60 nm nanoparticles were constructed from an amphiphilic block 
copolymer with a low hydrophilic/hydrophobic ratio, provided by a long polystyrene 
chain, PAA70-b-PS555.  Initially, a post-assembly loading method was attempted, where 
PTX dissolved in DMSO was added into aqueous solutions of pre-established SCK 
nanoparticles, but precipitation was observed after one hour.  Therefore, a co-assembly 
loading method was adapted, where water was introduced into a homogeneous solution 
of PTX dissolved in DMSO and the block copolymer precursor dissolved in DMF to 
induce self-assembled micelle formation, followed by extensive dialysis to remove the 
organic solvents.  Crosslinking with the chromophoric diamino pyrazine-based 
crosslinker then afforded the corresponding SCKs, and extensive dialysis was performed 
again to remove the free crosslinkers and EDCI byproducts.  By varying the feed ratio of 
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PTX concentration, four different PTX-loaded SCK formulations with targeted 
theoretical loading percentages of ca. 5, 10, 15 and 20 wt% were prepared.   
 The dimensions of the SCKs, with and without PTX, were characterized by 
transmission electron microscopy (TEM) and dynamic light scattering (DLS) (Table 
3.1).  From TEM micrographs, the nanoparticles were observed to have a circular shape, 
suggesting a spherical morphology with core diameters of ca. 60 ± 15 nm for both empty 
SCKs and PTX-loaded SCKs.  Their number-average hydrodynamic diameters, 
characterized by DLS, were also similar across loading percentages with narrow size 
distributions of ca. 120 ± 30 nm (Figure 3.2).   
 
 
 
Table 3.1.  Summary of characterization data for 60 nm SCKs by TEM and DLS. 
 
 
 
  
 Diameter by TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
SCK-60nm 55 ± 15 240 ± 110 150 ± 60 120 ± 30 
PTX-SCK-
60nm-20% 63 ± 17 230 ± 100 140 ± 60 110 ± 30 
PTX-SCK-
60nm-15% 57 ± 16 240 ± 100 140 ± 60 110 ± 30 
PTX-SCK-
60nm-10% 59 ± 12 230 ± 90 140 ± 60 110 ± 30 
PTX-SCK-
60nm-5% 65 ± 14 220 ± 90 150 ± 60 120 ± 30 
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Figure 3.2.  Left column: TEM images (drop deposited on carbon-coated copper grids 
and stained negatively with 1% aqueous uranyl acetate) of A. SCK-60nm; C. PTX-SCK-
60nm-20%; E. PTX-SCK-60nm-15%; G. PTX-SCK-60nm-10%; I. PTX-SCK-60nm-
5%.  Right column:  DLS histograms (determinations were average values from ten 
measurements, with the standard deviations being calculated as the breadth of the 
distributions) of B. SCK-60nm; D. PTX-SCK-60nm-20%; F. PTX-SCK-60nm-15%; H. 
PTX-SCK-60nm-10%; J. PTX-SCK-60nm-5%.   
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 All PTX-loaded 60 nm formulations showed excellent cell killing abilities that 
were comparable to free PTX cell killing effect when incubated with KB cells for 2 h 
and also continued incubation for 72 h, whereas empty nanoparticles did not show any 
cytotoxicity even at high concentrations (Table 3.2).  At various loading amounts that 
were attempted, the recovered PTX concentration analyzed by high performance liquid 
chromatography (HPLC) was ca. 50% of the targeted amount.  We hypothesized that 
during the long dialysis processes after the micelle assembly and crosslinking 
procedures, portions of PTX were gradually diffused from the nanoparticles resulting in 
the lowered final recovered concentration.  However, even at 50% of the targeted 
concentration, the PTX-loaded 60 nm SCKs were able to exhibit excellent cell killing, 
due to the localization of high PTX concentration within each nanoparticle and the slow 
release from each nanoparticle (Figure 3.3).  The PTX-loaded SCKs with the lowest 
targeted PTX concentration (PTX-SCK-60nm-5%) showed the best cell killing ability 
among all other samples, and achieved an 0.028 μM IC50 value, which was 
approximately half of that of free PTX (0.046 μM) at 2 h incubation periods.   
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Table 3.2.  Summary of various formulations of PTX-loaded SCKs (IC50 values were 
measured at both 2 h and 72 h incubation periods when incubated with KB cells in 
vitro).   
 
 
 
  
 
Polymer 
conc. 
(mg/mL) 
Attempted 
PTX conc. 
(µg/mL) 
Actual 
PTX 
conc. 
(µg/mL) 
Actual 
wt % 
% 
yield 
IC50 at 
2 h 
(μM) 
IC50  
at 72 h 
(μM) 
SCK-
60nm 0.267 - - - - - - 
Free PTX - - -  - 0.046 ± 0.001 
0.003 ± 
0.002 
PTX-SCK-
60nm-20% 0.233 46.5 21.7 8.5 47 
0.043 ± 
0.010 
0.011 ± 
0.001 
PTX-SCK-
60nm-15% 0.247 37.0 19.5 7.3 53 
0.050 ± 
0.011 
0.012 ± 
0.001 
PTX-SCK-
60nm-10% 0.253 25.3 15.7 5.8 62 
0.040 ± 
0.007 
0.009 ± 
0.001 
PTX-SCK-
60nm-5% 0.260 12.3 7.6 2.8 61 
0.028 ± 
0.003 
0.006 ± 
0.001 
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Figure 3.3.  Viability of  KB cells incubated with A. SCK-60nm; B. Free PTX; C. PTX-
SCK-60nm-20%; D. PTX-SCK-60nm-15%; E. PTX-SCK-60nm-10%; F. PTX-SCK-
60nm-5%.  The percentage cell viability was measured by WST-1 assay.  Blue squares, 
2 h; red diamonds, 72 h.   
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 The actual concentration of the PTX incorporated into the SCKs was only 50% 
of the attempted concentration, but analytical filtration experiments indicated that the 
cell killing was a result of the encapsulated PTX, instead of free PTX.  Both free PTX 
solution and PTX-SCK solution were passed through a centrifugal filtering device with a 
molecular weight cut-off (MWCO) of 50 kDa, the residues on the filter and the filtrate 
were analyzed by HPLC and liquid chromatography mass spectrometry (LC/MS), with 
both analyses giving similar results (Figure 3.4).  In the free PTX solution, there was no 
PTX detected on the filter, but rather 100% PTX was detected in the filtrate.  However, 
once the PTX was encapsulated into SCK nanoparticles, when passing through the 
filtering device, no PTX was observed in the filtrate.  Subsequently, the PTX was readily 
released from the PTX-SCK nanoparticles when exposed to the presence of organic 
solvent during the chromatography step of the methods.  This simple analytical 
experiment indicated that the cell killing was due to PTX-SCK, not free PTX.   
 
 
 
 
Figure 3.4.  Illustration of the location of free PTX vs. PTX-SCK in a centrifugal 
filtering experiment using 50 kDa MWCO filter.   
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 Since size and surface characteristics of the nanoparticles play important roles in 
passive targeting delivery methods through the EPR effect, we also wanted to investigate 
whether particle size and surface PEGylation had effects on the cell killing abilities.  
Therefore, a block copolymer, PAA120-b-PS100, with a relatively short hydrophobic 
segment was used to construct nanoparticles of 20 nm in diameter.  The 20 nm SCK 
nanoparticles were also functionalized with polyethylene oxide (PEO), by grafting a 
PEO unit onto the backbone of the polymer precursor through amidation chemistry with 
the coupling agent EDCI, to be used as a precursor to self assemble into PEGylated 
nanoparticles (Figure 3.5) to ultimately improve the in vivo biodistribution.  As 
previously reported,96 covalent attachment of PEO onto the block copolymer precursor 
was performed before self assembly, as opposed to onto a final nanoparticle, which 
allowed for control over the conjugation chemistry as well as determination of the extent 
of PEO chains that were actually covalently linked onto the final nanoparticle structures.  
Because the 5 wt%-loaded 60 nm SCKs gave optimum cell killing, the theoretical PTX 
loading in the non-PEGylated and PEGylated 20 nm SCKs was kept constant at 5 wt%.  
To minimize loss of PTX during the original extensive dialysis process both after 
micellization and crosslinking, in situ crosslinking was performed after the self assembly 
process, and dialysis was only performed once altogether after crosslinking.  The 
dialysis period was also shortened to one day, instead of three days, but with frequent 
water change to facilitate removal of the organic solvent, free crosslinker, and EDCI 
byproduct.   
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Figure 3.5.  Co-assembly of PAA-b-PS or PEGylated PAA-b-PS in DMF with PTX in 
DMSO to construct 20 nm PTX loaded micelles, followed by in situ crosslinking with 
the pyrazine chromophore crosslinker, using EDCI as the coupling agent.  The final 20 
nm PTX-loaded SCKs in aqueous solutions were obtained after performing dialysis to 
remove organic solvent, free crosslinker and EDCI by products.   
 
 
 
 The dimensions of both PTX-loaded SCKs and PTX-loaded PEGylated SCKs 
were characterized by TEM and DLS (Table 3.3).  As a comparison, non-PEGylated and 
PEGylated SCKs without PTX were also characterized.  The well-defined circularly-
shaped images observed by TEM suggested that the empty SCKs were spherical with a 
narrow size distribution of 23 ± 3 nm (Figure 3.6).  PTX-loaded SCKs were also 
spherical with a comparable size distribution of 24 ± 3 nm, indicating that the PTX 
incorporation did not affect the size or the shape of the SCKs.  However, the TEM 
micrographs of the PEGylated SCKs showed distinct differences in morphology than the 
non-PEGylated SCKs.  From the micrographs, the PEGylated SCKs appeared to be more 
ill defined in shape with thick corona and rough edges, presumably due to the 
interactions of the hydrophilic PEO chains with the stain and the grids.  The dry-state 
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core diameters of PEGylated SCKs were about the same as non-PEGylated SCKs, as 
measured by TEM, but the effect of the PEGylation on the SCK hydrodynamic diameter 
was more prominent, as confirmed by DLS measurements.  The intensity-average 
hydrodynamic diameters of the PEGylated SCKs were more than twice the diameters of 
non-PEGylated SCKs (ca. 300 nm vs. 120 nm).  However, the number-average 
hydrodynamic diameters of the SCKs were determined to be 50 ± 15 nm by DLS, 
regardless of PTX incorporation and PEGylation.   
 
 
 
Table 3.3.  Summary of characterization data for the 20 nm SCKs by TEM and DLS. 
 
 
 
  
 Diameter by TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
SCK-20nm 23 ± 3 110 ± 50 70 ± 30 56 ± 15 
PTX-SCK-
20nm-5% 24 ± 3 120 ± 60 60 ± 30 49 ± 13 
PEG-SCK-
20nm 25 ± 5 320 ± 280 70 ± 40 48 ± 14 
PEG-PTX-
SCK-20nm-5% 21 ± 6 400 ± 380 70 ± 50 49 ± 15 
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Figure 3.6.  Left column: TEM images (drop-deposited on carbon-coated copper grids 
and stained negatively with 1% aqueous uranyl acetate) of A. SCK-20nm; C. PTX-SCK-
20nm-5%; E. PEG-SCK-20nm; G. PTX-PEG-SCK-20nm-5%.  Right column:  DLS 
histograms (determinations were average values from ten measurements, with the 
standard deviations being calculated as the breadths of the distributions) of B. SCK-
20nm; D. PTX-SCK-20nm-5%; F. PEG-SCK-20nm; H. PTX-PEG-SCK-20nm-5%. 
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 All PTX-loaded 20 nm formulations showed excellent cell killing abilities that 
were comparable to free PTX cell killing effect when incubated with KB cells for 2 h 
and also continued incubation for 72 h (Table 3.4, Figure 3.7).  Similar to empty 60 nm 
SCKs without PTX, empty 20 nm SCKs showed no cytotoxicity even at high 
concentrations.  PEGylation did not appear to affect the cell killing abilities of PTX-
loaded SCK samples as evident from IC50 values that were comparable to those of non 
PEGylated PTX-loaded SCKs and free PTX.  PEGylation also did not affect the cell 
internalization ability of the SCKs, as demonstrated by confocal fluorescence 
microscopy (Figure 3.8A-D).  PEGylated and non-PEGylated nanoparticles internalized 
into KB cells within 2 h and those loaded with PTX released their payload, resulting in 
cytotoxicity, as evident from the fragmented nuclei present (Figure 3.8E-F).   
 
 
 
Table 3.4.  Summary of various formulations of PTX-loaded SCKs (IC50 values were 
measured at both 2 h and 72 h incubation periods when incubated with KB cells in 
vitro).   
 
 
Attempted 
PTX conc. 
(µg/mL) 
Actual 
PTX 
conc. 
(µg/mL) 
Actual 
wt % 
% 
yield 
IC50 
at 2 h 
(μM) 
IC50 
at 72 h 
( μM) 
SCK-20nm -  -  - - 
PTX-SCK-
20nm-5% 13.5 12.4 4.3 92 
0.021 ± 
0.013 
0.004 ±   
0.002 
PEG-SCK-
20nm -  -  - - 
PEG-PTX-
SCK-20nm-
5% 
11.1 11.0 4.7 100 0.055 ± 0.015 
0.009 ± 
0.007 
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Figure 3.7.  Viability of KB cells incubated with A. SCK-20nm; B. PEG-SCK-20nm; C. 
PTX-SCK-20nm-5%; D. PTX-PEG-SCK-20nm-5%.  The percentage cell viability was 
measured by WST-1 assay.  Red dots, 2 h; blue squares, 72 h.   
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Figure 3.8.  Intracellular uptake of A. SCK-20nm; B. PEG-SCK-20nm; C. PTX-SCK-
20nm-5%; D. PTX-PEG-SCK-20nm-5% in KB cells.  Cells were incubated with a single 
concentration of each different type of SCK for 2 h.  Cells were then fixed with 4% PFA, 
mounted with media containing DAPI, and subsequently imaged with Nikon A1 
confocal microscope.  Fragmented nuclei in cells were observed after incubation with 
PTX-SCK-20nm-5% for 2 h: E. DAPI staining; F. Transmission detector (TD) image; G. 
Acridine orange staining; H.  Overlay of DAPI staining, TD, and acridine orange 
staining.   
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3.4.  Conclusions 
 The main route of delivery for many simple, yet effective, formulations of PTX, 
such as Abraxane®, is through a leaky vasculature found in cancerous cells, a 
phenomenon known as the enhanced permeation and retention (EPR) effect.97  Although 
the EPR effect may provide some selectivity, to further reduce the overall toxicity of the 
drug-nanoparticle formulation, a combination with active targeting is favored over 
passive targeting alone.  Therefore, functional sub-100 nm platforms with a core shell 
morphology are highly desired for encapsulation of hydrophobic drug molecules within 
the core and covalent attachment of targeting ligands on the surface for combined 
passive and active modes of targeting, thereby maximizing the therapeutic efficacy upon 
delivery.  For instance, half-antibody functionalized lipid-polymer hybrid nanoparticles 
(ca. 100 nm) loaded with PTX have been reported for targeted drug delivery to 
carcinoembryonic antigen presenting pancreatic cancer cells.98  Herein, we have reported 
a successful preparation of PTX-loaded, functional nanoparticles with varying sizes and 
surface characteristics, all of which demonstrated cell killing abilities that were 
comparable to or better than free PTX.  The size variations in nanoparticles did not result 
in any significant differentiation in IC50 in KB cells.  However, we expect the size 
differences will have an effect on accumulation and micro distribution in solid tumors as 
suggested by Cabral et al.99,100  The nanoparticles had tunable hydrodynamic diameters 
as well as core/shell dimensions.  Facile tuning of these nanoscale dimensions arose 
from the ability to control the length of hydrophilic/hydrophobic units of the block 
copolymers that served as the building blocks for the nanoparticles.  The hydrophilic 
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PAA block was used to covalently attach PEO units.  Conjugation of targeting ligands 
onto the remaining PEO termini or to the PAA chains is expected to further enhance the 
ability of the overall nanoparticle system to actively target for increased potency.101,102  
In addition to the incorporation of targeting ligands, future studies will include in vivo 
evaluations of the PEGylated PTX-loaded SCKs and utilization of degradable core units 
for bioclearance of the nanoparticle upon delivery.   
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CHAPTER IV 
 
SYNTHESIS, CHARACTERIZATION, AND IN VIVO EFFICACY EVALUATION 
OF SHELL CROSSLINKED NANOPARTICLE FORMULATIONS CARRYING 
SILVER ANTIMICROBIALS AS ANTI-PSEUDOMONAL THERAPEUTICS 
 
4.1.  Introduction 
Cystic fibrosis (CF), a diseases that affects about 70,000 humans worldwide, 
results from mutations in both alleles of the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene,103 and is the most common life-shortening genetic disease 
among Caucasians.104  This disease affects multiple organs including the lungs and upper 
respiratory tract, the gastrointestinal tract, pancreas, liver, sweat glands, and 
genitourinary tract.  Compared with a biphasic mucus layer in the normal airway, CF 
airway is covered with a viscous mucus layer caused by either mucus secretion, mucus 
reabsorption or both.103  Consequently, the bacteria can easily colonize and persist in the 
airway and form biofilms.  A variety of opportunistic pathogens including Pseudomonas 
aeruginosa (P. aeruginosa), Staphylococcus aureus (SA), and Burkholderia cepacia 
complex (BCC) cause chronic pulmonary infections and subsequent intense persistent 
inflammation, which is a major cause of the morbidity and mortality in these patients.103   
The current paradigm for the treatment of chronically infected CF patients 
consists of frequent high-dose administration of intravenous antibiotics such as 
aminoglycosides and β-lactams.105  While antibiotic, chemotherapy and 
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chemoprophylaxis have reduced the morbidity and early mortality of CF patients from 
infections, the intrinsic ability of these pathogens to develop resistance against many 
commonly used antibiotics rendering this microbe to be highly problematic.  The ability 
of the organisms to form biofilm prevents their complete eradication even with 
aggressive therapy.  In the case of P. aeruginosa, the phenotypic variants with an 
enhanced capacity for biofilm formation are also highly antibiotic-resistant compared 
with the parent strains.106  P. aeruginosa develops antibiotic resistance through multiple 
mechanisms including mutations in single genes and up-regulation of efflux pumps, 
making these infections extremely difficult to treat.107,108  Similarly, the proportion of CF 
patients colonized with methicillin-resistant Staphylococcus aureus (MRSA) continues 
to escalate.109,110  Colonization with BCC organisms poses a life-threatening problem, as 
they are inherently antibiotic resistant.111  Furthermore, the frequent administration of 
intravenous high dose antibiotics necessary to achieve a clinically relevant serum 
concentration of the drug can potentially result in severe side effects.  Therefore, to 
combat the problems associated with toxicity and antimicrobial resistance, there is a 
great need for finding new modalities of treatment.112   
Silver, one of the oldest antimicrobial agents, has a historical significance.  
Humans have known and used silver for its natural antimicrobial properties for 
thousands of years.  Hippocrates had noted that silver possessed beneficial healing and 
anti-disease properties around 400 BC.  Today, silver’s antimicrobial property is utilized 
extensively: silver compounds are used as antimicrobial agents for the treatment of 
wounds and burns in topical cream containing 1% silver sulfadiazine,113,114 as coatings 
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when impregnated into polymers for catheters and endotracheal tubes,115 and as 
disinfectants.116,117  In addition to its broad-spectrum activity against microorganisms, 
the relatively few reported accounts of silver resistance despite its widespread and 
continuous use make silver-based antimicrobials very attractive.  Silver has been 
demonstrated to be effective against bacteria, including P. aeruginosa, Staphylococcus 
aureus, and Escherichia coli (E. coli) as well as fungal pathogens.118  The mechanisms 
of action are incompletely understood, but might include poisoning of the respiratory 
electron transport chain, inhibition of DNA replication, and/or direct or indirect damage 
to cell envelopes.119  Furthermore, the active component of silver-based antimicrobials, 
Ag+, exhibits low toxicity to human tissues.113,120,121  Therefore, there has been a recent 
resurgence in the development of silver-based systems in order to harness the advantages 
of silver for therapeutic delivery and anti-fouling purpose.  For instance, Sen and 
coworkers have reported poly (4-vinyl-N-hexylpyridinium bromide) cationic 
polymer/silver bromide nanoparticle composites that demonstrated potent long-lasting 
antibacterial activity.122  Tiller, Mecking and coworkers have developed nanoscaled 
hybrids of silver nanoparticles and amphiphilic hyperbranched macromolecules 
composed of polyethyleneimine, which exhibited antimicrobial properties when applied 
as surface coatings.123   
Our research group in collaboration with Youngs et al. have synthesized and 
characterized a series of N-heterocyclic silver carbene complexes (SCCs).124-127  This 
new class of silver-based antimicrobials with improved stability to light and aqueous 
solutions has been found to be active against a wide variety of Gram-positive and Gram-
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negative pathogens including antibiotic-resistant P. aeruginosa, MRSA, and BCC  
species isolated from the lungs of CF patients as well as biosafety level 3 (BSL3) 
organisms.124-127  These compounds can be easily nebulized, providing a means to 
directly administer these antimicrobials to the lung via an inhalational route, a method 
that has been previously explored and proven effective due to localized delivery at the 
site of infection.128  A major advantage of the nebulization method is the ability to 
achieve therapeutic outcomes with lower antibiotic dosages, which results in diminished 
systemic absorption and decreased systemic toxicity.  However, due to the relatively 
small size of these molecules, the challenge of rapid clearance from the lungs following 
administration can still be expected.128  Instead of relying on the administration of 
several inhaled dosages to maintain effective therapeutic concentration above the 
minimum inhibitory concentration (MIC) of the bacteria within the lung, a strategy that 
poses potential patient compliance problems, we have sought to investigate the use of 
inhaled nanoparticles loaded with SCCs.  For example, Cannon and Youngs et al. have 
previously reported on the antimicrobial efficacy of SCC10 encapsulated within L-
tyrosine polyphosphate (LTP) nanoparticles both in vitro and in vivo.129  These 
nanoparticles are capable of providing a sustained release of their therapeutic payload 
directly at the site of infection following their administration thereby promising 
improved therapeutic efficacy.129,130   
Thus, we have developed multifunctional, polymeric nanoparticles that are 
optimized for encapsulation and delivery of silver and/or SCC.  Through localization of 
the payloads onto the target site, these nanoconstructs serve as theranostics to treat lung 
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infections in cycstic fibrosis patients with increased therapeutic efficacy,.  Amphiphilic, 
shell crosslinked knedel-like nanoparticles (SCKs) are used as a novel drug delivery 
system for the packaging and delivery of silver antimicrobial agents.  These SCK 
nanoparticles were synthesized from an amphiphilic diblock copolymer, poly(acrylic 
acid)-b-polystyrene (PAA-b-PS), in which hydrophobic SCCs were encapsulated into 
the hydrophobic polystyrene of the SCK nanoparticles and silver cation was being 
complexed to the acrylic acid presented on the shell of the nanoparticles.  Previous in 
vitro studies of the silver-loaded SCKs have demonstrated good MIC in both E.coli 
UTI89 strain and P. aeruginosa PAM57-15 strain.131  Herein, we have investigated the 
therapeutic efficacy of these silver-loaded SCKs in vivo through nebulization treatment 
in P. aeruginosa infected mice, and demonstrated excellent efficacy towards rescuing 
mice from bacterial infection in the lung.   
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4.2.  Materials and methods 
4.2.1.  Materials 
All chemicals were purchased from Sigma-Aldrich Chemical Co. (St. Louis, 
MO) and used without further purification unless otherwise indicated.  SCC10 and SCK 
(20% crosslinked, 0.274 mg/mL, prepared from PAA120-b-PS40) were synthesized as 
previously reported.39  Amicon® ultra centrifugal filter devices (100 kDa MWCO) were 
purchased from Millipore Corp. (Bedford, MA). Nanopure water (18 MΩ·cm) was 
acquired by means of a Milli-Q water filtration system (Millipore Corp., Bedford, MA).   
4.2.2.  Instruments 
Ultraviolet-visible spectroscopy (UV-vis) absorption measurements were made 
using a UV-2550 system (Shimadzu Corp., Japan) with PMMA cuvettes.  Inductively 
coupled plasma-mass spectrometry (ICP-MS) was performed on a Perkin Elmer SCIEX 
ICP Mass Spectrometer ELAN DRC II, equipped with high speed quadrupole, Dynamic 
Reaction Cell™ (DRC) and Axial Field™ Technology (AFT) to completely eliminate 
polyatomic interferences, using 1% HNO3 as the matrix and indium as the internal 
standard.  Dynamic light scattering (DLS) measurements were conducted using Delsa 
Nano C from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode 
operating at 658 nm.  Size measurements were made in nanopure water.  Scattered light 
was detected at 15° angle and analyzed using a log correlator over 70 accumulations for 
a 0.5 mL of sample in a glass size cell (0.9 mL capacity).  The photomultiplier aperture 
and the attenuator were automatically adjusted to obtain a photon counting rate of ca. 10 
kcps.  The calculation of the particle size distribution and distribution averages was 
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performed using CONTIN particle size distribution analysis routines using Delsa Nano 
2.31 software.  The peak average of histograms from intensity, volume and number 
distributions out of 100 accumulations was reported as the average diameter of the 
particles, with the standard deviations being calculated as the breadth of the 
distributions.   
Transmission electron microscopy (TEM) bright-field imaging was conducted on 
a FEI Tecnai G2 F20 FE-TEM, operating at a voltage of 200 kV.  The samples were 
prepared as follows:  4 μL of the dilute solution (with a polymer concentration of ca. 0.2 
- 0.5 mg/mL) was deposited onto a carbon-coated copper grid, which was pre-treated 
with plasma to increase the surface hydrophilicity.  After 5 min, the excess of the 
solution was quickly wicked away by a piece of filter paper.  The samples were then 
negatively stained with 4 μL of 1 wt% uranyl acetate aqueous solution.  After 1 min, the 
excess PTA solution was quickly wicked away by a piece of filter paper and the samples 
were left to dry under ambient conditions overnight.  High resolution scanning 
transmission electron (STEM) microscopy was conducted on a FEI Tecnai G2 F20 FE-
TEM coupled with energy dispersive x-ray (EDX), operating at a voltage of 200 kV.  
The samples were prepared as follows:  4 μL of the dilute solution (with a polymer 
concentration of ca. 0.2 - 0.5 mg/mL) was deposited onto a carbon-coated copper grid, 
which was pre-treated with plasma to increase the surface hydrophilicity.  After 5 min, 
the excess of the solution was quickly wicked away by a piece of filter paper and the 
samples were left to dry under ambient conditions overnight.   
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4.2.3.  Experiment procedures 
Preparation of silver nitrate-loaded SCK (AgNO3-SCK):  A solution of AgNO3 (5.4 
mg/mL in nanopure water, 1.18 mL) was added to the SCK solution (15 mL, polymer 
concentration: 0.274 mg/mL) and the solution was shielded from light and allowed to 
stir overnight at room temperature.  The solution was transferred to a centrifugal filter 
device (100 kDa MWCO), and washed with nanopure water (> 3 cycles) to remove free 
silver and other small molecules.  Sodium chloride was added to the filtrate until no 
precipitation was observed to confirm the removal of free silver ion.  The resulting 
AgNO3-SCK was then reconstituted to a final volume of 15.31 mL and silver loading 
concentration was measured by ICP-MS to be 78 ppm.   
Preparation of silver acetate-loaded SCK (AgCOOCH3-SCK):  A solution of 
AgCOOCH3 (3.5 mg/mL in nanopure water, 1.82 mL) was added to the SCK solution 
(15 mL, polymer concentration: 0.274 mg/mL) and the solution was shielded from light 
and allowed to stir overnight at room temperature.  The solution was transferred to a 
centrifugal filter device (100 kDa MWCO), and washed with nanopure water (> 3 
cycles) to remove free silver and other small molecules.  Sodium chloride was added to 
the filtrate until no precipitation was observed to confirm the removal of free silver ion.  
The resulting AgCOOCH3-SCK was then reconstituted to a final volume of 15.45 mL 
and silver loading concentration was measured by ICP-MS to be 123 ppm.   
Preparation of SCC10-loaded SCK (SCC10-SCK):  A solution of SCC10 (6.3 mg/mL 
in chloroform 651 µL) was added to the SCK solution (15 mL, polymer concentration: 
0.274 mg/mL) and the solution was shielded from light and allowed to stir overnight at 
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room temperature.  The solution was transferred to a centrifugal filter device (100 kDa 
MWCO), and washed with nanopure water (> 3 cycles) to remove free silver and other 
small molecules.  The removal of free silver carbene moieties were confirmed by UV-vis 
spectroscopy.  The resulting SCC10-SCK was then reconstituted to a final volume of 
15.63 mL and silver loading concentration was measured by ICP-MS to be 38 ppm.   
4.2.4.  In vivo experiments 
Mice: Male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) at 6 - 8 weeks of 
age were used for these studies that were approved by the University of Texas 
Southwestern Medical Center IACUC committee. Animals were housed in a barrier 
facility under pathogen-free conditions until they were inoculated with bacteria.  
Drugs and delivery: SCC10-SCK, AgNO3-SCK, AgCOOCH3-SCK, SCC10-AgNO3 
SCK, and blank SCK nanoparticle formulations were always suspended in sterile 
nanopure water free of Cl- ions to avoid the precipitation of AgCl. The nanoparticle 
formulations were delivered via an Aeroneb Lab apparatus (Aerogen Inc., Galway, 
Ireland) connected to a multi-dosing animal chamber.  The Aerogen nebulizer was based 
on micropump technology that produced fine particles (1-5 µm) in a low velocity aerosol 
[Geller].  A square Plexiglas box with inner dimensions of 8 x 8 x 4.5 inches served as 
the multi-dosing chamber.  The nebulizer was mounted in the center of the lid.  
Infection model and treatment protocol: A clinical isolate of P. aeruginosa designated 
PAM57-15 was provided by Dr. Thomas Ferkol (Washington University, St. Louis, 
MO).  This isolate was a mucoid strain obtained from a patient with cystic fibrosis and 
has been extensively studied in animal models [van Heeckeren].  The bacteria were 
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streaked from glycerol-frozen stocks onto tryptic soy agar (TSA) plates and incubated 
overnight at 37 °C.  Cells from the fresh plate were suspended in Luria broth (LB, 10 
mL) to an OD650 of 0.2 and grown at 37 °C in a shaking incubator at 200 rpm to an 
OD650 of 0.4, which corresponded to 3.15 x 108 CFU/mL as determined by serial dilution 
and plating onto TSA plates.  The first infection model experiment was performed to 
evaluate and compare the efficacy of the core only silver loaded SCK nanoparticles 
(SCC10-SCK) and the shell only silver loaded SCK nanoparticles (AgNO3-SCK and 
AgCOOCH3- SCK).  Mice were anesthetized using 0.05 ml of intraperitoneally 
administered ketamine/xylazine cocktail (120 mg/kg ketamine and 16 mg/kg xylazine).  
Following anesthesia, 75 μL of PAM57-15 inoculum in LB broth was delivered to each 
mouse intranasally (1.0 x 106 CFU per mouse).  Subsequently, the mice were weighed, 
ear-tagged, and randomly assigned to one of the treatment groups.  The treatment groups 
comprised of sham treatment (90:10 v/v water:phosphate buffer), blank SCK, SCC10-
SCK, AgNO3-SCK, and AgCOOCH3- SCK with 5 mice per group.  One hour after 
inoculation with P. aeruginosa, the animals were exposed to a single dose of their 
respective treatments (15 mL administered over 30 minutes).  To allow nose-only 
delivery of drug, animals were placed in CH-247 tubes (CH Technologies, Westwood, 
NJ).  Five animals, each housed in individual tubes, were placed into a multi-dosing 
chamber at a time.  Once the concentration throughout the dosing chamber equilibrated 
as indicated by diffusion of the mist cloud, the tail movements of the animals were used 
as an indicator of their status.  Mice were weighed and scored daily and observed for a 
total of 72 h after inoculation for survival.   
 93 
4.3.  Results and discussion 
 The silver-loaded SCK nanoparticles were constructed from aqueous self 
assembly of previously reported PAA120-b-PS40 amphiphilic block copolymers into 
micelles, followed by covalent crosslinking throughout the shell region to afford 
discrete, robust shell crosslinked nanostructures.  The hydrophobic polystyrene core 
domain is capable of sequestering hydrophobic molecules, and the hydrophilic 
poly(acrylic acid) shell allowed for multi-valent functionalization such as crosslinking, 
complexation with small cationic molecules, or conjugation with chromophores or 
radiolabels for visualization in vitro or tracking in vivo.  Two procedures were then 
followed for either shell complexation of silver cation from AgNO3 or AgCOOCH3, or 
core loading of SCC into the SCKs (Figure 4.1).  Silver cation was incorporated into the 
hydrophilic PAA shell region (AgNO3-SCK, AgCOOCH3-SCK) by addition of AgNO3 
or AgCOOCH3 in water into the aqueous SCK solution, followed by stirring overnight to 
afford a homogeneous solution.  SCC10 (silver carbene complex 10, 1-hexyl-3-methyl-
4,5-dichloro-imidazole-2-ylidene silver (I) acetate, which undergoes decomposition in 
the presence of saline solution to release active Ag+) was encapsulated into the 
hydrophobic polystyrene core domain and/or the core-shell interface (SCC10-SCK) 
through addition of SCC10 in chloroform into the aqueous SCK solution, followed by 
stirring overnight and evaporation of the organic solvent at room temperature overnight.  
In all three cases, free silver was removed using a centrifugal filter device (100 kDa 
MWCO).  Sodium chloride was added to the filtrate of AgNO3-SCK, AgCOOCH3-SCK 
until no precipitation was observed to confirm the removal of free silver cation.  For 
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SCC10-SCK, UV-visible spectroscopy was used to confirm removal of free SCC.  The 
resulting silver-loaded SCKs were characterized and their antimicrobial activities were 
evaluated in vivo.   
 
 
 
 
Figure 4.1.  Schematic representation of physical encapsulation of AgNO3 or 
AgCOOCH3 partitioned into the shell of the SCK, and silver carbene complex 10 
(SCC10) being incorporated into the core of the SCK. 
 
 
 
 The dimensions of all silver-loaded SCKs were characterized by transmission 
electron microscopy (TEM) and dynamic light scattering (DLS) (Table 4.1). As a 
comparison, empty SCKs without silver were also characterized. The well-defined 
circularly shaped images observed by TEM suggested that the empty SCKs were 
spherical with a narrow size distribution of 14 ± 3 nm (Figure 4.2).  Silver-loaded SCKs 
were also spherical with a comparable size distribution of ca. 14 ± 3 nm, indicating that 
the silver incorporation did not affect the size or the shape of the SCKs.  Their 
hydrodynamic diameters, characterized by DLS, were similar across loading methods 
with narrow number average size distributions of ca. 30 ± 8 nm (Figure 4.3).   
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Table 4.1. Summary of characterization data for empty and silver-loaded SCK 
nanoparticles by TEM and DLS.   
 
 
 
 
Figure 4.2.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% aqueous uranyl acetate) of:  A. Empty SCK nanoparticles; B. 
AgNO3-SCK; C. AgCOOCH3-SCK, and D. SCC10-SCK. 
 
 
 
  
 Diameter by TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
Empty SCK 14 ± 3 180 ± 110 50 ± 30 30 ± 8 
AgNO3-SCK 14 ± 2 140 ± 90 35 ± 20 24 ± 6 
AgCOOCH3-
SCK 13 ± 3 150 ± 120 40 ± 20 25 ± 7 
SCC10-SCK 15 ± 4 150 ± 120 40 ± 25 28 ± 8 
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Figure 4.3.  DLS histograms of intensity-averaged (first row), volume-averaged (second 
row), and number-averaged (third row) hydrodynamic diameters (determinations were 
average values from ten measurements, with the standard deviations being calculated as 
the breadth of the distributions) of:  A. blank SCKs; B. AgNO3-SCK; C AgCOOCH3-
SCK, and D. SCC10-SCK. 
 
 
 
 To understand better where the silver species resided, we performed both dark 
and bright field scanning transmission electron microscopy (STEM) on unstained 
AgNO3-SCK and SCC10-SCK.  Typically in dark field STEM images, the contrast in 
unstained samples is especially enhanced when heavy metals like silver are present.  The 
dark field STEM image of AgNO3-SCK (Figure 4.4) showed that the shell of the 
nanoparticle was more illuminated compared with the core of the nanoparticle due to the 
silver cation in the shell, strongly supporting our hypothesis that the silver cation from 
the AgNO3 was more likely to complex with the poly(acrylic acid) residue throughout 
the shell of the nanoparticles.  In the case of SCC10-SCK, the SCC10 was hydrophobic 
and was more likely to be localized into the core of the nanoparticles and thus core of the 
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nanoparticles was illuminated as demonstrated by STEM images (Figure 4.4).  The 
bright field STEM images also showed the incorporation of the silver species into the 
nanoparticles.   
 
 
 
 
Figure 4.4.  STEM dark field images (drop deposited on carbon-coated copper grids with 
no stain) of A. AgNO3-SCK; B. SCC10-SCK; and STEM bright field images (drop 
deposited on carbon-coated copper grids with no stain) of C. AgNO3-SCK; D. SCC10-
SCK. 
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 Prelimilnary in vivo evaulation of the antimicrobial effects of silver-loaded SCK 
nanoparticles was conducted (in the laboratory of Prof. Carolyn Cannon at University of 
Texas Southwestern Medical Center, Dallas) to compare the efficacy of the shell only 
loaded nanoparticles (SCC10-SCK) to the core only loaded nanoparticles (AgNO3-SCK 
and AgCOOCH3-SCK) using the P. aeruginosa murine infection model.  Survival rates, 
weight loss and clinical scores of the animals were monitored and used as quantifiable 
parameters in the efficacy studies.  Blank SCKs and water are used as control treatment 
groups apart from AgNO3-SCK, AgCOOCH3-SCK, and SCC10-SCK treatment groups.  
The animals were first inoculized intranasally with P. aeruginosa M57-15 strain, and a 
single dose of nebulized treatment were delivered in a nose-only fashion one-hour post 
inoculation.  The corresponding total dose of silver ions delivered for the SCC10-SCK, 
AgNO3-SCK, and AgCOOCH3 SCK was 0.57 mg, 1.1 mg, and 1.84 mg Ag+, 
respectively.  All animal groups lost weight following inoculation and nebulization 
treatments.  However, by 48 hours, the animal group treated with SCC10-SCK had 
started to show signs of weight gaining for those that had survived (Figure 4.5).   
 Clinical scores were used to moniter the well being of the mice.  Each animal's 
activity, appearance and posture were recorded every day, with low scores indicating 
healthy animals (i.e. daily movement with smooth fur and normal posture), and high 
scores indicating sick or moribund mouse (i.e. no movement with ruffled fur and 
prostrate posture) (Figure 4.6).  All other treatment group have shown increasingly high 
average clinical scores, only the clinical score in the SCC-SCK treatment has decreased 
at 24 h meaning the treatment was effective and the mice were recovering.   
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Figure 4.5.  Wight loss diagram of mice inoculated with P. aeruginosa treated with 
sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and SCC10-SCK treatment groups.   
 
 
 
 
Figure 4.6.  Clinical score diagram of mice inoculated with P. aeruginosa treated with 
sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and SCC10-SCK treatment groups. 
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 The survival rate was another indication that the SCC10-SCK treatment group 
had better therapeutic effect than all the other treatment groups.  One hundred percent 
fatality was observed in all other treatment groups except the group treated with SCC10-
SCK at approximately 48 hours post-inoculation.  Treatment group with SCC10-SCK 
resulted in a 40% survival advantage (Figure 4.7).  The high therapeutic efficacy of 
SCC10-SCK was unexpected considering the dosage of Ag+ ions delivered with the 
AgNO3-SCK and AgCOOCH3-SCK formulations were approximately two- and three-
fold higher compared with the Ag+ dose delivered by SCC10-SCK.   
 
 
 
 
Figure 4.7.  Percent survival rate diagram of mice inoculated with P. aeruginosa treated 
with sham, blank SCK, AgNO3-SCK, AgCOOCH3-SCK and SCC10-SCK treatment 
groups.   
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4.4.  Conclusions 
 In this study, we have demonstrated that both novel silver carbene complex and 
silver cation could be encapsulated into multifunctional polymeric nanoparticles.  Thses 
silver-loaded SCKs were able to achieve high therapeutic efficacy in vivo with 
localization of the antimicrobials through nebulization treatment of P. aeruginosa 
inoculated mice.  High resolution revealed that SCC and silver cation are partitioned into 
the core or the shell of the nanoparticles, respectively.  However, even at much lower 
silver concentration, SCC incorporated SCKs were able to demonstrate better therapeutic 
efficacy than silver cation incorporated SCKs, perhaps due to the slow release of the 
SCC from the core over a longer period of time.   
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CHAPTER V 
 
SYNTHETIC POLYMER NANOPARTICLES CONJUGATED 
WITH FIMHA FROM E. COLI  PILI TO EMULATE THE BACTERIAL 
MODE OF EPITHELIAL INTERNALIZATION* 
 
5.1.  Introduction 
 
 Urinary tract infections (UTI) account annually for approximately 7 million 
office visits, and 100,000 hospitalizations, and are among the most common bacterial 
infections in the United States.132  Almost half of all women will experience an episode 
of UTI during their lifetime, and 1 in 3 women will require antimicrobial treatment by 
the age of 24.133  Although females are more susceptible to UTI than are males, many 
subpopulations that are also at increased risk include infants and the elderly, as well as 
patients with diabetes, spinal cord injuries and urologic abnormalities, resulting in 
economic costs associated with UTI of $2 billion annually, even more than a decade 
ago.134,135   
Uropathogenic strains of Escherichia coli (UPEC) are the predominant cause of 
community-onset and healthcare-associated UTI.136,137  Consequently, understanding the 
 
 
____________ 
*Reprinted with permission from Lily Yun Lin, Kristin M. Tiemann, Yali Li, Jerome S. 
Pinkner, Jennifer N. Walker, Scott J. Hultgren, David A. Hunstad and Karen L. Wooley,  
J. Am. Soc. Chem., 2012, 134, 3938-3940. Copyright 2012 American Chemical Society. 
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compositional and pathogenetic details of UPEC is important for the development of 
therapeutic systems.  UPEC’s ability to attach to superficial epithelial cells of the 
bladder is mediated by heteropolymeric surface fibers called type 1 pili.  Type 1 pili 
consist of a thick pilus rod composed of a helical polymer of the major subunit FimA; 
plus a thin, flexible tip fibrillum comprised of the adapter FimF, fibrillar subunit FimG 
and tip adhesin FimH.138  The terminal, adhesive domain of FimH (denoted FimHA) 
allows the pathogen to bind mannose moieties decorating the centers of the 16-nm 
uroplakin complexes found on the luminal surface of bladder epithelial cells.139-141  
Earlier work has shown that type 1 pili are necessary and sufficient to mediate 
internalization of UPEC into bladder epithelial cells,142 and this activity is conferred by 
the mannose binding pocket within the FimH adhesin domain.143,144  Internalized 
bacteria can replicate within the epithelial cell cytoplasm to form biofilm-like 
communities,145 and later establish a quiescent reservoir within bladder epithelium that 
avoids immune detection and might later re-emerge to cause recurrent UTI.144,145   
Our primary interest is to develop nanoparticle carriers that bind and enter 
bladder epithelial cells to deliver antimicrobial agents directly to the niche occupied by 
these harbored bacteria.  In this study, therefore, we have designed multifunctional shell-
crosslinked knedel-like nanoparticles (SCKs) that can be conjugated with FimHA for 
bladder epithelial cell binding and internalization, for the purpose of targeted delivery of 
various antimicrobial agents for the treatment and prevention of UTIs.  The SCKs were 
constructed from aqueous assembly of poly(acrylic acid)-block-polystyrene block 
copolymers, (PAA-b-PS) into micelles, followed by covalent crosslinking throughout the 
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shell region to afford discrete, robust shell crosslinked nanostructures.  The amphiphilic 
core-shell morphology provides opportunities to partition the various functions of 
therapeutic packaging,39,131 cell targeting, and imaging within different regions of the 
nanoparticle framework.146  In this study, the residual reactive acrylic acid residues on 
the surfaces and throughout the shell layers of the SCKs were utilized for amidation with 
native lysines of FimHA to conjugate the adhesin and promote epithelial cell targeting 
and internalization, and with the amine terminus of the fluorescein-based dye, 5-((5-
aminopentyl)thioureidyl)fluorescein (FITC cadaverine) to permit fluorescence 
microscopic imaging (Figure 5.1).   
 
 
 
 
Figure 5.1.  Schematic and chemical representation of FimHA-functionalized and FITC 
cadaverine-labeled SCK nanoparticles.   
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5.2.  Materials and methods 
5.2.1.  Materials 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise indicated.  PAA120-b-PS100 (MnNMR = 19,500 Da, PDI = 1.1, 
from PtBA120-b-PS100 precursor) polymer precursor was synthesized as previously 
reported.  5-((5-aminopentyl)thioureidyl)fluorescein, dihydrobromide salt (5-FITC 
cadaverine) (Invitrogen, Carlsbad, CA) and sulfonated N-hydroxysuccinimide (Sulfo-
NHS) (Thermo Scientific, Waltham, MA) were used as received.  Spectra/Por membrane 
tubes purchased from Spectrum Laboratory Inc. (Rancho Dominguez, CA) were used for 
dialysis.  Amicon® ultra centrifugal filter devices (100 kDa MWCO) were purchased 
from Millipore (Bedford, MA).  Nanopure water (18 MΩ•cm) was acquired by means of 
a Milli-Q water filtration system (Millipore, Billerica, MA).   
5.2.2.  Instruments 
UV-Vis spectra were collected at 37 °C in the region of 200 - 800 nm, using a 
Varian Cary 100 Bio UV-visible spectrophotometer.  Dynamic light scattering 
measurements were conducted with a Brookhaven Instruments (Holtsville, NY) DLS 
system equipped with a model BI-200SM goniometer, BI-9000AT digital correlator, a 
model EMI-9865 photomultiplier, and an Innova 300 Argon laser operated at 514.5 nm 
(Coherent Inc., Santa Clara, CA).  Measurements were made at 25 ± 1 °C.  Prior to 
analysis, solutions were filtered through a 0.45 μm Millex®-GV PVDF membrane filter 
(Millipore, Medford, MA) to remove dust particles.  Scattered light was collected at a 
fixed angle of 90°.  The digital correlator was operated with 522 ratio spaced channels, 
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and initial delay of 5 μs, a final delay of 50 ms, and a duration of 8 min.  A 
photomultiplier aperture of 400 μm was used, and incident laser intensity was adjusted to 
obtain photon counting between 200 and 300 kcps.  Calculations of particle size 
distributions and distribution averages were performed with the ISDA software package 
(Brookhaven Instruments), which employed single-exponential fitting, Cumulants 
analysis, and CONTIN particle size distribution analysis routines.  All determinations 
were average values from ten measurements, with the standard deviations being 
calculated as the breadth of the distributions.  Transmission electron microscopy (TEM) 
bright-field imaging was conducted on a Hitachi H-7500 microscope, operating at 80 
kV.  Immunogold EM samples were viewed on a JEOL 1200EX II microscope (JEOL 
USA, Peabody, MA).  Fluorescent and confocal images were collected with an LSM510 
fluorescent confocal microscope (Carl Zeiss Inc., Thornwood, NY).   
5.2.3.  Experiment procedures 
General procedure for the preparation of the micelles and SCKs:  PAA120-b-PS100 
block copolymer precursor (ca. 50 mg) was dissolved in THF (50 mL) in a 250-mL 
round bottom flask and allowed to stir for 30 min at room temperature.  To this solution, 
an equal volume of nanopure water was added dropwise via a syringe pump over a 
period of 3 h.  The reaction mixture was allowed to stir for an additional 24 h at room 
temperature and dialyzed against nanopure water for 4 d in presoaked dialysis tubing 
(MWCO ca. 6 - 8 kDa) to afford a micelle solution with a final polymer concentration of 
ca. 0.25 mg/mL.  To the micelle solution of PAA120-b-PS100 was added a solution of 
2,2′-(ethylenedioxy)bis(ethylamine) (EDDA) in nanopure water (ca. 15 mg/mL, 1.1 eq, 
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nominal 20% crosslinking) dropwise.  To this solution, 1-[3’-(dimethylamino)propyl]-3-
ethylcarbodiimide methiodide (EDCI) in nanopure water (ca. 14 mg/mL, 1.4 eq) was 
added dropwise via a syringe pump over 20 min, and the resulting mixture was allowed 
to stir overnight before dialysis against nanopure water for 4 d in presoaked dialysis 
tubing (MWCO.ca. 6 - 8 kDa) to afford SCK solutions with a final polymer 
concentration of ca. 0.25 mg/mL.  Samples for TEM were prepared as follows:  4 μL of 
the SCK solution (with a polymer concentration of ca. 0.25 mg/mL) was deposited onto 
a carbon-coated copper grid, which was pre-treated with absolute ethanol to increase the 
surface hydrophilicity.  After 5 min, the excess of the solution was quickly wicked away 
by a piece of filter paper.  The samples were then negatively stained with 4 μL of 1 wt% 
phosphotungstic acid (PTA) aqueous solution.  After 1 min, the excess PTA solution was 
quickly wicked away by a piece of filter paper and the samples were left to dry under 
ambient conditions overnight.  Diameter (TEM) = 18 ± 2 nm, Dh(intensity) = 100 ± 30 nm, 
Dh(volume) = 70 ± 20 nm, Dh(number) = 40 ± 10 nm.   
Preparation of 5-FITC cadaverine-labeled SCKs: A solution of EDCI in nanopure 
water (1.8 mg, 18 mg/mL, 30 eq., 6 µmol) was added dropwise over five minutes to a 
solution of SCK in nanopure water (15 mL, 0.25 mg/mL polymer concentration).  The 
reaction mixture was stirred for 30 min at room temperature.  To this solution, a solution 
of 5-FITC cadaverine in nanopure water (0.6 mg, 1.8 mg/mL, 1.1 µmol) was added 
dropwise over 2 min.  The reaction was allowed to proceed for 24 h at room temperature 
before being transferred to presoaked dialysis tubing (MWCO ca. 6 - 8 kDa), then 
dialyzed against nanopure water for 4 d to remove unconjugated chromophores and 
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other impurities, yielding a 5-FITC cadaverine-labeled SCK solution with a final 
concentration of ca. 0.21 mg/mL.  
Conjugation of FimHA to 5-FITC cadaverine-labeled SCKs:  A solution of 5-FITC 
cadaverine-labeled SCKs (3 mL, 0.21 mg/mL polymer concentration) was cooled to 4 
°C while the pH of the solution was adjusted to ca. 5 - 6 with the dropwise addition of 
0.1 N acetic acid.  Sulfo-NHS (ca. 1 mg, 12 mg/mL, 4.4 µmol, 1.2 eq.) and EDCI (ca. 
1.3 mg, 13 mg/mL, 4.4 µmol, 1.2 eq.) were added to the SCK solution and the reaction 
mixture was allowed to stir at 4 °C for another 30 minutes.  The solution pH was then 
adjusted to 7 - 8 with dropwise addition of saturated sodium phosphate followed by 
addition of FimHA in phosphate buffer saline (PBS) (optimal results obtained with 2.0 
mL, 0.65 mg/mL, 0.080 µmol).  The reaction was allowed to proceed at 4 °C and slowly 
warmed to room temperature over 24 h.  Unconjugated FimHA and other impurities were 
removed by extensive washing using a centrifugal filtration device (MWCO 100 kDa) 
with PBS (pH 7.4, 5 mM), and the final volume was reconstituted to 5 mL with PBS to 
give a FimHA-conjugated, 5-FITC cadaverine-labeled SCK solution (final polymer 
concentration ca. 0.13 mg/mL, 5-FITC cadaverine concentration 0.033 mg/mL, ca. 5 
dyes per particle; calculated by UV-vis spectroscopy using the extinction coefficient of 
5-FITC cadaverine at pH 7, ε = 82000 ± 6000 L/mol·cm).  Diameter (TEM) = 20 ± 3 
nm, Dh(intensity) = 80 ± 30 nm, Dh(volume) = 50 ± 20 nm, Dh(number) = 40 ± 10 nm. 
Immunogold electron microscopy:  FimHA-conjugated and naked SCKs were allowed 
to adsorb onto glow discharged, formvar/carbon-coated copper grids for 10 min.  The 
grids were washed twice with PBS, blocked with 1% fetal bovine serum (FBS) for 5 
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min, and subsequently incubated with rabbit anti-FimH antibody for 20 min at room 
temperature.  A set of comparator SCK-FimHA grids received no primary antibody.  
Grids were again washed twice with PBS, blocked with 1% FBS for 5 min, and 
incubated with 12-nm colloidal gold-conjugated anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) for 20 min at room temperature.  
Following three washes with distilled H2O, the grids were stained with 1% aqueous 
uranyl acetate (Ted Pella Inc., Redding, CA) for 1 min.  Excess liquid was gently wicked 
off and the grids were allowed to air dry.  Ten random frames were captured for each 
experimental condition, and ca. 500 SCKs per condition were assessed for immunogold 
labeling. 
Fluorescence and confocal microscopy:  For fluorescence microscopy, 5637 bladder 
epithelial cells (American Type Culture Collection HTB-9, Manassas, VA) were grown 
to sub-confluence on sterile glass coverslips in RPMI 1640 medium with 10% FBS.  On 
the day of experiment, cells were washed with PBS, inoculated with SCK solution as 
described above, and incubated for 1 h at 37 °C.  After additional washing, cells were 
fixed with 3% paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA) 
for 10 min, then stained with 1:1000 AlexaFluor 594-conjugated wheat germ agglutinin 
(WGA) (Molecular Probes).  For confocal microscopy, after SCK inoculation as above, 
cells were liberated by application of 0.05% trypsin-0.02% EDTA for 15 min, collected 
by gentle centrifugation, and fixed with 3% PFA for 10 min.  Subsequently, cell 
suspensions were washed 3 times with PBS, then stained by resuspending in PBS with 
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1:1000 AlexaFluor 594-conjugated WGA.   After a final PBS wash, cells were applied to 
poly-L-lysine coated slides by cytocentrifugation before microscopy.  
 
5.3.  Results and discussion 
The multi-functional SCK nanoparticles were prepared from previously reported 
PAA120-b-PS100 amphiphilic block copolymers, through aqueous micellization and 
further covalent crosslinking and chemical modification reactions.39  Water (a selective 
solvent for the PAA block segment) was introduced to a THF (a good solvent for both 
PAA and PS) solution of the block copolymer dropwise via a syringe pump to form 
discrete spherical micelles.  The PAA shell regions of these micelles were then 
crosslinked via amidation chemistry with 2,2′ -(ethylenedioxy)bis(ethylamine) (EDDA), 
as a diamine crosslinker, in the presence of 1-[3′-(dimethylamino)propyl]-3-
ethylcarbodiimide methiodide (EDCI) to afford SCK nanoparticles.  5-FITC cadaverine 
was attached through additional amidation chemistry using the coupling agent EDCI, 
rendering the SCKs fluorescent, to facilitate in vitro tracking of SCKs during functional 
studies (Figure 5.2A).  The conjugation of the targeting ligand FimHA was then 
accomplished by non-selective reaction between any of the four lysine residues on 
FimHA and residual carboxylic acids on the SCK surface, following a previously 
established method.147  The reaction was carried out by first lowering the pH of the SCK 
solution in nanopure water to 5 with acetic acid and incubating at 4 °C for 30 minutes.  
Addition of sulfonated N-hydroxysuccinimide and coupling agent EDCI followed, and 
the reaction mixture was then allowed to stir at 4 °C for another 30 minutes before the 
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pH of the solution was adjusted to 7-8 by addition of sodium phosphate.  FimHA (0.65 
mg/mL in PBS, pH 7.4) was added to the reaction solution slowly, and the conjugation 
process was allowed to proceed for 24 h at 4 °C.  Purification by extensive washing 
using a centrifugal filtration device (MWCO 100 kDa) with PBS solution was performed 
to remove FimHA that was not associated with the nanoparticles.  Including lower 
concentrations of FimHA gave less efficient functionalization, as judged by the analytical 
methods detailed below.  The final products were characterized physicochemically to 
determine their sizes, compositions and structures, and the effects of FimHA conjugation 
on their biological behaviors were evaluated.   
 The dimensions of the 5-FITC cadaverine-labeled and FimHA-functionalized 
SCK nanoparticles were characterized by transmission electron microscopy (TEM) and 
dynamic light scattering (DLS) (Figure 5.2B).  The circularly-shaped images observed 
by TEM suggested that these nanoparticles were spherical with a narrow size 
distribution of 20 ± 3 nm.  The number average hydrodynamic diameter of SCK 
nanoparticles was determined to be 40 ± 10 nm by DLS.   
 FimHA functionalization efficiency in a biologically active form was determined 
by immunogold electron microscopy (EM), using primary rabbit anti-FimHA secondary 
anti-rabbit IgG conjugated to 6-nm gold particles.  The SCK nanoparticles were readily 
visualized by EM, and gold particle labeling of FimHA-SCKs (33%) was significantly 
higher than that of naked SCKs (5.6%) or of FimHA-SCKs omitting primary antibody 
(8.8%; p<0.005 for both comparisons; Figure 5.3).  Since the efficiency of the 
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immunolabeling process was not precisely known, we concluded that the conjugation 
process accomplished FimHA attachment to a minimum of 1/3 of SCKs.   
 
 
 
 
Figure 5.2.  A. Schematic representation of 5-FITC cadaverine labeling and FimHA 
conjugation to the shell of SCK nanoparticles via amidation chemistry; B.  TEM and 
DLS characterization of 5-FITC cadaverine-tagged, FimHA-conjugated SCK 
nanoparticles.  Diameter (TEM) = 20 ± 3 nm, Dh(intensity) = 80 ± 30 nm, Dh(volume) = 50 ± 
20 nm, Dh(number) = 40 ± 10 nm.   
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Figure 5.3.  Functionalization of FimHA onto SCK surfaces.  Naked SCKs (A) and 
FimHA-functionalized SCKs (B) viewed by immunogold transmission EM after 
incubation with rabbit anti-FimHA antibody and gold-conjugated anti-rabbit IgG.  
Labeling of FimHA-SCKs was significantly greater than that of naked SCKs; 
representative images are shown.  Scale bars, 100 nm.   
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We next demonstrated FimHA-SCK-specific binding to cultured bladder 
epithelial cells.  We then assessed epithelial cell binding and internalization by 
fluorescent confocal microscopy.  Cells were grown to sub-confluence on sterile glass 
coverslips, overlaid with 5-FITC cadaverine-labeled-, naked- or FimHA-SCKs, washed 
and stained with AlexaFluor 594-conjugated wheat germ to visualize the cell surfaces.  
By fluorescence microscopy the association of SCKs with the cell surfaces was shown to 
be dose dependent, FimHA specific, and inhibited by addition of mannose to the medium 
(Figure 5.4).  Confocal analysis demonstrated several examples of internalized SCKs 
(Figure 5.5), though the majority of particles were localized to the cell surfaces, and 
internalized SCKs were only occasionally observed. 
We then prepared samples by incubating FimHA protein and nanoparticles in the 
absence vs. presence of the amidation coupling agents to evaluate the relative amount of 
FimHA that was physically associated vs. covalently conjugated with the SCKs, 
respectively.  More free protein (non-covalently attached) was observed in samples that 
lacked the coupling agents; however, even the samples that had undergone the complete 
conjugation conditions contained a minor amount of free protein or protein that was 
strongly but noncovalently (perhaps electrostatically) associated with the SCKs.  On 
sodium dodecyl sulfate (SDS) gels, the nanoparticles remained mostly in the sample 
wells but a portion entered the stacking gel (5% acrylamide) and stopped at the interface 
of the resolving gel (12% acrylamide).  By Western blot, FimHA was co-localized with 
the FITC signal arising from SCKs in sample wells and at the gel interface.  This co-
localized signal indicates covalent, detergent-resistant SCK-FimHA association, although 
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the final functionalized SCKs, even with centrifugal filtration, existed as a mixture of 
physically- and covalently-associated protein and nanoparticle.   
 
 
 
 
Figure 5.4.  Binding of FimHA-SCK nanoparticles to cultured bladder epithelial cells.  
Monolayers of 5637 cells were treated with the indicated doses of 5-FITC cadaverine-
tagged (green) SCKs, naked or conjugated with FimHA, and with or without 2% 
mannose.  Cells were liberated from the surface and stained circumferentially with 
AlexaFluor 594-conjugated wheat germ agglutinin (WGA; red).  Scale bar (upper left 
panel), 20 µm.   
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Figure 5.5.  Epithelial cell internalization of FimHA-SCKs.  In this example of an 
internalized particle, the SCK of interest is viewed at the cross-hairs in the XY plane; 
orthogonal views (top and right of the panel) show the particle encircled by the red cell-
surface stain (arrowheads).  Scale bar, 20 µm.   
 
 
 
5.4.  Conclusions 
We have demonstrated the feasibility of leveraging a known bacterial-host 
interaction to direct nanostructures to an epithelial cell surface for potential therapeutic 
use.  We recognize a number of opportunities for our ongoing work to optimize facets of 
our synthetic scheme:  increasing FimHA density on the SCK surface (with full covalent 
attachment), improving the orientation of conjugated FimHA (i.e., altering lysine content 
to make the mannose binding pocket consistently available upon NP conjugation), and 
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promoting increased internalization of SCKs into epithelial cells (e.g., by varying the 
size and shape of the functionalized SCKs).148,149  FimHA is readily amenable to genetic 
engineering approaches to optimize these parameters and to study the efficiency of 
alternative conjugation chemistries, and the conservation of mannose-binding capacity in 
engineered FimHA variants can be confirmed by readily available methods.  Aside from 
the primary therapeutic aim, an antimicrobial-bearing SCK that would coat the luminal 
surface of the bladder would also be of interest for prophylaxis against UTI in special 
populations (those with indwelling catheters, who intermittently catheterize, or who are 
undergoing cystoscopy or other procedures).  Upon identification of a lead FimHA 
construct, we will employ a murine model of cystitis to begin studying in vivo 
activities.150   
An array of antimicrobials might be considered for loading into the 
functionalized SCKs described here, but silver is an attractive potential cargo,121-123,151 as 
it may be loaded in cationic form or incorporated into hydrophobic organometallic 
compounds and might be effective against reservoir bacteria that appear metabolically 
quiescent.  In fact, our previous work demonstrated loading and release of cationic and 
organometallic silver with SCKs, as well as antimicrobial activity of these silver-loaded 
systems against both E. coli and Pseudomonas aeruginosa at physiologically relevant 
concentrations.   
Finally, functionalized SCKs targeting bladder epithelial cells might be 
employed in antigen delivery for epithelial vaccines.  FimH itself has been studied as a 
component of candidate vaccines against UTI,152-154 but results so far have not translated 
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into human efficacy.  However, if alternative antigens and adjuvants that induce 
protective antibody and/or T-cell responses are identified, these could be adapted for 
presentation alongside FimHA on the SCK shell, where epithelial adhesion would 
promote prolonged antigen exposure in the urinary tract.   
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CHAPTER VI 
 
MORPHOLOGICAL EVOLUTION OF A TRIBLOCK COPOLYMER AND 
CHEMICAL MANIPULATIONS THEREOF 
 
6.1.  Introduction 
The self assembly of amphiphilic block copolymer into nanoscale objects with 
complex morphology that have potential biomedical application in the field of 
nanomedicine is an ever expanding field.2,3,38,155-157  In recent years, multicompartment 
micelles (MCMs), which are supramolecular assemblies resulting from phase-segregated 
block copolymers have attracted significant attention.158,159  The miktoarm star 
copolymers are particularly suitable for the formation of MCMs,158,160-171 however, the 
self assembly of linear triblock copolymers into MCMs is also being explored.119,159,172-
178  Both the miktoarm star copolymer and linear triblock copolymer consisted of a 
hydrophilic block segment and two incompatible hydrophobic block segments that are 
favourable for the formation of MCMs through compartmentalization of the two 
incompatible blocks during aqueous assembly.   
In our previous studies, we have shown self assembly of a linear triblock 
copolymer composed of hydrophilic ethylene oxide segment for water dispersibility, 
hydrophobic N-acryloxysuccinimide for functionalization and hydrophobic styrene   
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blocks for nucleation into micellar assemblies (PEO-b-PNAS-b-PS).95  We have 
demonstrated the manipulation of the size and number of internal compartments of the 
assembled MCMs through the hydrolysis of the PNAS domain, and their pH-responsive 
photophysical properties through functionalization with a pyrazine dye-based 
crosslinker.  Similarly, a diblock copolymer, poly(acrylic acid)-b-poly(p-hydroxystyrene) 
(PAA-b-PpHS), has been shown to access both spherical and cylindrical morphologies, 
whose unique chemical environments were probed through shell crosslinking 
chemistry.93  In this study, with the incorporation of an active ester functionality for 
facile chemical manipulations,16,179 the construction of both cylindrical and 
multicompartment nanostructure with a single type of linear triblock copolymer, PEO45-
b-PNAS66-b-PS30 was achieved, and their dynamic disembodiment into individual 
spherical nanoparticles and retention of morphology through shell crosslinking were 
observed.  (Figure 6.1).   
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Figure 6.1.  Schematic representation of self assembly of PEO45-b-PNAS66-b-PS30 to 
form both cylindrical nanostructure and multicompartment nanostructure:  A. 
micellization in DMF to form cylindrical micelles; B. crosslinking with pyrazine 
crosslinker to form shell crosslinked cylindrical nanostructures (SCCN); C. SCCN after 
dialysis for 3 days; D. SCCN after 3 months storage at room temperature; E. cylindrical 
micelles after dialysis for 3 days; F. cylindrical micelles after 3 month storage at room 
temperature; G. micellization in DMSO to form multicompartment micelles (MCM); H. 
crosslinking with pyrazine crosslinker to form shell crosslinked multicompartment 
nanostructure (MCN); I. MCN after dialysis for 3 days; J. MCN after 3 months storage 
at room temperature. K. MCM dissasembled into individual micelles upon dialysis; L. 
individual micelles disassembled from MCM are stable after 3 months storage at room 
temperature.   
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6.2.  Materials and methods 
6.2.1.  Materials 
The mono-methoxy terminated mono-hydroxy poly(ethylene glycol) (mPEG2k, 
MW = 2,000 Da, PDI = 1.06) was purchased from Intezyne Technologies and was used 
for the synthesis of macro-CTA without further purification.  The PEO-b-PNAS-b-PS 
triblock copolymer (vide infra) and the crosslinkers were synthesized according to 
previous reports.  All other chemicals were purchased from Aldrich Chemical Co. (St. 
Louis, MO) and used without further purification unless otherwise noted.  The Supor 25 
mm 0.1 µm Spectra/Por Membrane tubes (MWCO 6-8 kDa), used for dialysis, were 
purchased from Spectrum Medical Industries Inc.  Nanopure water (18 MΩ•cm) was 
acquired by means of a Milli-Q water filtration system, Millipore Corp. (Bedford, MA).   
6.2.2.  Instruments 
The molecular weight distribution was determined by Gel Permeation 
Chromatography (GPC). The N,N-dimethylformamide (DMF) GPC was conducted on a 
Waters Chromatography Inc. (Milford, MA) system equipped with an isocratic pump 
model 1515, a differential refractometer model 2414, and a two-column set of Styragel 
HR 4 and HR 4E 5 μm DMF 7.8 ×300 mm columns. The system was equilibrated  at 70 
°C in pre-filtered DMF containing 0.05 M LiBr, which served as polymer solvent and 
eluent (flow rate set to 1.00 mL/min). Polymer solutions were prepared at a 
concentration of ca. 3 mg/mL and an injection volume of 200 μL was used. Data 
collection and analysis was performed with Empower Pro software (Waters Inc.).  The 
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system was calibrated with poly(ethylene glycol) standards (Polymer Laboratories) 
ranging from 615 to 442,800 Da.   
IR spectra were recorded on an IR Prestige 21 system (Shimadzu Corp.) and 
analyzed by using the IRsolution software.  Dynamic light scattering (DLS) 
measurements were conducted using Delsa Nano C from Beckman Coulter, Inc. 
(Fullerton, CA) equipped with a laser diode operating at 658 nm.  Size measurements 
were made in nanopure water.  Scattered light was detected at 15° angle and analyzed 
using a log correlator over 70 accumulations for a 0.5 mL of sample in a glass size cell 
(0.9 mL capacity).  The photomultiplier aperture and the attenuator were automatically 
adjusted to obtain a photon counting rate of ca. 10 kcps.  The calculation of the particle 
size distribution and distribution averages was performed using CONTIN particle size 
distribution analysis routines using Delsa Nano 2.31 software.  The peak average of 
histograms from intensity, volume and number distributions out of 100 accumulations 
were reported as the average diameter of the particles, with the standard deviations being 
calculated as the breadth of the distributions.   
Transmission electron microscopy (TEM) bright-field imaging was conducted on 
a JOEL 1200 microscope, operating at 100 kV.  The samples were prepared as follows:  
4 μL of the dilute solution (with a polymer concentration of ca. 0.2 - 0.5 mg/mL) was 
deposited onto a carbon-coated copper grid, which was glow charged to increase the 
surface hydrophilicity.  After 5 min, the excess of the solution was quickly wicked away 
by a piece of filter paper.  The samples were then negatively stained with 4 μL of 1 wt% 
uranyl acetate aqueous solution.  After 1 min, the excess uranyl acetate solution was 
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quickly wicked away by a piece of filter paper and the samples were left to dry under 
ambient conditions overnight. 
6.2.3.  Experiment procedures 
Synthesis of mPEG2k macro CTA:  To a solution of mPEG2k (3.028 g, 1.5 mmol, 1 
eq.) in CH2Cl2 (30 mL) was added DDMAT (1.940 g, 5.3 mmol, 1.5 eq.) and 
dicyclohexylcarbodiimide (0.464 g, 2.3 mmol, 1.5 eq.).  The reaction was allowed to stir 
for 10 min at room temperature before 4-di(methylamino)pyridine (0.055 g, 0.45 mmol, 
0.3 eq.) was added to the reaction mixture and was allow to stir for 20 h at room 
temperature.  The reaction mixture was filtered and the filtrate was place at 4 °C 
overnight and filtered again and concentrated to ca. 10 mL before precipitated into 250 
mL ether twice.  The crude produce was purified further by column chromatography (2 - 
3% MeOH/CH2Cl2) to afford mPEG2k-CTA as a yellow solid product (2.035 g, 62% 
yield).   
Synthesis of NAS monomer:  To a 100 mL round bottom flask, N-
Hydroxysuccinimide (NHS, 10.4 g, 90.4 mmol) was dissolved in CHCl3 (75 mL).  The 
solution appeared to be cloudy and remained cloudy after the addition of triethylamine 
(TEA, 10.0 g, 99.4 mmol).  Acryol chloride (9.03 g, 99.4 mmol) was added dropwise, 
the solution became yellowish clear color and allowed to stir in ice/water bath for  
approximately 30 min, right before white cloudy precipitants appeared.  The reaction 
mixture was washed with nanopure water( 50 mL x 3) and brine (50 mL x 2), and the 
organic layer was dried with MgSO4, and concentrated by rotovap to yield white 
powdery product.  The product was recrystallized with ethyl acetate and pentane and left 
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in the fridge over night to yield 8.0365 g of white crystal product (53% yield).  1H NMR 
(300 MHz, DMSO-d6, ppm): δ2.83 (s, OCH2CH2O), 6.70, 6.35 (d, CH2CH), 6.51 (m, 
CH2CH).   
Synthesis of PEO45-b-PNAS66:  To a 25 mL Schlenk flask equipped with a magnetic 
stir bar dried with flame under N2 atmosphere, mPEG2k macro-CTA (0.120 g, 50 μmol) 
and 1,4-dioxane (10 mL) was added. The reaction mixture was stirred for 30 min at 
room temperature to obtain a homogeneous solution. To this solution was added NAS 
(0.910 g, 5.38 mmol) and AIBN (0.486 mg, 3 μmol).  The reaction flask was sealed and 
allowed to stir for 20 min at room temperature.  The reaction mixture was degassed 
through several cycles of freeze-pump-thaw (>3).  After the last cycle, the reaction 
mixture was allowed to stir for 10 min at room temperature before being immersed into a 
pre-heated oil bath at 60 °C to start the polymerization.  The polymerization was 
monitored by analyzing reaction aliqouts with 1H NMR spectroscopy and after two and 
half hours it has reached the desired degree of polymerization.  The polymerization was 
quenched by cooling the reaction flask with liquid N2.  The polymer was purified by 
precipitation into 400 mL of cold diethyl ether at 0 °C three times.  The precipitants were 
collected, washed with 100 mL of cold ether, and dried under vacuum overnight to 
afford the PEO45-b-PNAS66 block copolymer precursor as a yellow solid (550 mg, 81% 
yield based upon monomer conversion).  1H NMR (300 MHz, DMSO-d6, ppm): δ 0.86 
(t, J = 6 Hz, 3H, dodecyl CH3), 1.15 (br, 5H, CH3 and dodecyl CH2), 1.25 (br, 19H, 
CH3 and dodecyl CH2s), 1.30 (br, 2H, dodecyl CH2), 1.65 (t, J = 6 Hz, 2H, dodecyl 
CH2), 2.10 (br, PNAS backbone protons), 2.82 (NAS CH2CH2s), 3.20 (br, PNAS 
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backbone protons), 3.34 (s, mPEG terminal OCH3), 3.52 (m, OCH2CH2O from the 
PEG backbone), 4.12 (br, 2H from the PEO backbone terminus connected to the ester 
linkage);  13C NMR (150 MHz, DMSO-d6, ppm): δ 25.6, 42.0, 70.1, 172.4. MnNMR = 
136,00 Da, PDI = 1.3 (DMF GPC).   
Synthesis of PEO45-b-PNAS66-b-PS30:  To a 100 mL Schlenk flask equipped with a 
magnetic stir bar dried with flame under N2 atmosphere, was added the PEO45-b-PNAS66 
macro-CTA (0.550 g, 40 μmol), 1,4-dioxane (15 mL), and DMF (5 mL).  The reaction 
mixture was allowed to stir for 30 min at room temperature to obtain a homogeneous 
solution.  To this solution was added styrene (1.26 g, 12 mmol) and AIBN (0.39 mg, 2.4 
μmol).  The reaction flask was sealed and allowed to stir for 10 min at room temperature.  
The reaction mixture was degassed through several cycles of freeze-pump-thaw (>3).  
After the last cycle, the reaction mixture was allowed to stir for 10 min at room 
temperature before being immersed into a pre-heated oil bath at 60 °C to start the 
polymerization.  After 30 h, the monomer conversion reached ca. 10% by analyzing 
aliquots collected through 1H NMR spectroscopy.  The polymerization was quenched by 
cooling the reaction flask with liquid N2. The polymer was purified by precipitation into 
500 mL of cold diethyl ether at 0 °C three times.  The precipitants were collected and 
dried under vacuum overnight to afford the block copolymer precursor as a yellow solid 
(206 mg, quantitative yield based upon monomer conversion).  1H NMR (300 MHz, 
DMSO-d6, ppm): δ 0.86 (br, dodecyl CH3), 1.20-1.40 (br, dodecyl Hs, PNAS, and PS 
backbone protons), 2.90 (NAS CH2CH2s), 3.18 (br, PNAS backbone protons), 3.24 (s, 
mPEG terminal OCH3), 3.56 (m, OCH2CH2O from the PEG backbone), 6.30-7.30 (br, 
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Ar Hs); 13C NMR (150 MHz, DMSO-d6, ppm): δ 25.7, 42.1, 69.6, 126.2, 127.9, 145.7, 
173.0.  MnNMR = 167,00 Da,  PDI = 1.3 (DMF GPC). 
General procedure for assembly of PEO45-b-PNAS66-b-PS30 into micelles:  PEO45-b-
PNAS66-b-PS30 (ca. 20 mg) polymers were dissolved in either DMF / DMSO (20 mL) in 
a 100 mL round bottom flask and allowed to stir for 30 min at room temperature.  To 
this solution, an equal volume of nanopure water was added dropwise via a syringe 
pump at an addition rate of 15 mL/h.  The reaction mixture was allowed to stir for 
additional 24 h at room temperature and dialyzed against nanopure water for 3 days in a 
presoaked dialysis tubing (MWCO ca. 6 - 8 kDa) to afford a micelle solution with a final 
polymer concentration of ca. 0.25 mg/mL.   
General procedure for crosslinking the PEO45-b-PNAS66-b-PS30 micelles with the 
fluorescent crosslinker to afford SCKs:  To the PEO45-b-PNAS66-b-PS30 MCM 
solution was added a solution of pyrazine crosslinker in nanopure water (1.1 eq, nominal 
20% crosslinking) dropwise via a syringe pump over a period of 2 h and the resulting 
mixture was allowed to stir overnight before dialysis against nanopure water or PBS for 
3 days in a presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) to afford MCN solutions 
with a final polymer concentration of ca. 0.25 mg/mL.  The crosslinking density was 
measured by UV-vis spectroscopy to be about 7 - 10%.   
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6.3.  Results and discussion 
 The cylindrical micelles were obtained upon introduction of water into a solution 
of PEO45-b-PNAS66-b-PS30 dissolved in dimethylformamide (DMF).  Variation of water 
addition rate from 10 mL/h, 15 mL/h, 20 mL/h to 30 mL/h, caused no effect on the final 
cylindrical morphology, and maintained the width and the length comparable across the 
rates.  Number average hydrodynamic diameters were ca. 90 ± 30 nm as characterized 
by dynamic light scattering (DLS, Figure 6.2).  Dry state widths were ca. 57 ± 5 nm and 
lengths were ca. 180 ± 60 nm by transmission electron microscopy (TEM, Figure 6.3, 
data summarized in Table 6.1).  A closer look at one of the addition rates, 15 mL/h, 
revealed that as the water weight percent (wt%) increased from 10 wt% to 21 wt% to 32 
wt% to 41 wt%, spherical micelles gradually transformed into cylindrical micelles 
(Figure 6.4).  Upon dialysis against water, pH 6.3, pH 7.4 or pH 8.1 PBS for 3 days, 
cylindrical morphology and size were retained under each condition characterized by 
both DLS and TEM (Figure 6.5 and Figure 6.6, data summarized in Table 6.2).   
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Figure 6.2.  DLS histograms of intensity-averaged (first row), volume averaged (second 
row), and number averaged (third row) hydrodynamic diameters (determinations were 
average values from ten measurements, with the standard deviations being calculated as 
the breadth of the distributions) of PEO45-b-PNAS66-b-PS30 in DMF self assembled into 
cylindrical micelles upon addition of water at various water addition rate:  A. 10 mL/h; 
B. 15 mL/h; C. 20 mL/h, and D. 30 mL/h.   
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Figure 6.3.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30 in DMF self assembled into 
cylindrical micelles upon addition of water at :  A. 10 mL/h; B. 15 mL/h; C. 20 mL/h; 
and D. 30 mL/h.   
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Table 6.1.  Summary of characterization data for cylindrical micelles assembled from 
PEO45-b-PNAS66-b-PS30 in DMF by TEM and DLS.   
 
  
Water 
addition rate 
(mL/h) 
Diameter by 
TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
10 Width: 60 ± 5 Length:186 ± 65 220 ± 104 124 ± 53 93 ± 25 
15 Width: 55 ± 6 Length:212 ± 55 235 ± 102 145 ± 56 110 ± 29 
20 Width: 59 ± 4 Length:146 ± 73 312 ± 196 123 ± 65 85 ± 25 
30 Width: 52 ± 4 Length:168 ± 48 240 ± 122 130 ± 50 97 ± 26 
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Figure 6.4.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of the transition of PEO45-b-PNAS66-b-PS30 in DMF self 
assembled into spherical micelles to cylindrical micelles upon increased addition of 
water from:  A. 10 wt%; B. 21 wt%; C. 32 wt%; to D. 41 wt% at a rate of 15 mL/h.   
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Figure 6.5.  DLS histograms of intensity-averaged (first row), volume averaged (second 
row), and number averaged (third row) hydrodynamic diameters (determinations were 
average values from ten measurements, with the standard deviations being calculated as 
the breadth of the distributions) of PEO45-b-PNAS66-b-PS30 shell crosslinked cylindrical 
nanoparticles (SCCN) dialyzed against A. nanopure water; B. pH 6.3 PBS; C. pH 7.4 
PBS and D. pH 8.1 PBS.   
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Figure 6.6.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30 cylindrical micelles dialyzed 
against A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS for 3 
days.   
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Table 6.2.  Summary of characterization data for PEO45-b-PNAS66-b-PS30 cylindrical 
micelles dialyzed against nanopure water and PBS by TEM and DLS.   
 
  
 Diameter by TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
Nanopure 
water 
Width: 62 ± 6 
Length:190 ± 82 190 ± 80 136 ± 47 112 ± 35 
pH 6.3 PBS Width: 58 ± 4 Length:185 ± 65 240 ± 130 152 ± 49 105 ± 23 
pH 7.2 PBS Width: 54 ± 6 Length:189 ± 54 235 ± 78 108 ± 72 94 ± 31 
pH 8.4 PBS Width: 59 ± 7 Length:182 ± 42 220 ± 134 142 ± 65 110 ± 34 
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 The outer periphery of cylindrical micelles, consisting partly of PNAS residues, 
was covalently crosslinked by a facile one-step approach,93,95 utilizing a pyrazine-based 
diamine crosslinker, which was designed to determine the crosslinking efficiency.  
Compared with non-crosslinked cylindrical micelles, the shell crosslinked cylindrical 
nanostructures (SCCN) with a crosslinking density of ca. 7 ~ 10% had the same 
morphology and comparable size of ca. 60 nm by TEM (Figure 6.7), indicating that the 
crosslinking procedure and crosslinker loading did not affect the size of the 
nanostructure.  After 3 months of storage at room temperature, the cylindrical 
morphology was retained but the width of SCCNs had become much smaller by TEM 
(60 nm vs. 30 nm), for both the non-crosslinked cylindrical micelle (Figure 6.8) and 
SCCN (Figure 6.9).  It is conceivable that the hydrolysis of PNAS groups over time has 
increased the effective hydrophilic block lengths together with the PEG thus constituting 
a smaller final nanostructure.   
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Figure 6.7.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of shell crosslinked cylindrical nanostructures (SCCN) 
dialyzed against A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS 
for 3 days.   
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Figure 6.8.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of cylindrical micelles dialyzed against A. nanopure water 6.3; 
B. pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS after 3 months of storage at room 
temperature   
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Figure 6.9.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of shell crosslinked cylindrical nanostructures (SCCN) 
dialyzed against A. nanopure water; B. pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS 
after 3 months storage at room temperature.   
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 Another key parameter that can be used to control the morphology is solvent 
selectivity.  We also investigated the self assembly process of PEO45-b-PNAS66-b-PS30 
in dimethyl sulfoxide (DMSO) and characterized by DLS (Figure 6.10) and TEM 
(Figure 6.11, data summarized in Table 6.3).  Upon introduction of water into a solution 
of PEO45-b-PNAS66-b-PS30 in DMSO, clusters of individual micelles were observed at 9 
wt% water.  As the water wt% increased to 19 wt%, 31 wt% and 40 wt%, the transition 
of individual micelles emerging into multicompartment micelles (MCMs) was captured 
by TEM (Figure 6.12).  The reason for the striking differences in the self assembly 
process and the final morphology obtained through two different organic solvents is not 
clear but may be, in part, attributed to the differences in the surface tension of the 
organic solvents (DMSO 43 mJ/m2, DMF 34 mJ/cm2, THF 27 mJ/cm2, water 73 mJ/cm2 
at 25 °C) among others.   
  
 141 
 
Figure 6.10.  DLS histograms of intensity-averaged (first row), volume averaged (second 
row), and number averaged (third row) hydrodynamic diameters (determinations were 
average values from ten measurements, with the standard deviations being calculated as 
the breadth of the distributions) of PEO45-b-PNAS66-b-PS30 in DMSO self assembled 
upon addition of water at various water addition rate:  A. 10 mL/h; B. 15 mL/h; C. 20 
mL/h, and D. 30 mL/h.   
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Figure 6.11.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of PEO45-b-PNAS66-b-PS30 in DMSO self assembled into 
MCM upon addition of water at :  A. 10 mL/h; B. 15 mL/h; C. 20 mL/h; and D. 30 
mL/h.   
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Table 6.3.  Summary of characterization data for MCMs assembled from PEO45-b-
PNAS66-b-PS30 in DMSO by TEM and DLS.   
 
  
Water 
addition rate 
(mL/h) 
Diameter by 
TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
10 222 ± 25 730 ± 128 667 ± 116 615 ± 98 
15 215 ± 35 722 ± 200 584 ± 153 499 ± 107 
20 195 ± 19 770 ± 221 613 ± 166 520 ± 113 
30 210 ± 21 689 ± 83 660 ± 80 634 ± 73 
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Figure 6.12.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of the transition of PEO45-b-PNAS66-b-PS30 in DMSO self 
assembled into spherical micelles to MCMs upon increased addition of water from:  A. 9 
wt%; B. 19 wt%; C. 31 wt%; to D. 40 wt% at a rate of 15 mL/h.   
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 The multicompartment micelle exhibited a more dynamic state of morphology 
compared to cylinders, where dialysis conditions and the length of storage influenced the 
stability of the original structure.  The multicompartment micelle was not affected when 
the water addition rate increased from 10 mL/h to 30 mL/h with the number average 
hydrodynamic diameter of ca. 560 ± 100 by DLS (Figure 6.10) and dry state diameter of 
ca. 210 ± 25 nm by TEM (Figure 6.11, Table 6.4).  Upon dialysis against nanopure 
water, the number average hydrodynamic diameter of MCM decreased to ca. 300 ± 100 
nm (Figure 6.13), the dry state diameter by TEM remained at ca. 220 ± 25 nm (Figure 
6.14).  However, when dialyzed against pH 6.3, pH 7.4 or pH 8.1 PBS, the 
multicompartment micelles disassembled into individual micelles with hydrodynamic 
diameter of ca. 40 ± 10 nm (Figure 6.13) and dry state diameter of ca. 25 ± 5 nm (Figure 
6.14).  Interestingly, after 3 months of storage at room temperature, MCMs that were 
dialyzed against water eventually disassembled into individual micelles as well (Figure 
6.15).   
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Figure 6.13.  DLS histograms of intensity-averaged (first row), volume averaged (second 
row), and number averaged (third row) hydrodynamic diameters (determinations were 
average values from ten measurements, with the standard deviations being calculated as 
the breadth of the distributions) of PEO45-b-PNAS66-b-PS30 MCM dialyzed against A. 
nanopure water; B. pH 6.3 PBS; C. pH 7.4 PBS and D. pH 8.1 PBS.   
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Table 6.4.  Summary of characterization data for PEO45-b-PNAS66-b-PS30 MCMs 
dialyzed against nanopure water and PBS by TEM and DLS.   
 
  
 Diameter by TEM (nm) 
Dh (intensity) 
(nm) 
Dh (volume) 
(nm) 
Dh (number) 
(nm) 
Nanopure 
water 220 ± 42 340 ± 53 315 ± 50 295 ± 42 
pH 6.3 PBS 25 ± 4 332 ± 332 54 ± 36 36 ± 10 
pH 7.2 PBS 24 ± 3 384 ± 398 60 ± 40 40 ± 11 
pH 8.4 PBS 24 ± 5 310 ± 310 54 ± 35 37 ± 10 
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Figure 6.14.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of MCMs retained structure integrity when dialyzed against A. 
nanopure water but disassembled into individual nanoparticles upon dialysis against B. 
pH 6.3 PBS; C. pH 7.2 PBS, and D. pH 8.0 PBS for 3 days.   
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Figure 6.15.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of MCM dialyzed against A. nanopure water; B. pH 6.3 PBS; 
C. pH 7.2 PBS, and D. pH 8.0 PBS after 3 months of storage at room temperature   
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Figure 6.16.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of MCNs dialyzed against A. nanopure water; B. pH 6.3 PBS; 
C. pH 7.2 PBS, and D. pH 8.0 PBS for 3 days with retention to morphology.   
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Figure 6.17.  TEM images (drop deposited on carbon-coated copper grids and stained 
negatively with 1% PTA) of MCNs dialyzed against A. nanopure water; B. pH 6.3 PBS; 
C. pH 7.2 PBS, and D. pH 8.0 PBS after 3 months storage at room temperature.   
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 The dynamic nature of the multicompartment aggregates was suppressed by 
chemical covalent crosslinking reactions.  The MCMs were crosslinked with pyrazine 
crosslinker to form more stable multicompartment nanostructures (MCNs).  The MCNs 
displayed a similar size of ca. 210 ± 30 nm compared with MCMs by TEM, and did not 
disassemble into individual micelles upon dialysis against water or PBS of varying pH 
values (Figure 6.16).  Even after 3 months of storage at room temperature, the 
aggregates remained intact with more prominent phase segregation especially at pH 7.2 
and pH 8.0 (Figure 6.17).   
 
6.4.  Conclusions 
 Versatility of a triblock copolymer, PEO45-b-PNAS66-b-PS30, was demonstrated 
through accessing two distinct morphologies via facile preparation methods in organic 
solvent and water mixture.  It was further shown that chemically functional moieties 
regioselectively present within the nanoscale framework of the multicompartment 
micelles had allowed for a control over morphology stability despite the energetically 
favourable route to individual spheres.   
 
6.5.  Acknowledgements 
Financial support from Covidien is gratefully acknowledged.  K. L. Wooley 
serves as a consultant to Covidien.  This work was also supported by the Welch 
Foundation through the W. T. Doherty-Welch Chair in Chemistry, Grant No. A-0001 
  
 153 
CHAPTER VII 
 
F3-PEPTIDE-CONJUGATED, DOXORUBICIN LOADED NANOPARTICLES AS 
COMPLEX THERANOSTICS IN THE TREATMENT OF PEDIATRIC BRAIN 
CANCERS 
 
7.1.  Introduction 
 
Current treatments of brain tumors, especially malignant glioblastomas, the most 
common and aggressive type of primary brain tumors in human, include surgery, 
radiation and chemotherapy.180-182  However, surgical resection is only to the extent that 
is safely feasible and sometimes poses the greatest challenge as crucial tissues near the 
tumor that controls critical functions may also be damaged.182  To further improve 
eradiation of tumors, other regimens such as radiation and chemotherapy are developed, 
but radiation is limited by serious side effects including decline in cognitive function and 
development of secondary malignancy183 whereas chemotherapy suffers from systemic 
side effects, and is also limited by the fact that therapeutic agents are unable to penetrate 
the blood-brain barrier (BBB).184   
The BBB, formed by the endothelial cells of the cerebral capillaries that line the 
microvasculatures of the brain, prevents the entry of most blood-borne substance, 
including potential toxins and therapeutics, into the central nervous system (CNS) 
through its selective permeability.185  Doxorubicin (DOX) is a widely used 
chemotherapy drug in glioblastoma cell lines,186-188 which unfortunately causes serious 
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side effects and seldom has any effect in brain tumors patients because it lacks the ability 
to cross the BBB.189  Passive diffusion of substances across the BBB could sometimes 
occur but is highly dependent on its lipophilicity and molecular weight.186,190,191  
Therefore, designing paradigm-changing drug delivery systems that can penetrate 
through the BBB and offer the possibility for local delivery of drugs to the tumor sites 
are of prime importance.   
Nanoparticle-based drug delivery systems for cancer therapy have been 
successful, in part, due to their size, which allows for biased accumulation of the drug in 
the tumor sites by enhanced permeability and retention (EPR) effect through leaky 
vasculature around the tumor cells to achieve passive targeting.97  Many of such systems 
have been approved by the U. S. Food and Drug Administration:  liposomal doxorubicin 
(MyocetTM, Elan pharmaceuticals), PEGylated liposomal doxorubicin (Doxil®, Ortho 
Biotech, and Caelyx®, Schering Plough) and albumin-bound paclitaxel-loaded 
nanoparticles (Abranxane®, Abraxis Bioscience) as some of the examples.192-194  The 
EPR effect is a consequence of inherently leaky vasculature created due to the rapid 
vascularization that is required to serve aggressive cancer cell growth and poor 
lymphotropic clearance.97  Small molecular weight compounds, such as conventional 
chemotherapeutic drugs, can be taken up through free diffusion by both tumor tissue and 
cancerous tissue with no bias.180  With increased vascular permeability around the tumor 
environment, nanoparticles and liposomes ranging from 10 nm to 500 nm in size can 
accumulate in the tumor area to a greater extent than in the normal tissue area.156  
Nanoparticles loaded with therapeutic cargo in the sub-100 nm size region show much 
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stronger activity with increased drug concentration through the EPR effect compared 
with free anticancer drugs while avoiding uptake by the mononuclear phagocytic system 
(MPS).180,195  For instance, polymeric micelles (ca. 80 nm) constructed from 
poly(ethyleneglycol)-b-poly(N-2-hydroxypropyl methacrylamide-lactate) conjugated 
with DOX demonstrated better suppression in the growth rate of melanoma carcinoma 
tumors in mice compared with free DOX.196  Pluronic polymer micelles (ca. 25 nm) 
encapsulated with paclitaxel (PTX) showed significant tumor growth delay and 
increased survival compared with PTX alone.197  However, accumulation of drugs within 
the tumor microenviroment by the EPR effect may not be enough for drugs that require 
cellular internalization for efficacy, thus a combination with active targeting is favored 
over passive targeting alone.  Towards ultimate specificity and elimination of toxicity to 
healthy cells, active targeting through incorporation of targeting ligands within the 
nanoparticles delivery system is necessary in addition to the benefits given from being in 
the nanoscale regime.   
Active targeting can be achieved by conjugation of a targeting ligand that 
recognizes and interacts with a specific site on the tumor cells, which leads to an 
accumulation of the nanoparticles around the tumor site to increase the therapeutic 
effectiveness.75  Many nanoparticle delivery systems today achieve high efficacy in drug 
delivery through active targeting based on markers for angiogenesis and tumor 
vasculature, such as vascular endothelial growth factor (VEGF), or markers of tumor 
cells, such as EGFR.  Nucleolin, a shuttle protein that controls DNA and RNA 
metabolism traffic between the cytoplasm and the nucleus, is found to be over-expressed 
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on the surface of both proliferating angiogenic microvascular endothelial cells and tumor 
cells, thus has been used as an angiogenesis marker and tumor specific moiety for 
binding with targeting ligands and/or peptides.198-200  A 31-amino acid fragment, F3 
peptide, corresponds to the nucleosomal binding domain of a high mobility group 
protein HMGN2 and functions as a tumor homing peptide to the vasculature of various 
types of tumors by binding to the endothelial cell.199,201  The attachment of F3 peptide to 
tumor blood vessel and internalization into tumor cells is due to the binding with the 
surface over-expressed nucleolin receptor.202  Many studies have demonstrated that 
peptide-nanoparticle conjugates retain the ability of peptides to achieve specific 
targeting:  F3 peptide-targeted polyacrylamide nanoparticles were internalized by rat 
glioma cells in vitro, to a higher extent (more than 100 fold) compared with non-targeted 
nanoparticles,203 dextran-coated iron oxide nanoparticles conjugated with F3 peptide 
specifically bound to nucleolin expressed on the surface of breast tumor cells and were 
quickly internalized and shuttled to the nuclei of the cell.204  F3 peptide-targeted 
cisplatin-loaded polyacrylamide nanoparticles showed cytotoxic activity against ovarian 
tumor cells in vitro and bound to tumor vessels in vivo and achieved near complete loss 
of all tumor vessels in a murine model of ovarian cancer.205   
Our group has developed shell-crosslinked knedel-like nanoparticle (SCK) drug 
delivery systems as potential treatments for various aspects of disease146 and investigated 
their size,39 shape effect,91 and conjugation with targeting ligands for active delivery of 
therapeutics.206  Among many nanoparticulate systems, supramolecular self-assembled 
nanoparticle micelles from amphiphilic block copolymers provide unique core-shell 
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morphology, where the hydrophobic core can serve as a reservoir for hydrophobic 
therapeutic cargos and imaging agents while the hydrophilic shell protects the 
encapsulated drug molecules from the environment and can be tailored for attaching 
targeting ligands.  The SCK nanoparticles are covalently crosslinked in the shell region 
allowing them to have greater stability and also gate transport of encapsulated drug 
molecules.91,93  The dimensions of the nanoparticles can be easily tuned, by 
manipulation of polymer precursor length and composition, to accommodate specific 
drug agents and to control nanoparticle surface chemistry for functionalization to allow 
site-specific delivery of imaging and therapeutic agents.   
In this study, we have designed a multifunctional nanodevice for imaging and 
drug delivery, constructed from poly(acrylic acid)-b-polystyrene (PAA-b-PS) polymer 
precursor, functionalized with a chelator for radio-labeling, polyethylene glycol (PEG) 
for improved circulation time, targeting ligands, a chromophore and a therapeutic agent 
for in vivo active-targeted delivery and tracking.  We were able to tune the dimensions of 
the nanoparticles, by controlling the relative and overall volumes occupied by the 
hydrophilic and hydrophobic polymer chain segments, and to alter the surface chemistry 
for attachment of targeting ligands to achieve high therapeutic efficacy through both 
passive and active targeting.   
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7.2.  Materials and methods 
7.2.1.  Materials 
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) and used as 
received unless otherwise indicated.  PAA52-b-PS30 polymer 1 was synthesized as 
previously reported.  Boc-NH-PEG3kDa-NH2 (Rapp Polymere, Tübingen, Germany), 
MeO-PEG2kDa-NH2 (Rapp Polymere, Tübingen, Germany), N-hydroxysulfosuccinimide 
(Sulfo-NHS) (Thermo Scientific, Waltham, MA.), N-succinimidyl-S-
acetylthiopropionate (SATP)  (Pierce, Waltham, MA.) and Ellman's reagent kit (Pierce, 
Waltham, MA.), Cascade Blue® ethylenediamine, trisodium salt (Invitrogen, Carlsbad, 
CA.) were used as received.  FITC-F3-peptide (FITC-
KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK), scrambled FITC peptide (FITC-
KDEARALPSQRSRKPAPPKPEPKPKKAPAKK, and unlabeled F3-peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) was obtained from Tianma Pharma, 
China.  Spectra/Por membrane tubes were purchased from Spectrum Medical Industries, 
Inc., and were used for dialysis.  Sephadex-G75 medium was obtained from GE 
Healthcare.  Nanopure water (18 MΩ•cm) was acquired by means of a Milli-Q water 
filtration system (Millipore Corp., Billerica, MA.) 
7.2.2.  Instruments 
1H NMR and 13C NMR spectra were collected on a Varian Mercury 300 
spectrometer, using the residual solvent signal as internal standard.  Infrared spectra 
were acquired on an IR Prestige 21 instrument from Shimadzu Corporation (Columbia, 
MD).  UV-Vis spectra were collected at 37 °C in the region of 200 - 800 nm, using a 
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Varian Cary 100 Bio UV-visible spectrophotometer.  Dynamic light scattering 
measurements were conducted with a Brookhaven Instruments, Co. (Holtsville, NY) 
DLS system equipped with a model BI-200SM goniometer, BI-9000AT digital 
correlator, and a model EMI-9865 photomultiplier, and a model Innova 300 Ar ion laser 
operated at 514.5 nm (Coherent Inc., Santa Clara, CA).  Measurements were made at 25 
± 1 °C.  Prior to analysis, solutions were filtered through a 0.45 μm Millex®-GV PVDF 
membrane filter (Millipore Corp., Medford, MA) to remove dust particles.  Scattered 
light was collected at a fixed angle of 90°.  The digital correlator was operated with 522 
ratio spaced channels, and initial delay of 5 μs, a final delay of 50 ms, and a duration of 
8 minutes.  A photomultiplier aperture of 400 μm was used, and the incident laser 
intensity was adjusted to obtain a photon counting of between, 200 and 300 kcps.  The 
calculations of the particle size distributions and distribution averages were performed 
with the ISDA software package (Brookhaven Instruments Company), which employed 
single-exponential fitting, Cumulants analysis, and CONTIN particle size distribution 
analysis routines.  All determinations were average values from ten measurements.  
Transmission electron microscopy (TEM) bright-field imaging was conducted on a 
Hitachi H-7500 microscope, operating at 80 kV.  The samples were prepared as follows:  
4 μL of the dilute solution (with a polymer concentration of ca. 0.2 - 0.5 mg/mL) was 
deposited onto a carbon-coated copper grid, which was pre-treated with absolute ethanol 
to increase the surface hydrophilicity.  After 5 min, the excess of the solution was 
quickly wicked away by a piece of filter paper.  The samples were then negatively 
stained with 4 μL of 1 wt% phosphotungstic acid (PTA) aqueous solution.  After 1 min, 
 160 
the excess PTA solution was quickly wicked away by a piece of filter paper and the 
samples were left to dry under ambient conditions overnight. 
7.2.3.  Experiment procedures 
Preparation of PAA52-g-(CONH-lysine-DOTA-Boc)-b-PS30, (2):  A flame-dried 10 
mL round bottom flask equipped with a magnetic stir bar was charged with polymer 
PAA52-b-PS30, (1) (200 mg, 27 µmol) and dry DMF (5 mL).  To the stirred solution 1-
hydroxy-benzotriazole (HOBt) (38 mg, 280 µmol) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI) (54 mg, 282 µmol) were added and the 
reaction was left to proceed for 1 h, after which a solution of Boc-DOTA-lysine 3 (58 
mg, 83 µmol, 3 eq. with respect to the acrylic acid unit) dissolved in 1 mL of DMF was 
added.  The reaction mixture was further stirred 20 h at room temperature before being 
transferred to a presoaked dialysis tubing (MWCO ca. 6 - 8 kDa), and dialyzed against 
nanopure water for 4 days, to remove all of the impurities and to afford polymer 2 as a 
white solid after lyophilization (367 mg, 60 %, 2 DOTA/polymer chain).  1H-NMR: Mn 
= 8600 Da.  1H NMR (DMF-d7): δ 0.84 (t, CH3CH2-), 1.15 (br, -CH2- of lysine) 1.24-
1.83 (br, -CHCH2- of the polymer backbone, alkyl chain of initiator, and 
HOOCC(CH3)2-), 1.49 (s, -CCH3 DOTA), 1.90-2.21 (br, -CHCH2- of the polymer 
backbone), 2.33-2.52 and 2.92-4.10 (br, DOTA), 6.49-7.32 (br, Ar-H) ppm.  
Preparation of PAA45-g-(CONH-lysine-DOTA-Boc)3-g-(CONH-PEG3kDa-NH-Boc)2-
g-(CONH-PEG2kDa-OMe)2-b-PS30 (3):  A flame-dried 10 mL round bottom flask 
equipped with a magnetic stir bar was charged with 2 (0.2 mg, 23 µmol) and dry DMF 
(5 mL).  To the stirred solution HOBt (38 mg, 0.28 mmol, 12 eq.) and EDCI (54 mg, 
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0.28 mmol) were added and the reaction was left to proceed for 1 h, after which a 
solution of NH2-PEG3kDa-NH-Boc (0.21 g, 70 µmol, ~3 eq. with respect to acrylic acid 
unit), NH2-PEG2kDa-OMe (0.14 mg, 70 µmol, ~3 eq. with respect to acrylic acid unit) 
dissolved in DMF (1 mL) was added. The reaction mixture was further allowed to stir 
for 20 h at room temperature before being transferred to a presoaked dialysis tubing 
(MWCO ca. 6 - 8 kDa), and dialyzed against nanopure water for 4 days, to remove all of 
the impurities and afford polymer 3 as a white solid after lyophilization (0.44 mg, 76 %, 
5 PEG/polymer chain).  1H-NMR: Mn = 18,700 Da.  1H-NMR (DMSO-d6): δ 0.86 (t, 
CH3CH2-), 1.08 (br, -CH2- of lysine) 1.21-1.87 (br, -CHCH2- of the polymer backbone, 
alkyl chain of initiator, and HOOCC(CH3)2-), 1.40 (s, -CCH3 of PEG),  1.47 (s, -CCH3 
DOTA), 2.10-2.41 (br, -CHCH2- of the polymer backbone), 2.45-2.61 and 3.12 (br, -
OCH3 of PEG), 3.42-4.12 (br, DOTA, -CH2CH2O-), 6.49-7.32 (br, Ar-H) ppm. 
Preparation of PAA45-g-(CONH-lysine-DOTA-COOH)3-g-(CONH-PEG3kDa-NH2)2-
g-(CONH-PEG2kDa-OMe)2-b-PS30 (4):  A flame-dried 25 mL round bottom flask 
equipped with a magnetic stir bar was charged with 3 (0.27 mg), and dichloromethane 
(15 mL).  Trifluoroacetic acid (TFA, 10 mL) was added to the stirring solution and the 
reaction was allowed to stir overnight at room temperature, after which the solvent was 
removed under vacuum.  The crude product was re-suspended in 10 mL of THF and 
transferred to a pre-soaked dialysis tubing (MWCO ca. 6 - 8 kDa), and dialyzed against 
nanopure water for 4 days, to remove all of the impurities.  The solution was then 
lyophilized to yield the resulting yellowish solid of 4 (218 mg, 85% yield).  1H-NMR: 
Mn = 18,300 Da.  1H-NMR (DMF-d7): δ 0.84 (t, CH3CH2-), 1.26 (br, -CH2- of lysine) 
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1.20-2.12 (br, -CHCH2- of the polymer backbone, alkyl chain of initiator, and 
HOOCC(CH3)2-), 2.16-2.51 (br, -CHCH2- of the polymer backbone), 2.40-2.60 and 3.18 
(br, -OCH3 of PEG), 3.32-4.24 (br, DOTA) and (br, -CH2CH2O-), 6.42-7.41 (br, Ar-H) 
ppm. 
Preparation of PAA45-g-(CONH-lysine-DOTA-COOH)3-g-(CONH-PEG3kDa-
NHCO-C3H6-SCOCH3)2-g-(CONH-PEG2kDa-OMe)2-b-PS30 (5), General procedure 
for the introduction of masked SH groups:  Polymer 4 (0.17 g, 9.3 µmol), and SATP 
(46 mg, 0.19 mmol, 10 eq./NH2) were reacted in dry DMF (5.0 mL) for 24 h at room 
temperature before being transferred to a presoaked dialysis tubing (MWCO ca. 6 - 8 
kDa), and dialyzed against nanopure water for 4 days, to remove all of the impurities and 
afford polymer 5 as a white solid after lyophilization (0.18 g, 95 % yield).  1H-NMR: Mn 
= 18,800 Da.  1H-NMR (DMSO-d6): δ 0.83 (t, CH3CH2-), 1.08-2.01 (br, -CHCH2- of the 
polymer backbone, alkyl chain of initiator, and HOOCC(CH3)2-), 2.10-2.40 (br, -
CHCH2- of the polymer backbone), 2.30 (s, -SCOCH3), 2.68-2.81 (br, -CH2S), 3.47-3.53 
(br, -OCH2CH2O-), 3.12 (br, -OCH3 of PEG), 6.21-7.31 (br, Ar-H) ppm.  
General procedure for the preparation of the micelles and SCKs (6):  Polymer 5 (ca. 
50 mg) polymers were dissolved in DMF (50 mL) in a 250 mL round bottom flask and 
allowed to stir for 30 min at room temperature.  To this solution, an equal volume of 
nanopure water was added dropwise via a syringe pump over a period of 3 h.  The 
reaction mixture was allowed to stir for additional 24 h at room temperature and 
dialyzed against nanopure water for 4 days in a presoaked dialysis tubing (MWCO ca. 6 
- 8 kDa) to afford a micelle solution with a final polymer concentration of 0.24 mg/mL.  
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To the micelle solution was added a solution of 2,2′-(ethylenedioxy)bis(ethylamine) 
(EDDA) in nanopure water (ca. 10 mg/mL, 1.1 eq, nominal 20% crosslinking) dropwise 
via a syringe pump over a period of 2 h.  To this solution, EDCI in nanopure water (12 
mg/mL, 1.4 eq) was added dropwise via a syringe pump over 20 min and the resulting 
mixture was allowed to stir overnight before dialysis against nanopure water for 4 days 
in presoaked dialysis tubing (MWCO.ca. 6 - 8 kDa) to afford SCK solutions 6 with a 
final polymer concentration of ca. 0.24 mg/mL.  Dav (TEM) = 8 ± 2 nm, (Dh)n (DLS) = 
22 ± 6 nm; (Dh)v (DLS) = 53 ± 11 nm; (Dh)i (DLS) = 127 ± 15 nm. 
General procedure for the fluorescein labeling of the SCKs with cascade blue:  A 
solution of EDCI in nanopure water (20 mg, 66 µmol) was added dropwise over 2 min to 
a solution of SCK in nanopure water (20 mL, 0.24 mg/mL polymer concentration).  The 
reaction mixture was stirred for ca. 15 min at 4 °C.  To this solution, a solution of sulfo-
NHS in nanopure water (26 mg, 0.12 mmol) was added drop wise over 5 min.  The 
reaction mixture was further stirred 2 h at room temperature, then the pH was adjusted to 
7.4 by the addition of 0.1 M PBS pH 8.3 buffer (250 µL), and a solution of 1,3,6-
pyrenetrisulfonic acid, 8-[2-[(2-aminoethyl)amino]-2-oxoethoxy], trisodium salt 
(Cascade Blue® ethylenediamine, trisodium salt) (13 µg, in nanopure water) was added 
to the reaction.  The reaction was left to proceed for 20 h at room temperature before 
being transferred to presoaked dialysis tubing (MWCO ca. 6 - 8 kDa), and dialyzed 
against buffer (100 mM PBS, 0.1 M NaCl, 10 mM EDTA, pH 7.4) for 4 days, to remove 
all of the impurities and afford the Cascade Blue labeled SCK solution (CB-SCK) with a 
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final concentration of 0.24 mg/mL.  Number of dye molecules was found to be ca. 10 
per SCK. 
General deprotection step for the Cascade Blue labeled SCKs:  Hydroxyl amine 
hydrochloride (200 µL, 0.5 M in aqueous buffer, 100 mM PBS, 0.1 M NaCl, 10 mM 
EDTA, pH 7.4) was added to a stirred solution of CB-SCK suspended in buffer (2 mL, 
100 mM PBS, 0.1 M NaCl, 10 mM EDTA, pH 7.4) and allowed to stir for 3 h at room 
temperature to expose the thiol group on the CB-SCK.   The solution was assayed by 
Ellman’s method resulting in a concentration of 105 ± 12 µM [SH], after which the 
coupling of maleimide-F3 peptide was performed immediately. 
Sulfo-SMCC modification of the F3 peptide and general conjugation protocol to 
produce F3-CB-SCK, 7:  F3 peptide (3.0 mg, 0.75 µmol (Mn = 3,985 Da) was 
dissolved in buffer (2 mL, 150 mM PBS, 100 mM NaCl, pH 7.2).  To this solution, 
Sulfo-SMCC solution (89 µL, 0.88 mg, 8 eq., 100 % of the available lysine groups) 
suspended in DMF was added and the reaction was allowed to stir in the dark for 3 h.  
SMCC activated F3 peptide (122 µL, ca. 200 peptides per nanoparticle, 10 µmol/mL) 
was then added to a stirred solution of CB-SCK (6 mL, 0.235 mg/mL) suspended in 
buffer (100 mM PBS, 0.1 M NaCl, 10 mM EDTA, pH 7.4).  The pH of the reaction was 
adjusted to 6.7 by the addition of 0.1 M citric acid buffer.  The reaction was allowed to 
proceed for 6 h in the dark at room temperature, after which the reaction was quenched 
by the addition of 4-maleimido-butyric acid (0.3 mg, suspended in 100 mM PBS, 150 
mM NaCl, pH 7.4).  The solution was then allowed to stirred for additional 16 h before 
being transferred to a presoaked dialysis tubing (MWCO ca. 15 kDa) and dialyzed 
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against aqueous buffer (5 mM PBS, 5 mM NaCl, pH 7.4) for 2 days.  The conjugates 
were then purified on a 100 mL Sephadex-G75 medium gravity column eluting with 
aqueous buffer (150 mM PBS, 100 mM NaCl, pH 7.4).  Nanoparticles conjugated with 
F3-peptide were collected and reconstituted to the original volume of 6 mL to give the 
F3-CB-SCK, 7. 
General procedure for doxorubicin (DOX) loading experiments into F3-CB-DOX-
SCK nanoparticles, 8:  To a vial containing a magnetic stir bar and F3-CB-SCK 
solution, 7 (5 mL, polymer concentration 0.24 mg/mL), a solution of DOX (0.5 mg/mL 
in CHCl3 and 3 eq of triethylamine, 50 wt% with respect to the SCK) was added.  The 
solution was shielded from light and stirred over-night before being transferred to a 
centrifugal filter device (Amicon Ultra 4, 100 kDa MWCO, Millipore corp., Billerica, 
MA, USA) and washed extensively with 5 mM pH 7.4 PBS at 37 °C to remove free 
DOX.  The filtrate was analyzed by UV-Vis spectroscopy to confirm the removal of free 
DOX after several washing cycles.  The DOX-nanoparticle solution was then 
reconstituted to a final volume of 5 mL with 5 mM pH 7.4 PBS buffer.  The amount of 
DOX was determined by UV-vis spectroscopy (488 nm, ε = 13,050 M-1cm-1 determined 
by a calibration curve in a 4:1 v/v mixture of DMF and DOX-nanoparticle in PBS). 
Surface binding of FITC-labeled F3 peptide (FITC-F3) on U87MG glioma Cells by 
FACS analysis: Human glioma cell line (U87MG, ca. 10000 cells ) were lifted and 
incubated with 10 µg/mL of FITC-labeled F3 peptide in vitro at 4 °C for 2 h before fixed 
in 70% ethanol and assayed by FACS analysis. 
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Cellular uptake of FITC-F3 and scramble F3 peptide (scramble-F3) in normal 
human astrocytes and human glioma cell line: Primary normal human astrocytes 
(NHA, SciCell) were cultured with astrocyte conditional media containing 10% FBS and 
astrocyte supplements.  U87MG glioma cells  were cultured in DMEM with 10% FBS.  
Approximately 3000 cells/well of NHA or U87MG cells were plated on 24 well 
coverslips and were incubated with 1 µM (final concentration) of either FITC-F3 or 
scrambled-F3 overnight at 37 °C. At the end of incubation, cells were first fixed with 4% 
paraformaldehyde (PFA) at room temperature for 15 minutes and mounted for 
microscopic observation. Nuclei were counterstained with 0.5 µg/mL of DAPI for 15 
minutes. 
In vitro cellular uptake of DOX loaded naked SCK (DOX-SCK) and F3-peptide 
conjugated DOX- loaded SCK (F3-DOX-SCK) in human glioma cell line: NHA 
were cultured with astrocyte conditional media containing 10% FBS and astrocyte 
supplements.  U87MG glioma cells were cultured in DMEM with 10% FBS and plated 
24 hours before the experiment.  DOX-SCK and F3-SCK were directly added into the 
cells at the same concentration (100 ng/mL). Cells were observed live 24 hours later 
with an inverted immunofluorescence microscope.  
Cell viability assay by MTT: At the end of experiment, U87MG glioma cells that had 
been treated with naked SCK, DOX-SCK or F3-DOX-SCK, were incubated with MTT 
stock solution (10 µL of 5mg/mL of MTT solution added into one well in 96-well plate) 
for 3 hours at 37 °C. At the end of incubation cells were stopped with 10% SDS solution 
 167 
and the blue crystals were dissolved overnight and then the absorbance was read by 
spectrophotometry at 570 nm. Viability was normalized to the untreated control. 
In vivo delivery of naked SCK and F3-SCK in U87MG xenograft tumors: 1 x 106 of 
U87MG cells were injected into immunodeficient nude mice intracranially. When 
intracranial tumors were fully developed (normally around 3-4 weeks post injection), 
mice were injected with naked SCK or F3-SCK by tail vein.  An intracardiac perfusion 
was performed on these mice 24 hours later, first with PBS and then with 4% PFA 
before all internal organs were harvested. All tissues were fixed in 4% PFA overnight 
and paraffin-embedded sections were used for immunostaining. For the immuno-
detection of SCKs, all the tissue sections were stained with anti-cascade blue antibody 
by ABC method and cellular nuclei were counterstained by hematoxylin for 
observations. 
 
7.3.  Results and discussion 
The multi-functional SCK nanoparticles were prepared from previously reported 
PAA120-b-PS100 amphiphilic block copolymers, through aqueous micellization and 
further covalent crosslinking and chemical modification reactions.  Water (a selective 
solvent for the PAA block segment) was introduced to a THF (a good solvent for both 
PAA and PS) solution of the block copolymer dropwise via a syringe pump to form 
discrete spherical micelles.  The PAA shell regions of these micelles were then 
crosslinked via amidation chemistry with 2,2′ -(ethylenedioxy)bis(ethylamine) (EDDA), 
as a diamine crosslinker, in the presence of 1-[3′-(dimethylamino)propyl]-3-
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ethylcarbodiimide methiodide (EDCI) to afford SCK nanoparticles.  5-FITC cadaverine 
was attached through additional amidation chemistry using the coupling agent EDCI, 
rendering the SCKs fluorescent, to facilitate in vitro tracking of SCKs during functional 
studies (Figure 7.1).  The conjugation of the targeting ligand FimHA was then 
accomplished by non-selective reaction between any of the four lysine residues on 
FimHA and residual carboxylic acids on the SCK surface, following a previously 
established method.  The reaction was carried out by first lowering the pH of the SCK 
solution in nanopure water to 5 with acetic acid and incubating at 4 °C for 30 minutes.  
Addition of sulfonated N-hydroxysuccinimide and coupling agent EDCI followed, and 
the reaction mixture was then allowed to stir at 4 °C for another 30 minutes before the 
pH of the solution was adjusted to 7-8 by addition of sodium phosphate.  FimHA (0.65 
mg/mL in PBS, pH 7.4) was added to the reaction solution slowly, and the conjugation 
process was allowed to proceed for 24 h at 4 °C.  Purification by extensive washing 
using a centrifugal filtration device (MWCO 100 kDa) with PBS solution was performed 
to remove FimHA that was not associated with the nanoparticles.  Including lower 
concentrations of FimHA gave less efficient functionalization, as judged by the analytical 
methods detailed below.  The final products were characterized physicochemically to 
determine their sizes, compositions and structures, and the effects of FimHA conjugation 
on their biological behaviors were evaluated.   
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Figure 7.1.  Schematic representation of synthesis of DOTA containing PEGylated 
PAA52-b-PS30 with activated ester-functionalized PEG, PAA45-g-(CONH-lysine-DOTA-
COOH)3-g-(CONH-PEG3kDa-NHCO-C3H6-SCOCH3)2-g-(CONH-PEG2kDa-OMe)2-b-
PS30. 
 
 
 
 The F3-peptide-, cascade blue (CB)-conjugated SCKs (F3-CB-SCK 7) were 
modified from naked SCK 6, constructed from polymer precursor 5, through aqueous 
self assembly.  Aqueous micellization methodology was adopted to prepare spherical 
micelles, where block copolymer precursors were dissolved in organic solvent DMF (1 
mg/mL) and an equal amount of water was added to the solution drop-wise via a syringe 
pump over a period of 3 h to induce self assembly.  The micelles were crosslinked in the 
PAA shell regions via amidation chemistry with 2,2’-(ethylenedioxy)bis(ethylamine), as 
the diamine crosslinker, in the presence of 1-[3’-(dimethylamino)propyl]-3-
ethylcarbodiimide methiodide (EDCI), resulting stable SCK nanoparticles.  To allow for 
immunofluorescence labeling, the PAA shell of the SCKs was conjugated with the 
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chromophore cascade blue (CB) by using sulfonated N-hydroxysuccinimide ester as a 
coupling agent to yield CB-SCK 6 (Figure 7.2).  The protected sulfohydryl groups on the 
PEG3k chains on the SCKs allowed the nanoparticles to maintain storage stability and 
also introduced surface functionality to conjugate with maleimido functionalized 
moieties such as peptides and antibodies.  The methylester protecting groups on the PEG 
spacer were removed by treatment with hydroxylamine (0.5 M) in buffer (100 mM PBS, 
0.1 M NaCl, 10 mM EDTA, pH 7.4) to expose active -SH groups (the concentration of -
SH groups was determined by Ellman’s essay in solution to be 100 ± 5 µM, theoretical 
concentration was 120 µM).  Deprotected SCKs with active -SH groups were then 
conjugated with maleimido-functionalized F3-peptide that had been modified with 
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC).  
Free –SH groups were capped by reacting with an excess amount of maleimido butyric 
acid.  F3-CB-SCK 7 was purified with Sephadex G75 gel chromatography column, and 
the removal of unconjugated peptide and dye was confirmed by fast protein liquid 
chromatography (FPLC).   
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Figure 7.2.  Schematic representation of incorporation of cascade blue dye with sulfo-
NHS onto the polymer backbone segments within the shell of the SCKs, conjugation of 
maleimide-functionalized F3 peptide onto the thiol functionalized PEG graft termini to 
produce F3-CB-SCK 7, followed by encapsulation of DOX into the nanoparticles 
through physical encapsulation to produce F3-CB-DOX-SCK 8.   
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 F3-CB-SCK 7 nanoparticles can also encapsulate therapeutic agents such as 
DOX for active drug delivery.  The incorporation of DOX into the targeted SCK 
nanoparticles was accomplished by incubating DOX solutions in DMF with SCK 
nanoparticles in aqueous solutions.  The polystyrene core was swollen with the addition 
of the organic solvent DMF and provided a large hydrophobic reservoir to encapsulate 
DOX and drive the diffusion-controlled loading/encapsulation process.  The 
unincorporated DOX molecules were purified from the DOX-loaded SCK nanoparticles 
by centrifugation and extensive washing using a centrifugal-filtration membrane device 
with PBS (5 mM, with 5 mM NaCl).  The F3-peptide-, cascade blue-conjugated, DOX-
loaded SCK nanoparticle 8 (F3-CB-DOX-SCK 8) solution was reconstituted to its 
original concentration by the addition of PBS, and the resulting DOX concentrations 
(0.028 mg/mL) in the SCKs were determined using the absorption of DOX at 488 nm.   
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Figure 7.3.  Upper row:  A. TEM image (drop deposited on carbon-coated copper grids 
and stained negatively with 1% aqueous uranyl acetate) of SCK, diameter = 8 ± 3 nm;  
DLS histograms (determinations were average values from ten measurements, with the 
standard deviations being calculated as the breadth of the distributions) of B. SCK 
intensity average, 130 ± 60 nm; C. SCK volume average, 40 ± 20 nm; D. SCK number 
average 26 ± 6 nm;  Lower row:  E. TEM image of F3-CB-DOX-SCK, diameter = 7 ± 3 
nm; DLS histograms of F. F3-CB-DOX-SCK intensity average, 100 ± 70 nm; G. F3-CB-
DOX-SCK volume average, 30 ± 10 nm; H. F3-CB-DOX-SCK number average, 21 ± 4 
nm.   
 
 
 
 The dimensions of F3-CB-DOX–SCK 8 nanoparticles were characterized by 
transmission electron microscopy (TEM) and dynamic light scattering (DLS) (Figure 
7.3).  As a comparison, non-conjugated SCKs were also characterized.  The well-defined, 
circularly-shaped images observed by TEM suggested that the empty SCKs were 
spherical with a narrow size distribution of 8 ± 3 nm (Figure 7.3).  After F3-peptide 
conjugation and DOX encapsulation, the SCKs retained the spherical morphology with a 
comparable size distribution of 7 ± 2 nm, indicating that the peptide conjugation and the 
drug loading did not affect the size or the shape of the SCKs.  The dry-state core 
diameter of F3-CB-DOX-SCK 8 was about the same as non-conjugated SCKs, as 
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measured by TEM.  Their hydrodynamic diameters were also similar with a narrow 
distribution, as confirmed by DLS measurements.   
 
 
 
 
Figure 7.4.  Cellular uptake of FITC labeled F3 peptide in primary normal human 
astrocytes (NHA) and U87MG glioma cells.  Primary normal human astrocytes and 
U87MG glioma cells were both incubated with FITC-labeled F3 peptide (1μM) at 37 °C 
for 2 h before fixed with 4% PFA and then mounted for observation.  As a control, 
U87MG glioma cells were pre-incubated with anti-human specific nucleolin antibody 
(10µg/ml) to block the binding.  The nuclei were counterstained with DAPI.   
 
 
 
 To test the hypothesis that F3 peptide preferentially targeted tumor cells 
compared to scramble-peptide, we utilized two model cell line systems: normal human 
astrocytes (NHA) and a human glioma cell line (U87MG).  Previously, we found that 
U87MG glioma cells demonstrated significant amount of nucleolin expression both 
within their nucleolus and on their cell surface compared to normal human astrocytes.  
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As expected, U87MG glioma cells showed significant uptake of FITC-labeled F3 
peptide within their nuclei whereas the amount of FITC-F3 peptide within normal 
human astrocytes was essentially negligible (Figure 7.4).  Likewise, neither NHA nor 
U87MG cells showed any significant uptake of FITC-labeled scrambled peptide.   
 We observed that non-targeted naked SCKs (DOX-SCKs) were preferentially 
being taken up into lysosomal structures and/or the peri-nuclear region among the 
treated cells, although currently the cellular mechanism of uptake for these SCKs is still 
unknown.  Lysosome localization of SCKs especially with DOX-SCKs among treated 
cells may potentially attenuate their anti-tumor effects with this system.  By conjugating 
with F3-peptide, which showed specific nuclear targeting in U87MG glioma cells, we 
hypothesized that there would be enhanced nuclear delivery of DOX by F3-peptide 
conjugated SCKs compared to naked SCKs.  As shown in Figure 7.5, U87MG cells 
treated with F3-DOX-SCKs indeed had more DOX within their nuclei compared to 
naked SCKs.  Even though free DOX also accumulated within the nuclei of treated cells 
in vitro, the advantage of tumor specific delivery by the F3-peptide conjugated SCKs 
may potentially lower the dosage of DOX that is needed for killing the tumors and 
therefore help to prevent systemic side effects observed in vivo by free DOX (Figure 
7.6).   
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Figure 7.5.  Live cell imaging of cellular uptake of untargeted DOX-loaded (DOX-SCK) 
vs. targeted DOX-loaded (F3-DOX-SCK) nanoparticles (at 1 µg/mL x 1 h) into U87MG 
glioma cells, 20 x magnifications.  DOX molecules were shown by intrinsic red 
fluorescence within the treated cells.   
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Figure 7.6.  Enhanced tumor cell killing effects by F3-DOX-SCK nanoparticle in vitro 
compared with non-targeted SCKs.  U87MG glioma cells were treated with naked SCK, 
DOX-SCK or F3-DOX-SCK for 3 days before assayed for their viability by MTT assay. 
 
 
 
 To further validate the hypothesis that F3-CB-DOX-SCKs specifically target 
tumor cells in vivo and to investigate the differences of bio-distribution between 
untargeted SCKs and targeted SCKs, we generated immunodeficient mice bearing 
intracranial U87MG glioma cells (Figure 7.7).  Three to four weeks after tumor 
implantation, we systemically delivered F3-CB-DOX-SCKs by tail vein injection and 
subsequently harvested the internal organs including the tumor-bearing mouse brains.  
To demonstrate cellular localization of targeted SCKs, we used a specific antibody 
against cascade blue, which was also incorporated into SCKs as a fluorescent label.  F3-
CB-DOX-SCKs and CB-DOX-SCKs were clearly detected in heart, kidney, liver, and 
brain tumor tissues.  In general, staining was more intense in heart, kidney, and liver in 
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the CB-DOX-SCK treated group, indicating greater system distribution in untargeted 
SCKs. F3-CD-DOX-SCK treated animals showed greater staining within tumors 
compared to tumors from untargeted SCKs-treated animals.  Both in vitro results and in 
vivo tumor specific targeting ability of our F3-peptide conjugated SCKs in U87MG 
xenograft animals demonstrated a feasibility and clear advantage of the current 
therapeutic systems as a novel treatment of malignant gliomas.  We are currently testing 
the long-term anti-tumor effects from F3-CB-DOX-SCKs on U87MG xenograft animals.   
 
 
 
 
Figure 7.7.  Enhanced tumor specific delivery of targeted nanoparticle in U87MG 
intracranial xenograft in vivo of targeted nanoparticles, F3-CB-DOX-SCK, compared 
with systemic distribution with non-targeted nanoparticles, CB-DOX-SCK, especially 
within the heart, kidney and liver.   
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7.4.  Conclusions 
 In this study, multifunctional SCK nanoparticles were conjugated with F3-
peptide and physically loaded with DOX to actively deliver the therapeutic payload for 
the potential treatment of glioblastoma and were able to successfully achieve nuclear 
localization of the DOX in vitro and enhanced uptake into U87MG intracranial 
xenografts in vivo.  Compared with non-targeted SCKs, which accumulated mostly in 
the peri-nuclear region, enhanced nuclear delivery of DOX was observed with F3-
peptide conjugated SCKs, resulting in higher killing abilities against U87MG cells in 
vitro compared with the non-targeted analogue.  In addition, systemic distribution 
throughout the heart, kidney and liver was observed with non-targeted SCKs, whereas 
enhanced tumor uptake was observed with targeted SCKs in vivo.  We were able to 
utilize fully the multi-functionality of the SCK nanoparticle system to introduce 
targeting ligands, imaging moieties and PEG corona layer with facile control over the 
number of each entity, tailored to maximize the EPR effect and therapeutic efficacy 
through both passive and active targeting.   
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CHAPTER VIII 
 
CONCLUSIONS 
 
 Shell crosslinked knedel-like nanoparticles (SCKs) are promising drug delivery 
platforms in biomedical applications as the treatment of a wide range of diseases.  The 
construction of SCKs involves the supramolecular assembly of amphiphilic block 
copolymers into micelles with core-shell morphology, followed by regioselective 
crosslinking throughout the peripheral region to impart the robustness of the 
nanoparticles.  The engineering of multifunctional SCK nanoparticles with precise 
control over composition, dimension, structure, morphology, external surface chemistry 
and functionalization has benefited from the advances in polymerization chemistries and 
the application of efficient and orthogonal chemical modification.  The careful design 
and control over these properties of the SCKs will enable their future development and 
application as the next generation nanomaterials.  In this dissertation, nanoparticle-based 
drug delivery system was designed and developed for the treatment of cancer, urinary 
tract infection, lung infection associated with cystic fibrosis and pediatric brain cancer 
through compositional, dimensional and structural control.   
 In an effort to understand how the dimension of a nanoparticle, specifically the 
core volume and shell thickness, can affect their performance as drug delivery vehicles 
in drug loading and release characteristics, SCK nanoparticles were designed to have 
various relative and absolute core and shell dimensions to mediate the packaging and 
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release of DOX as a model chemotherapeutic system.  Variation over the nanoparticle 
dimensions was achieved through controlling of the block copolymer precursor chain 
lengths, to afford a series of well-defined and rigorously characterized nanoscopic 
vessels for drug molecule loading and release studies.  The nanoparticles were 
constructed from amphiphilic block copolymer poly(acrylic acid)-block-polystyrene 
(PAA-b-PS).  PAA-b-PS block copolymers having different relative block lengths and 
absolute chain lengths were synthesized via sequential reversible addition-fragmentation 
chain transfer (RAFT) polymerization reactions of t-butyl acrylate (tBA) and styrene, 
followed by removal of the t-butyl ester protecting groups.  The amphiphilic core-shell 
morphology of the SCK nanostructures provided opportunities for tuning of the drug 
loading capacities and rates of release.  Increasing core diameters and core-shell 
interfacial surface areas were important for superior guest packaging capacity while 
lower proportions of shell-to-core volume was the critical parameter for increased 
kinetics of release.  The variety of contributing factors, including chemical composition, 
dimensions of the core and shell domains and total particle concentrations, made direct 
determination of the effects of each parameter complicated, although the greatest 
correlation appeared to be the ratio of the volume of the shell vs. the volume of the core.  
As the relative proportion of PAA shell to PS core volumes decreased, the rate and 
extent of release increased.  These studies, therefore, point to future directions to craft 
sophisticated devices for controlled drug release.   
 Continuous efforts were made towards understanding whether or not dimension 
of the nanoparticle would affect their therapeutic performance in vitro.  Paclitaxel (PTX), 
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another chemotherapy drug was encapsulated into functional nanoparticles with varying 
sizes and surface characteristics, all of which demonstrated cell killing abilities that were 
comparable to or better than free PTX.  The size variations in nanoparticles did not result 
in any significant differentiation in cell killing.  In addition, incorporation polyethylene 
glycol (PEG), which imparts the stealthiness of the nanoparticle, did not affect PTX-
loaded SCKs performance in vitro.  Conjugation of targeting ligands onto the PEG 
termini or to the PAA chains is expected to further enhance the ability of the overall 
nanoparticle system to actively target for increased potency.  Future studies also include 
utilization of degradable core or shell units for bioclearance of the nanoparticle upon 
delivery.   
 The well-defined SCK nanoparticles were explored as novel antimicrobial agents 
nanocarriers for the treatment of Pseudomonas aeruginosa bacteria caused lung 
infections associated with cystic fibrosis.  The hydrophobic core of the SCK 
nanoparticles was able to encapsulate novel silver carbene complexes, while the acrylic 
acid residue on the hydrophilic shell could complex to silver cation moieties.  The silver 
concentrations were determined by inductively coupled plasma mass spectrometry (ICP-
MS) and the location of different silver species was revealed by high resolution scanning 
transmission microscopy (STEM) coupled with energy dispersive X-ray spectroscopy 
(EDX).  The in vivo efficacy was investigated by nebuilization treatment in 
Pseudomonas aeruginosa bacteria inoculated mice models to reveal that high therapeutic 
efficacy was achieved through localization of the silver moieties by the nanoparticles.  
Targeted delivery of antimicrobial could be achieved with conjugation of targeting 
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ligands onto the surface of these silver loaded SCK nanoparticles resulting in higher 
therapeutic efficacy.   
 Next, we demonstrated the feasibility of leveraging a known bacterial-host 
interaction to direct nanostructures to an epithelial cell surface for potential therapeutic 
use.  Amphiphilic block copolymer nanoparticles were conjugated with uropathogenic 
Escherichia coli type 1 pilus adhesin FimHA through amidation chemistry to enable 
bladder epithelial cell binding and internalization of the nanoparticles in vitro thus 
emulating the bacteria mode of invasion.  By fluorescence microscopy the association of 
SCKs with the cell surfaces was shown to be dose dependent, FimHA specific and 
inhibited by addition of mannose to the medium.  Combination of incorporation of 
antimicrobial agents and conjugation with targeting ligand could allow these SCK 
nanoparticles to be served as powerful theranostics and play an important role in the 
prevention and treatment of various infection diseases.   
 Nanoscale assemblies with complex morphologies have been applied as potential 
biomedical devices and considerable efforts have been devoted to understanding and 
manipulating the aqueous self assembly process of amphiphilic block copolymers to 
obtain theses complex morphologies.  As a fundamental study, the construction of both 
cylindrical and multicompartment nanostructure (MCN) with a single type of linear 
triblock copolymer, PEO45-b-PNAS66-b-PS30 was investigated and their dynamic 
disembodiment into individual spherical nanoparticles and retention of morphology 
through shell crosslinking were observed.  The formation of these intricate 
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morphologies, from facile process manipulation of a triblock copolymer, coupled with 
unique properties, is certainly interesting in biomedical applications.   
 SCK nanoparticles hold great promise as versatile nanocarriers for a wide range 
of therapeutics in the diagnosis and treatment of a variety of diseases.  In this 
dissertation, the ease of control over size, shape, composition, structure, surface 
characteristics and morphology of the SCK nanoparticles was achieved through 
advanced polymerization techniques, facile and practical chemical manipulations, and 
control over the supramolecular assembly process, which will secure their future 
development and success in the biomedical and nanomedicine field.   
 We have designed and developed a highly multifunctional nanodevice for 
imaging and therapeutic delivery, functionalized with a chelator for radio-labeling, a 
chromophore for visualization, polyethylene glycol for improved biodistribution, 
targeting peptides to redirect biodistribution, and a therapeutic agent for treatment of 
pediatric glioblastomas.  This complex yet sophisticated system, employed the 
combination of passive targeting with control over the size of the nanoparticle through 
advanced polymerization techniques, and active targeting with chemical manipulation 
and functionalization utilizing a targeting peptide, was able to achieve high in vitro 
therapeutic performance and in vivo tumor specific targeting.  However, there are still 
parameters that need to be optimized in order to perfect the therapeutic performances 
SCK nanoparticles and achieve efficacy as natural systems.  For example, while some 
active agents, such as DOX, have the tendency to be prematurely diffused out of the 
nanoparticles and being released before they reach the desired location, other payloads, 
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including PTX, will not release even over an extended period of time and need 
degradation triggered release to achieve high therapeutic performance.  Other therapeutic 
cargos, such as silver, if released early in the blood stream, precipitation issue can 
become problematic, and the loss of its active form will lower its therapeutic 
performance.  Thus, the development to balance the nanoparticle as a robust and stable 
drug delivery vehicle but also incorporating stimuli-responsive degradation to allow 
triggered release still remains as a challenge.   
 There are other factors related to these synthetic nanoparticles’ performance and 
parameters that need to be optimized to allow them to be as efficient as natural systems.  
For instance, challenges towards optimizing the coupling chemistry used to efficiently 
introduce the targeting ligands still exist.  Once the targeting ligands are conjugated onto 
the nanoparticle system, quantification and their surface accessibility and bioavailability 
must be further looked into.  Other considerations such as physical, chemical and 
biological evaluations of the nanoparticle systems, their immunological reaction and 
toxicity need to be addressed with a combined effort of scientists from all fields, which 
create exciting opportunities for collaboration and interdisciplinary research. 
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